

(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 200031236 B2**
(10) Patent No. **777786**

(54) Title
Camptothecin analogs and methods of preparation thereof

(51)⁶ International Patent Classification(s)
C07F 007/02

(21) Application No: 200031236 (22) Application Date: 1999.12.15

(87) WIPO No: W000/35924

(30) Priority Data

(31) Number	(32) Date	(33) Country
09/212178	1998.12.15	US

(43) Publication Date : 2000.07.03

(43) Publication Journal Date : 2000.08.31

(44) Accepted Journal Date : 2004.10.28

(71) Applicant(s)
University of Pittsburgh

(72) Inventor(s)
Dennis P. Curran; Hubert Josien; David Bom; Thomas G. Burke

(74) Agent/Attorney
Mallesons Stephen Jaques,Rialto,525 Collins Street,MELBOURNE
VIC 3000

(56) Related Art
WO 1998/007727
WO 1998/035940

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

31236/60


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07F 7/02	A1	(11) International Publication Number: WO 00/35924 (43) International Publication Date: 22 June 2000 (22.06.00)
(21) International Application Number: PCT/US99/29937 (22) International Filing Date: 15 December 1999 (15.12.99) (30) Priority Data: 09/212,178 15 December 1998 (15.12.98) US (71) Applicant: UNIVERSITY OF PITTSBURGH [US/US]; Cathedral of Learning, Pittsburgh, PA 15260 (US). (72) Inventors: CURRAN, Dennis, P.; 506 South Linden Avenue, Pittsburgh, PA 15208 (US). JOSIEN, Hubert; 5441 Washington Boulevard, Jersey City, NJ 07310 (US). BOM, David; 885 Mirror Street, Pittsburgh, PA 15217 (US). BURKE, Thomas, G.; 1227 Scoville Road, Lexington, KY 40502 (US). (74) Agent: BARTONY, Henry, E., Jr.; Bartony & Hare, Suite 1801, 429 Fourth Avenue, Pittsburgh, PA 15219 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report.

(54) Title: CAMPTOTHECIN ANALOGS AND METHODS OF PREPARATION THEREOF

(57) Abstract

A compound and a method of synthesizing a compound having general formula (1): wherein R^1 and R^2 are independently the same or different and are hydrogen, an alkyl group, an alkenyl group, a benzyl group, an alkynyl group, an alkoxy group, an aryloxy group, an acyloxy group, $-OC(O)OR^d$, wherein R^d is an alkyl group, a carbamoyloxy group, a halogen, a hydroxy group, a nitro group, a cyano group, an azido group, a formyl group, a hydrazino group, an acyl group, an amino group, $-SR^c$, wherein R^c is hydrogen, an acyl group, an alkyl group, or an aryl group, or R^1 and R^2 together form a group of the formula $-O(CH_2)_nO-$ wherein n represents the integer 1 or 2; R^3 is H, F, a halogen atom, a nitro group, an amino group, a hydroxy group, or a cyano group; or R^2 and R^3 together form a group of the formula $-O(CH_2)_nO-$ wherein n represents the integer 1 or 2; R^4 is H, a trialkylsilyl group, F, a C_{1-3} alkyl group, a C_{2-3} alkenyl group, a C_{2-3} alkynyl group, or a C_{1-3} alkoxy group; R^5 is a C_{1-10} alkyl group, an allyl group, a benzyl group or a propargyl group; and R^6 , R^7 and R^8 are independently a C_{1-10} alkyl group, a C_{2-10} alkenyl group, a C_{2-10} alkynyl group, an aryl group or a $-(CH_2)_nR^9$ group, wherein N is an integer within the range of 1 through 10 and R^9 is a hydroxy group, alkoxy group, an amino group, alkylamino group, a dialkylamino group, a halogen atom, a cyano group or a nitro group; and R^{11} is an alkylene group or an alkenylene group, and pharmaceutically acceptable salts thereof.



CAMPTOTHECIN ANALOGS AND METHODS OF PREPARATION THEREOF**Related Applications**

This application is a continuation-in-part application of United States Patent Application Serial No. 08/921,102, which is a continuation-in-part application of United States Patent Application Serial No. 08/436,799, which is a continuation-in-part application of United States Patent Application Serial No. 08/085,190, the disclosures of which are incorporated herein by reference.

Field of the Invention


The present invention relates to novel compounds and methods of preparation thereof, and, particularly, to silyl camptothecin derivatives or analogs and to methods of preparation of such silyl camptothecin analogs.

Background to the Invention


In this specification, where a document, act or item of knowledge is referred to or discussed, this reference or discussion is not an admission that the document, act or item of knowledge or any combination thereof was at the priority date (i) part of common general knowledge; or (ii) known to be relevant to an attempt to solve any problem with which this specification is concerned.

(20S)-Camptothecin (CPT, see below) and its derivatives are some of the most promising agents for the treatment of solid tumours by chemotherapy. See, for example, Wall, M.E. *et al*, *J. Ethnopharmacol.*, 51, 239 (1996); *Camptothecin: New Anticancer Agents*; Potmesil, M. and Pinedo, H., CRC, Boca Raton, FL (1995);


Bonnetterre, J., *Bull. Canc.*, 82, 623 (1995); Sinha, D. K., *Drugs*, 49, 11 (1995). This natural alkaloid was first isolated in 1966 from the extract of a Chinese plant, *Camptotheca accuminata*, by Wall. Wall, M. E. et al, *J. Am. Chem. Soc.*, 88, 3888 (1966). As depicted below, camptothecin has a fused ring system generally comprising a pyrrolo[3,4-b]quinoline system (rings ABC) fused to a 2-pyridone ring (ring D), which, in turn, is fused to a lactone ring (ring E).




(2S)-camptothecin, CPT
Rings are labeled A-E from left to right



topotecan, TPT



irinotecan, IRT



GI-147211C

10

SUBSTITUTE SHEET (RULE 26)

Camptothecin belongs to the family of topoisomerase I poisons. See, for example, Froelich-Ammon, S. J. et al., *J. Biol. Chem.*, 270, 21429 (1995). Research to date strongly suggests that this molecule acts by interfering with the unwinding of supercoiled DNA by the cellular enzyme topoisomerase I, an enzyme which is usually overexpressed in malignant cells. In the highly replicating cancer cells, this triggers a cascade of events leading to apoptosis and programmed death. See Slichenmyer, W. J. et al., *J. Natl. Cancer Inst.*, 85, 271 (1993). Recent advances at the molecular pharmacology level are reviewed in Pommier, Y. et al., *Proc. Natl. Acad. Sci. USA*, 92, 8861 (1995).

Camptothecin's initial clinical trials were limited by its poor solubility in physiologically compatible media. Moreover, early attempts to form a water-soluble sodium salt of camptothecin by opening the lactone ring with sodium hydroxide resulted in a compound having a poor antitumor activity. It was later reported that the closed lactone-form is an absolute requisite for antitumor activity. See Wani, M. C. et al., *J. Med. Chem.*, 23, 554 (1980). More recently, structure-activity studies have identified analogous compounds with better solubility and better antitumor activity. For example, topotecan (TPT) and irinotecan (IRT) have recently been approved for sale in the United States, while GI-147211C is in late stage clinical trials. These analogs are effective against a variety of refractory solid tumors such as malignant melanoma, stomach, breast, ovarian, lung and colorectal cancers, and seem particularly promising for the treatment of slow-dividing cancer lines. See, for example, Kingsbury, W. D. et al., *J. Med. Chem.*, 34, 98 (1991); Sawada, S. et al., *Chem.*

SUBSTITUTE SHEET (RULE 26)

Pharm. Bull., 39, 1446 (1991); Luzzio, M. J. et al., *J. Med. Chem.*, 38, 395 (1995); Abigerges, D. et al., *J. Clin. Oncol.*, 13, 210 (1995). Furthermore, synergistic or additive effects have been observed in combination
5 therapies with cisplatin, irradiation, or hyperthermia. See Fukuda, M. et al., *Canc. Res.*, 56, 789 (1996); Goldwasser, F. et al., *Clin. Canc. Res.*, 2, 687 (1996); Wang, D. S. et al., *Biol. Pharm. Bull.*, 19, 354 (1996).

Although most research has focused on the
10 development of water-soluble derivatives of camptothecin, new formulations, such as lipid-complexation, liposomal encapsulation, and wet milling technology have recently been developed. Such formulations result in new therapeutic opportunities for poorly water-soluble
15 camptothecins. See Daoud, S. S. et al., *Anti-Cancer Drugs*, 6, 83 (1995); Merisko-Liversidge, E. et al., *Pharm. Res.*, 13, 272 (1996); and Pantazis, P., *Leukemia Res.*, 19, 775 (1995). An attractive feature of these formulations is their impact on drug biodistribution.
20 Sugarman and coworkers have recently reported that while free camptothecin achieves the greatest concentration in the pulmonary parenchyma, lipid-complexed camptothecin has the highest concentration in the gastrointestinal tract. These results open new and interesting
25 perspectives for the treatment of colon cancer. See Sugarman, S. M. et al., *Canc. Chemother. Pharmacol.*, 37, 531 (1996). Another interesting aspect of using insoluble camptothecin analogs is that they are usually more active than their water-soluble congeners and seem
30 less likely to create drug-induced resistance, probably because they are not substrates of the p-glycoprotein multi-drug transporter. See Pantazis, P., *Clin. Canc. Res.*, 1, 1235 (1995).

SUBSTITUTE SHEET (RULE 26)

In this context, new camptothecin analogs that combine good to excellent anti-tumor activities with different solubility and biodistribution profiles could play a crucial role in the therapeutic arsenal for the treatment of various types of cancers.

Given the proven beneficial biological activity of camptothecin and analogs thereof, it is desirable to develop additional camptothecin analogs and methods of preparation of camptothecin analogs.


10

Summary of the Invention

The present invention provides generally a compound having the following formula (1):



The present invention also provides a method of




synthesizing compounds having the formula (2):


SUBSTITUTE SHEET (RULE 26)

6

via a 4+1 radical annulation/cyclization wherein the precursor



is reacted with an aryl isonitrile having the formula



5

R^1 and R^2 are independently the same or different and are preferably hydrogen, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an aryloxy group, an acyloxy group, $-OC(O)OR^d$, wherein R^d is an alkyl group, a carbamoyloxy group, a halogen, a hydroxy group, a nitro group, a cyano group, an azido group, a formyl group, a hydrazino group, an acyl group ($-C(O)R^f$ wherein R^f is preferably an alkyl group, an alkoxy group, an amino group or a hydroxy group), an amino group, $-SR^c$, wherein, R^c is hydrogen, an acyl group, an alkyl group, or an aryl group, or R^1 and R^2 together form a group of the formula $-O(CH_2)_nO-$ wherein n represents the integer 1 or 2.

R^3 is preferably H, a halogen, a nitro group, an amino group, a hydroxy group, or a cyano group. R^2 and R^3 can also together form a group of the formula $-O(CH_2)_nO-$ wherein n represents the integer 1 or 2.

SUBSTITUTE SHEET (RULE 26)

R⁴ is preferably H, F, a trialkylsilyl group, a C₁-3 alkyl group, a C₂-3 alkenyl group, a C₂-3 alkynyl group, or a C₁-3 alkoxy group. R⁵ is preferably a C₁-10 alkyl group. A preferred alkyl group is an ethyl group.

5 Preferred substituted alkyl groups for R⁵ include an allyl group, a propargyl and a benzyl group.


R⁶, R⁷ and R⁸ preferably are independently (the same or different) a C₁-10 alkyl group, a C₂-10 alkenyl group, a C₂-10 alkynyl group, or an aryl group. A

10 preferred substituted alkyl group for R⁶, R⁷ and R⁸ is a -(CH₂)_NR⁹ group, wherein N is an integer within the range of 1 through 10 and R⁹ is a hydroxy group, an alkoxy group, an amino group, a halogen atom, a cyano group or a nitro group. Preferred amino groups for R⁹ include

15 alkylamino groups and a dialkylamino groups.

R¹¹ is preferably an alkylene group, an alkenylene or an alkynylene group. R¹² is preferably -CH=CH-CH₂- or -C≡C-CH₂-. X is preferably Cl, Br or I. More preferably, X is Br or I. Most preferably, X is Br.

The present invention also provides a compound having the formula (2):




wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ and R¹¹ are as defined

20 prior to this paragraph. The present invention further


SUBSTITUTE SHEET (RULE 26)

provides a compound of the above formula wherein one of R^1 , R^2 , R^3 , and R^4 is not H. The present invention still further provides a compound of the above formula wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 and R^{11} are as defined prior to this paragraph and wherein R^5 is a methyl group, a C3-10 alkyl group, an allyl group, a benzyl group or a propargyl group.

The present invention further provides a compound having the following formula (3):



The present invention further provides a compound having the following formula (4):



The terms "alkyl", "aryl" and other groups refer generally to both unsubstituted and substituted groups unless specified to the contrary. Unless otherwise specified, alkyl groups are hydrocarbon groups

SUBSTITUTE SHEET (RULE 26)

and are preferably C₁-C₁₅ (that is, having 1 to 15 carbon atoms) alkyl groups, and more preferably C₁-C₁₀ alkyl groups, and can be branched or unbranched, acyclic or cyclic. The above definition of an alkyl group and other
5 definitions apply also when the group is a substituent on another group (for example, an alkyl group as a substituent of an alkylamino group or a dialkylamino group). The term "aryl" refers to phenyl or naphthyl. As used herein, the terms "halogen" or "halo" refer to
10 fluoro, chloro, bromo and iodo.

The term "alkoxy" refers to -OR^d, wherein R^d is an alkyl group. The term "aryloxy" refers to -OR^e, wherein R^e is an aryl group. The term acyl refers to -C(O)R^f. The term "alkenyl" refers to a straight or
15 branched chain hydrocarbon group with at least one double bond, preferably with 2-15 carbon atoms, and more preferably with 3-10 carbon atoms (for example, -CH=CHR^g). The term "alkynyl" refers to a straight or branched chain hydrocarbon group with at least one triple bond,
20 preferably with 2-15 carbon atoms, and more preferably with 3-10 carbon atoms (for example, -C≡CR^h). The terms "alkylene," "alkenylene" and "alkynylene" refer to bivalent forms of alkyl, alkenyl and alkynyl groups, respectively.

25 The groups set forth above, can be substituted with a wide variety of substituents to synthesize camptothecin analogs retaining activity. For example, alkyl groups may preferably be substituted with a group or groups including, but not limited to, a benzyl group,
30 a phenyl group, an alkoxy group, a hydroxy group, an amino group (including, for example, free amino groups, alkylamino, dialkylamino groups and arylamino groups), an

SUBSTITUTE SHEET (RULE 26)

alkenyl group, an alkynyl group and an acyloxy group. In the case of amino groups ($-NR^aR^b$), R^a and R^b are preferably independently hydrogen, an acyl group, an alkyl group, or an aryl group. Acyl groups may preferably be substituted with (that is, R^f is) an alkyl group, a haloalkyl group (for example, a perfluoroalkyl group), an alkoxy group, an amino group and a hydroxy group. Alkynyl groups and alkenyl groups may preferably be substituted with (that is, R^g and R^h are preferably) a group or groups including, but not limited to, an alkyl group, an alkoxyalkyl group, an amino alkyl group and a benzyl group.

The term "acyloxy" as used herein refers to the group $-OC(O)R^d$.

The term "alkoxycarbonyloxy" as used herein refers to the group $-OC(O)OR^d$.

The term "carbamoyloxy" as used herein refers to the group $-OC(O)NR^aR^b$.

Amino and hydroxy groups may include protective groups as known in the art. Preferred protective groups for amino groups include *tert*-butyloxycarbonyl, formyl, acetyl, benzyl, *p*-methoxybenzyloxycarbonyl, trityl. Other suitable protecting groups as known to those skilled in the art are disclosed in Greene, T., Wuts, P.G.M., *Protective Groups in Organic Synthesis*, Wiley (1991), the disclosure of which is incorporated herein by reference.

In general, R^1 , R^2 , R^3 , R^6 , R^7 and R^8 are preferably not excessively bulky to maintain activity of

SUBSTITUTE SHEET (RULE 26)

the resultant camptothecin analog. Preferably, therefore, R¹, R², R³, R⁶, R⁷ and R⁸ independently have a molecular weight less than approximately 250. More preferably R¹, R², R³, R⁶, R⁷ and R⁸ independently have a
5 molecular weight less than approximately 200.

Some of the camptothecin analogs of the present invention can be prepared for pharmaceutical use as salts with inorganic acids such as, but not limited to, hydrochloride, hydrobromide, sulfate, phosphate, and
10 nitrate. The camptothecin analogs can also be prepared as salts with organic acids such as, but not limited to, acetate, tartrate, fumarate, succinate, citrate, methanesulfonate, p-toluenesulfonate, and stearate. Other acids can be used as intermediates in the
15 preparation of the compounds of the present invention and their pharmaceutically acceptable salts.

For purification, administration or other purposes, the E-ring (the lactone ring) may be opened with alkali metal such as, but not limited to, sodium
20 hydroxide or calcium hydroxide, to form opened E-ring analogs of compounds of formula (1) as set forth in the compounds of formula (4). The intermediates thus obtained are more soluble in water and may be purified to produce, after treatment with an acid, a purified form of
25 the camptothecin analogs of the present invention.

The E-ring may also be modified to produce analogs of compounds of formula (1) with different solubility profiles in water or other solvents. Methods to achieve this goal include, but are not limited to,
30 opening the E-ring with hydroxide or a water-soluble amino group or functionalizing the hydroxy group at

SUBSTITUTE SHEET (RULE 26)

position 20 of the E-ring with a water-soluble group such as a polyethylene glycol group. The analogs thus prepared act as pro-drugs. In other words, these analogs regenerate the compounds of formula (1) (with the closed
5 E-ring structure) when administered to a living organism. See, Greenwald, R.B. et al., *J. Med. Chem.*, 39, 1938 (1996).

The analogs of the present invention are highly lipophilic and have been shown to enhance activity both
10 in vivo and in vitro. Moreover, their A-ring substitution(s) have been shown to enhance blood stability.

The present invention also provides a method of treating a patient, which comprises administering a
15 pharmaceutically effective amount of a compound of formulas (1) and/or (2) or a pharmaceutically acceptable salt thereof. The compound may, for example, be administered to a patient afflicted with cancer and/or leukemia by any conventional route of administration,
20 including, but not limited to, intravenously, intramuscularly, orally, subcutaneously, intratumorally, intradermally, and parenterally. The pharmaceutically effective amount or dosage is preferably between 0.01 to 60 mg of one of the compounds of formulas (1) and (2) per
25 kg of body weight. More preferably, the pharmaceutically effective amount or dosage is preferably between 0.1 to 40 mg of one of the compounds of formulas (1) and (2) per kg of body weight. In general, a pharmaceutically effective amount or dosage contains an amount of one of
30 the compounds of formulas (1) and (2) effective to display antileukemic and/or antitumor (anticancer) behavior. Pharmaceutical compositions containing as an

SUBSTITUTE SHEET (RULE 26)

active ingredient of one of the compounds of formulas (1) and (2) or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier or diluent are also within the scope of the present invention.

The present invention also provides a pharmaceutical composition comprising any of the compounds of formulas (1) and (2) and a pharmaceutically acceptable carrier. The composition may, for example, contain between .1 mg and 3 g, and preferably between approximately .1 mg and 500 mg of the compounds of formulas (1), (2) and/or (4), and may be constituted into any form suitable for the mode of administration.

Brief Description of the Drawings

Figure 1 is an illustration of a general synthetic scheme for the preparation of compounds of formula (1).

Figure 2 is an illustration of a synthesis of (20S)-11-fluoro-7-trimethylsilylcamptothecin.

Figure 3 is an illustration of a synthesis of (20S)-10-acetoxy-7-trimethylsilylcamptothecin and (20S)-10-hydroxy-7-trimethylsilylcamptothecin.

Figure 4 is an illustration of a synthesis of (20S)-10-amino-7-trimethylsilylcamptothecin.

Figure 5 is an illustration of a synthesis of (20S)-10-amino-11-fluoro-7-trimethylsilylcamptothecin.

SUBSTITUTE SHEET (RULE 26)

14

Figure 6 is an illustration of a synthesis of a novel analog of irinotecan.

Figure 7 is an illustration of three representative silylcamptothecin analogs of formula (2).

5 Figure 8 is an illustration of the synthesis of a propargyl bromide precursor.

Figure 9 is an illustration of the synthesis of a radical precursor of formula (3).

10 Figure 10 is an illustration of the reaction of the radical precursor of Figure 9 with three isonitriles.

Figure 11 is an illustration of the final step of the synthesis of the representative silylcamptothecin analogs of Figure 7.

15 Figure 12 is an illustration of excitation and emission fluorescence spectra of 1 μ M (20S)-7-[(2-trimethylsilyl)ethyl]camptothecin, 7-TMSEt CPT, (36c) (DB-172).

20 Figure 13 is an illustration of emission fluorescence spectra of 1 μ M (20S)-10-amino-7-[(2-trimethylsilyl)ethyl]camptothecin, 10-NH₂-7-TMSEt CPT (DB-173).

25 Figure 14 is an illustration of emission fluorescence spectra of 1 μ M (20S)-10-hydroxy-7-[(2-trimethylsilyl)ethyl]camptothecin, 10-OH-7-TMSEt CPT (DB-174).

SUBSTITUTE SHEET (RULE 26)

15

Figure 15 is an illustration of fluorescence spectra of 1 μ M (20S)-10-hydroxy-7(*tert*-butyldimethylsilyl)camptothecin, 10-OH-7-TBS CPT (DB-67) in ethanol, 0.29 M DMPG and PBS.

5 Figure 16 is an illustration of equilibrium binding of camptothecin analogs to DMPC.

Figure 17 is an illustration of equilibrium binding of highly lipophilic camptothecin analogs of the present invention to DMPC.

10 Figure 18 is an illustration of equilibrium binding of highly lipophilic camptothecin analogs of the present invention to DMPG.

Figure 19 is an illustration of double-reciprocal plots for the binding of highly lipophilic camptothecin analogs of the present invention to DMPC
15 small unilamellar vesicles (SUVs) at 37°C.

Figure 20 is an illustration of double-reciprocal plots for the binding of highly lipophilic camptothecin analogs of the present invention to DMPG
20 SUVs at 37°C.

Figure 21 is an illustration of the stability of DB-172 in PBS buffer pH 7.4 at 37°C.

Figure 22 is an illustration of the dependence of fluorescence intensity of DB-172 on time and drug
25 concentration.

SUBSTITUTE SHEET (RULE 26)

16

Figure 23 is an illustration of the fluorescence intensity of DB-172 in dependence on time and concentration.

Figure 24 is an illustration of the dependence of the total fluorescence intensity on time and pH for the carboxylate form of DB-172.

Figure 25 is an illustration of the dependence of total fluorescence intensity on time for several camptothecin analogs of the present invention.

Figure 26 is an illustration of the drug stability of several camptothecin analogs of the present invention in phosphate buffered saline (PBS) and human blood.

Figure 27 is an illustration of the drug stability of several camptothecin analogs of the present invention in PBS, whole blood and PBS/human serum albumin (HSA).

Figure 28 is an illustration of the plasma concentration of DB-67 after oral dosage.

Detailed Description of the Invention

Compounds

Among the compounds of formulas (1) and (2), those having the (S)-configuration at position 20 of the E-ring are preferred for pharmaceutical use.

SUBSTITUTE SHEET (RULE 26)

R¹ and R² are preferably and independently (the same or different) H, a hydroxy group, a halo group, an amino group, a nitro group, a cyano group, a C₁₋₃ alkyl group, a C₁₋₃ perhaloalkyl group, a C₁₋₃ alkenyl group, a C₁₋₃ alkynyl group, a C₁₋₃ alkoxy group, a C₁₋₃ aminoalkyl group, a C₁₋₃ alkylamino group, a C₁₋₃ dialkylamino group, or R¹ and R² together form a group of the formula -O(CH₂)_nO- wherein n represents the integer 1 or 2. More preferably, R¹ and R² are independently (the same or different) H, a methyl group, an amino group, a nitro group, a cyano group, a hydroxy group, a hydroxymethyl group, a methylamino group, a dimethylamino group, an ethylamino group, a diethylamino group, an aminomethyl group, a methylaminomethyl group, a dimethylaminomethyl group, and the like.

R³ is preferably F, an amino group, or a hydroxy group. R⁴ is preferably H, a trialkylsilyl group or F. R⁵ is preferably an ethyl group. R⁶, R⁷ and R⁸ are preferably independently (the same or different) a C₁₋₆ alkyl group, a phenyl group or a -(CH₂)_NR¹⁰ group, wherein N is an integer within the range of 1 through 6 and R¹⁰ is a halogen or a cyano group.

Method of Preparation

The compounds of formula (1) of the present invention can be prepared according to the general synthetic scheme shown in Figure 1. In the synthetic scheme of Figure 1, an iodopyridone (2) is first N-alkylated with a propargyl derivative (3) to produce radical precursor (4). Radical precursor (4) then undergoes a radical cascade with arylisonitrile (5) to

SUBSTITUTE SHEET (RULE 26)

generate product (1). The *N*-alkylation proceeds smoothly following optimized conditions. See Curran, D.P. et al., *Tetrahedron Lett.*, 36, 8917 (1995), the disclosure of which is incorporated herein by reference. The synthesis of iodopyridone (2) and the conditions of the radical cascade have been previously reported. The propargylating agent (3) is readily prepared by the standard silylation of the dianion of propargyl alcohol with a suitable silylating agent $R^6R^7R^8SiX$ followed by conversion of the propargyl alcohol to a leaving group such as a bromide, iodide or sulfonate. See Curran, D.P. et al., *Angew. Chem. Int. Ed. Engl.*, 34, 2683 (1995), the disclosure of which is incorporated herein by reference, and U.S. Patent Application Serial No. 08,436,799, filed May 8, 1995, the disclosures of which are incorporated herein by reference.

Generally, various reagents can be used in the radical cascade including, but not limited to, hexamethylditin, hexamethyldisilane, or tetrakis(trimethylsilyl)silane. The source of energy for this reaction can be a sun lamp or an ultraviolet lamp. The temperature is preferably set between approximately 25 and 150°C. More preferably, the temperature is set at approximately 70°C. There are generally no limitations upon the choice of solvent used other than inertness to the radical cascade. Preferred solvents include benzene, toluene, acetonitrile, THF and tert-butanol. Also, there is very broad latitude in the choice of substituents on the alkyne and the isonitrile because of the mildness of the reaction conditions.

Figure 2 illustrates an embodiment of a general synthetic scheme for the synthesis of (20*S*)-11-fluoro-7-

SUBSTITUTE SHEET (RULE 26)

trimethylsilylcamptothecin (**12**). A problem in this synthetic scheme is to control the regioselectivity of the radical cascade when both *ortho* positions in the arylisonitrile are available for cyclization (that is, R⁴ is H in the final compound of formula (1)). One solution to this problem relies upon the introduction of a trimethylsilyl group on the aryl isonitrile, (e.g. 3-fluoro-2-trimethylsilylphenyl isonitrile (**9**)). The trimethylsilyl substituent blocks one of the *ortho* sites of the isonitrile toward cyclization and can be removed after the cascade reaction by hydrodesilylation. In this example, the selectivity proceeds further in the sense that only one of the trimethylsilyl groups is removed in the last step.

Other embodiments of the general synthetic scheme for the preparation of several novel camptothecin derivatives of formula (1) are illustrated in Figures 3 to 6, and in the Examples.

The preparation of the compounds of formula (2) is illustrated in Figures 7 through 11. In that regard, three representative, novel A,B ring substituted silylcamptothecin compounds (**36a**), (**36b**), and (**36c**) are illustrated in Figure 7.

The first step in the synthesis of these analogs was to prepare propargyl bromide (**41**) as illustrated in Figure 8. Swern oxidation of the commercially available trimethylsilylpropanol (**37**) gave trimethylsilylpropanal (**38**) in 85% yield. Sakar, T.K. et al., *Tetrahedron* 46, 1885 (1990). Following procedure A of Corey, E.J. and Fuchs, P.L., *Tetrahedron Lett.*, 36, 3769 (1972), aldehyde (**38**) was converted to the

SUBSTITUTE SHEET (RULE 26)

dibromoolefin (39) in 55% yield. Piers, E. and Gaval, A.V., *J. Org. Chem.*, 55, 2374 (1990). Addition of 2 equivalents of n-BuLi at -78°C in THF followed by warming to 22°C and the quenching with paraformaldehyde at reflux to give (40) in 84% yield. Finally, a solution of triphenylphosphine and Br₂ in anhydrous CH₂Cl₂ gave the propargyl bromide (41) in 87% yield.

With the preparation of propargyl bromide (41) completed, radical precursor (43) was prepared as illustrated in Figure 9. Following an *N*-alkylation procedure, (42) was alkylated with (41) to give the desired radical precursor (43) in 74 % yield. Reaction of (43) with the respective isonitrile (44a) or (44b) gave the protected silylcamptothecin derivatives (45a) and (45b) in 55% and 56% yields, respectively, as illustrated in Figure 10. Finally, deprotection of (45a) with 2 equivalents of K₂CO₃ in MeOH/H₂O solution gave a 47% yield of the 10-hydroxy derivative (36a) as illustrated in Figure 10. Finally, treatment with trifluoroacetic acid in CH₂Cl₂ converted (45b) to the 10-amino derivative (36b) in 65% yield.

The method of the present invention also provides ready synthesis of (20*S*)-7-[(2-trimethylsilyl)ethyl]camptothecin (36c, Figure 7). Reaction of phenyl isonitrile with iodo pyridone (43) gives this derivative in 52% yield (Figure 10). The (20*S*)-7-[(2-trimethylsilyl)ethyl]camptothecin (36c) and (20*S*)-7-(2-trimethylsilyl)camptothecin (disclosed in U.S. Patent Application Serial No. 08/436,799) structures have recently been described by Hausheer et al. in International Patent Application Publication Number

SUBSTITUTE SHEET (RULE 26)

WO 98/07727. It appears that the characterization information regarding these compounds set forth in International Patent Application Publication Number WO 98/07727 is not correct. Specifically, the spectroscopic data provided for both of these compounds are inconsistent with the assigned structures and do not match in any respect the spectroscopic data reported in the examples of this patent. Additionally, the spectroscopic data for all of the silyl-containing camptothecins in WO 98/07727 appear to be inconsistent with the assigned structures.


The present invention thus provides a short and efficient synthetic scheme well suited to known structure-activity relationships in the camptothecin family. Indeed, the biological activity of the camptothecin skeleton is generally intolerant or has very little tolerance to substituents other than at the 7 and/or 9-11 positions. Following synthesis, these substituents are introduced via the alkynylderivative (3) and arylisonitrile (5), respectively.

Antitumor Activities and Human Blood Stability Characteristics

The antitumor activities of several compounds of formula (1) are shown in Table 1 and compared to those of several well known camptothecin analogs using several known assays as described further below. The syntheses of the various exemplary compounds of the present invention set forth in Table 1 are discussed in further detail in an Example section following this section.

SUBSTITUTE SHEET (RULE 26)

Table 1. Biological Activities of
(20S)-7-Silyl-Camptothecin Derivatives.

Ex.	γ^a					Inhibition of cancer cell growth IC ₅₀ (nM)			Enhancement of Topo I Mediated DNA Cleavage	Inhibition of Topo I mediated DNA relaxation
		9	10	11	12	HL-60	833K	DC-3F		
CPT	H	H	H	H	H	5	10	6-9	+++	+++
IRT	Et	H	OPP ^a	H	H	270	487	372	—	—
1	TMS	H	H	H	H	3.8	5.6	4.2	++++	+++
2	TBDMS	H	H	H	H	0.12	1.2	2.9	++++	+++
3	TBDPS	H	H	H	H	339	243	663	++	+
4	TMS	H	OAc	H	H	2.7	—	6.7	++++	+++++
5	TMS	H	OH	H	H	2.6	7.0	6.9	++++	+++++
5a	Example 5 with opened E ring					9.7	15.0	14.2	+++	+
6	TMS	H	OPP ^a	H	H	66	214	256	—	—
7	TMS	H	H	F	H	0.75	0.92	2.0	++++	+++++
7a	TMS	F	H	H	H	3.0	2.9	8.2	++++	++++
	TMS	H	H	F	H (2:1)	—	—	—	—	—
8	TMS	H	NH ₂	H	H	0.52	5.7	0.72	—	—
9	TMS	H	H	NH ₂	H	2.6	7.4	6.4	—	—
10	TMS	H	NH ₂	F	H	0.07	0.14	0.29	++++	++++
11	TMS	H	H	F	F	1.01	2.1	2.5	+++	+++
	TMS	F	F	H	H (3/1)	—	—	—	—	—
12	TIPS	H	H	H	H	1506	10730	1038	—	—
13	TES	H	H	H	H	31.9	122	57.1	—	—
14	DMNPS	H	H	H	H	66.9	197	64.1	—	—
15	DMCPS	H	H	H	H	0.91	2.7	2.7	—	—
16	DMHPS	H	H	H	H	2.1	5.4	2.3	—	—
17	TBDMS	H	OAc	H	H	1.86	—	3.57	—	—
18	TBDMS	H	OH	H	H	2.60	—	5.20	—	—

- 5 a) OPP = irinotecan's pyrrolidinyl pyrrolidine carbamate; TMS = trimethylsilyl; TBDMS = t-butyldimethylsilyl; TBDPS = t-butyldiphenyl silyl; TES = triethylsilyl; TIPS = trisopropylsilyl; DMNPS = dimethylnorpinylsilyl; DMCPS = dimethyl-3-cyanopropylsilyl; DMHPS = dimethyl-3-halopropylsilyl; b) More active than CPT in S-180 in BD₂F₁ mice testing. c) More active than CPT in Lewis lung Carcinoma in BD₂F₁ mice. The designation "—" means "not determined."

SUBSTITUTE SHEET (RULE 26)

As illustrated in Table 1, the compounds of the present invention exhibit good to excellent antitumor activity as compared to camptothecin (CPT) and irinotecan (IRT).

Cytotoxicity Assays

5 The camptothecin derivatives were evaluated for their cytotoxic effects on the growth of HL-60 (human promyelocytic leukemic), 833K (human teratocarcinoma) and DC-3F (hamster lung) cells *in vitro*. The cells were cultured in an initial density of 5×10^{-4} cell/ml. They
10 were maintained in a 5% CO₂ humidified atmosphere at 37°C in RPMI-1640 media (GIBCO-BRL Grand Island, New York) containing penicillin 100u/ml/streptomycin (100 µg/ml) (GIBCO-BRL) and 10% heat inactivated fetal bovine serum. The assay was performed in duplicate in 96-well
15 microplates. The cytotoxicity of the compounds toward HL-60 cells following 72 hr incubation was determined by XTT-microculture tetrazolium assay. Scudiero, D.A., et al., *Cancer Res.*, 48, 4827 (1988), the disclosure of which is incorporated herein by reference. 2',
20 3'-bis(-methoxy-4-nitro-5-sulpheny)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) was prepared at 1 mg/ml in prewarmed (37°C) medium without serum. Phenazine methosulfate (PMS) and fresh XTT were mixed together to obtain 0.075 mM PMS-XTT
25 solution (25 µl of the stock 5 mM PMS was added per 5 ml of 1 mg/ml XTT). Fifty µl of this mixture was added to each well of the cell culture at the end of 72 hr incubation. After incubation at 37°C for 4 hr., absorbance at 450 nm and 630 nm was measured with a
30 microplate reader (EL340, Bio-Tek Instruments, Inc., Winooski, Vermont).

SUBSTITUTE SHEET (RULE 26)

The cytotoxicity of the camptothecin compounds toward 833K teratocarcinoma solid tumor cells and DC-3F hamster lung cells was determined in 96-well microplates by a method described by Skehan et al. for measuring cellular protein content. Skehan et al., "New Colorimetric Cytotoxicity Assay for Anticancer Drug Screening," *J. Nat'l Cancer Inst.*, 82, 1107 (1990), the disclosure of which is incorporated herein by reference. Cultures were fixed with trichloroacetic acid and then stained for 30 minutes with 0.4% sulforhodamine B dissolved in 1% acetic acid. Unbound dye was removed by acetic acid washes, and the protein-bound dye was extracted with an unbuffered Tris base [tris(hydroxy-methyl)aminomethan] for determination of absorbance at 570 nm in a 96-well microplate reader. The experiments were carried out in duplicate using five to six concentrations of the drugs tested. Data were analyzed via computer software. See, Chou, J, and Chou, T.C., *Dose-Effect Analysis With Microcomputers: Quantitation of ED₅₀, LD₅₀, Synergism, Antagonism, Low-Dose Risk, Receptor-Ligand Binding and Enzyme Kinetics*, 2nd ed., Biosoft, Cambridge (1987); and Chou, T.C., "The Median-Effect Principle and the Combination Index for Quantitation of Synergism and Antagonism," *Synergism and Antagonism in Chemotherapy*, Academic Press, San Diego, 61-102 (1991), the disclosures of which are incorporated herein by reference.

Topo I Mediated DNA Cleavage Assay

For DNA cleavage assay the reaction mixture comprised Tris-HCl buffer 10 mM, pH7.5; PBR₃₂₂ supercoiled double stranded circular DNA (4363 base pairs, from Boehringer Mannheim Biochemicals) 0.125 µg/ml, drug

SUBSTITUTE SHEET (RULE 26)

(camptothecin or its derivatives) concentration at 1, 10 and 100 μ M, in the presence of purified DNA topoisomerase I with final volume of 20 μ l as described previously. Hsiang, Y.H., et al., "Camptothecin Induces Protein-Linked DNA Breaks Via Mammalian DNA Topoisomerase I," *J. Biol. Chem.*, 260, 14873 (1985), the disclosure of which is incorporated herein by reference. Incubation was carried out at 37°C for 60 min. The reaction was stopped by adding the loading buffer dye (2% sodium dodesyl sulfate, 0.05% bromophenol blue and 6% glycerol). Electrophoresis was carried out on 1% agarose gel plus ethidium bromide (1 μ g/ml) in TBE buffer (Tris-base-boric acid-EDTA) and ran at 25 V for 18 hrs. Photographs were taken under UV light using Polaroid film type 55/N and developed as indicated by the manufacturer.

Inhibition of Topo I Mediated Relaxation of Supercoiled DNA

To study the inhibiting effect on DNA topoisomerase I mediated relaxation of DNA, the method described by Liu and Miller was used. Liu, H.F. et al., "Cleavage of DNA by Mammalian DNA Topoisomerase II," *J. Biol. Chem.*, 258, 15365 (1980), the disclosure of which is incorporated herein by reference. For this assay, 0.18 μ g of PBR₃₂₂ DNA, 0.5 U of Topo I (GIBCO-BRL), various concentrations (1-100 μ M of camptothecin or an analog, in a reaction mixture (20 μ l) containing 50 mM Tris-HCl, pH 7.5, 120 mM KCl, 10 mM MgCl₂, 0.5 mM DTT, 0.5 mM EDTA, 30 μ g/ml BSA, 20 μ g/ml PBR₃₂₂ DNA and various amounts of the enzyme was incubated at 37°C for 30 min., and stopped with 5% SBS and 150 μ g/ml proteinase K. The samples were loaded onto 1% agarose in TAE running

SUBSTITUTE SHEET (RULE 26)

buffer, electrophoresed overnight at 39 V, stained with EtBr, and photographed under UV light.

Antitumor Activity in vivo

Antitumor activities of camptothecin derivatives were tested in B₆D₂F₁ mice bearing sarcoma-180 or Lewis lung murine solid tumor. For S-180, 3 x 10⁶ cells were inoculated subcutaneously on day 3. Antitumor treatment started on day 1 intraperitoneously twice daily for five days. Tumor volumes on day 7 and day 14 were measured. Average tumor volumes were described as the ratio of treated versus untreated control (T/C). The control (treated with DMSO vehicle only) tumor volumes for day 7 and day 14 were 0.11 cm³ and 0.61 cm³, respectively. The T/C camptothecin is designated with "+++" An increment or decrement of 10% as compared to the camptothecin T/C on day 14 at 2 mg/kg dosage is designated with increase or decrease of one "+" unit, respectively.

For Lewis lung carcinoma, tumor cells (1 x 10⁶) were inoculated subcutaneously on day 0 and treatment started on day 1, intraperitoneously twice daily for five days. The grading of effects was as described above.

As shown Table 1, many of the camptothecin derivatives of formula (1) tested for the antitumor cytotoxicity *in vitro* exhibited higher potency than camptothecin in one to three cell lines. Most of those compounds exhibiting higher antitumor cytotoxicity also exhibited higher potency in enhancing the DNA-topoisomerase I-mediated cleavage of PBR₃₂₂ DNA, or in inhibiting the DNA-topoisomerase I-mediated relaxation of

SUBSTITUTE SHEET (RULE 26)

PBR₃₂₂ DNA. These results suggest excellent correlation between the antitumor cytotoxicity of the camptothecin compounds with their ability to inhibit the functions of DNA-topoisomerase I.

5 For in vivo chemotherapeutic effects in tumor-bearing mice, for example, 7-trimethylsilyl camptothecin showed better activity than camptothecin against sarcoma 180 in B₆D₂F₁ mice at several equivalent doses in a dose dependent manner in terms of tumor volume
10 reduction. Similarly, for Lewis lung carcinoma, 7-trimethylsilyl-11-fluoro camptothecin exhibited a similar antitumor effect to camptothecin in terms of tumor volume reduction at 4-fold lower doses than camptothecin. Thus, 7-trimethylsilyl-11-fluoro
15 camptothecin is more efficacious than camptothecin in its antitumor effects in vivo.

Stability in Human Blood

Recently the intrinsic fluorescent emissions from the lactone and carboxylate forms of camptothecin
20 have been studied to elucidate their markedly different interactions with human blood components. Burke, T. G. and Mi, Z., "Ethyl substitution at the 7 position extends the half-life of 10-hydroxycamptothecin in the presence of human serum albumin," *J. Med. Chem.* **36**: 2580-2582
25 (1993); Burke, T. G., Mishra, A. K., Wani, M. C. and Wall, M. E., "Lipid bilayer partitioning and stability of camptothecin drugs," *Biochemistry.* **32**: 5352-5364 (1993); Burke, T.G. and Mi, Z.: "Preferential Binding of the Carboxylate Form of Camptothecin by Human Serum Albumin,"
30 (1993) *Anal. Biochem.* **212**, 285-287; Burke, T.G. and Mi, Z., "The Structural Basis of Camptothecin Interactions

SUBSTITUTE SHEET (RULE 26)

- with Human Serum Albumin: Impact on Drug Stability," (1994) *J. Med. Chem.* 37, 40-46; Burke, T.G. Munshi, C.B., Mi, Z., and Jiang, Y., "The Important Role of Albumin in Determining the Relative Human Blood Stabilities of the Camptothecin Anticancer Drugs," (1995) *J. Pharma. Sci.* 84, 518-519; Mi, Z. and Burke, T.G., "Differential Interactions of Camptothecin Lactone and Carboxylate Forms with Human Blood Components," (1994) *Biochemistry*, 33, 10325-10336; Mi, Z. and Burke, T.G., "Marked Interspecies Variations Concerning the Interactions of Camptothecin with Serum Albumins: A Frequency-Domain Fluorescence Spectroscopic Study," (1994) *Biochemistry* 33, 12540-12545; Mi, Z., Malak, H., and Burke, T.G., "Reduced Albumin Binding Promotes the Stability and Activity of Topotecan in Human Blood," (1995) *Biochemistry*, 34, 13722-13728, the disclosures of which are incorporated herein by reference.

In phosphate buffered saline (PBS) at pH 7.4, frequency-domain fluorescence lifetime spectroscopy reveals that human serum albumin (HSA) preferentially binds the carboxylate form of camptothecin with a 200-fold higher affinity than the lactone form. These interactions result in camptothecin opening more rapidly and completely in the presence of HSA than in the absence of the protein. In human plasma, pH 7.4 and 37 °C, camptothecin lactone opens rapidly and completely to the carboxylate form with a $t_{1/2}$ value of 11 min and an almost negligible % lactone at equilibrium value of 0.2%. In whole blood versus plasma, camptothecin displayed enhanced stability ($t_{1/2}$ value of 22 min and a % lactone at equilibrium value of 5.3 %). The enhanced stability of camptothecin lactone in human blood was found to be due to drug associations with the lipid bilayers of red blood cells. Camptothecin binds erythrocyte membranes,

SUBSTITUTE SHEET (RULE 26)

the drug localizes within the acyl chain region, and accordingly remains protected from hydrolysis.

The human blood stabilities of the several camptothecin analogues of clinical interest have been compared. As was observed in the case of camptothecin, 9-aminocamptothecin was observed to hydrolyze almost completely (>97 %) in PBS solution containing HSA. Although no attempt was made to spectroscopically quantify the relative binding affinities of the lactone and carboxylate forms of the 9-amino congener due to their significantly reduced fluorescence quantum yields relative to camptothecin, HPLC data were consistent with HSA preferentially binding the carboxylate form of this agent over its lactone form. In plasma it was observed that >99.5% of the 9-amino analog converted to carboxylate, a finding which again closely parallels stability data obtained using camptothecin. In whole blood, < 0.5% and 5.3% are the fractions of 9-aminocamptothecin and camptothecin, respectively, which remained in the lactone form at equilibrium. The approximately 10-fold higher level of lactone remaining at equilibrium for camptothecin relative to 9-aminocamptothecin may, in part, be accounted for by the enhanced lipophilicity and greater ability of camptothecin to transition from the aqueous environment and into erythrocyte membranes present in whole blood.

In stark contrast to the low levels of lactone remaining at equilibrium in whole human blood for camptothecin and 9-aminocamptothecin (<0.5 % and 5.3 %, respectively), topotecan (11.9 %), CPT-11 (21.0 %), and SN-38 (19.5 %) all display improved blood stabilities. While lactone levels at equilibrium for topotecan are

SUBSTITUTE SHEET (RULE 26)

20-fold greater than for 9-aminocamptothecin, the corresponding levels of lactone for IRT (CPT-11) and 10-hydroxy-7-ethylcamptothecin (SN-38) are approximately 40-fold greater than in the case of 9-aminocamptothecin.

5 The significant gains in the relative stabilities of topotecan, CPT-11, and SN-38 can be correlated to their favorable interactions with HSA. These agents contain structural substituents at the 7- and 9- positions which hinder and prevent the preferential binding of the

10 carboxylate drug forms by HSA. The technique of time-resolved fluorescence anisotropy has recently been used to demonstrate that, under experimental conditions where camptothecin carboxylate associates with HSA and tumbles in solution closely associated with the protein, the

15 carboxylate forms of topotecan and CPT-11 do not associate with HAS. In the case of SN-38, direct spectroscopic evidence has been obtained which indicates that HSA preferentially binds the *lactone* form of this agent, thereby shifting the lactone-carboxylate

20 equilibrium to the lactone.

Thus, it is clear from these observations that HSA plays an important role in determining the relative human blood stabilities of the camptothecins. In the cases of camptothecin and 9-aminocamptothecin, the

25 protein acts as a sink for the carboxylate drug form, binding the opened ring species and thereby shifting the lactone-carboxylate equilibria to the carboxylate. However, in the cases of topotecan, CPT-11, and SN-38, no such preferential binding of the carboxylate drug form by

30 HSA is observed. Opposite to the situation with camptothecin and its 9-amino analogue, HSA preferentially binds the lactone form of SN-38 which thereby promotes higher circulatory levels of this biologically active species.

SUBSTITUTE SHEET (RULE 26)

The rapid and extensive loss of active drug that occurs with currently clinically relevant camptothecins indicates that it would be highly advantageous to identify camptothecins with reduced protein binding interactions and improved human blood stabilities. In that regard, the camptothecin analogs of the present invention exhibit unique properties that result in the agents displaying improved human blood stabilities while maintaining high anticancer activities.

10 **Experimental Methods for the Determination of Lipid Bilayer Partitioning (i.e. Lipophilicity) and Lactone Ring Stability.**

15 **Chemicals.** All camptothecin analogs were in the 20(S) configuration and were of high purity (>98%) as determined by HPLC assays with fluorescence detection. All other agents were reagent grade and were used without further purification. High purity water provided by a Milli-Q UV PLUS purification system (Bedford, MA) was utilized in all experiments.

20 **Drug Stock Solution Preparation.** Stock solutions of the drugs were prepared in dimethylsulfoxide (A.C.S. spectrophotometric grade, Aldrich, Milwaukee, WI) at a concentration of 2×10^{-3} M and stored in dark at 4°C. L- α -Dimyristoylphosphatidylcholine (DMPC) and L- α -
25 dimyristoylphosphatidylglycerol (DMPG) were obtained from Avanti Polar Lipids, Alabaster, AL, and were used without further purification. All other chemicals were reagent grade and were used without further purification.

Vesicle Preparation. Small unilamellar vesicle (SUV) suspensions were prepared the day of an experiment by the method of Burke and Tritton, "The Structure Basis of

SUBSTITUTE SHEET (RULE 26)

Anthracycline Selectivity for Unilamellar
Phosphatidylcholine Vesicles: An Equilibrium Binomial
Study," *Biochem* **24**:1768-1776 (1985). Briefly, stock
lipid suspensions containing 200 mg/mL lipid in phosphate
5 buffered saline (PBS, pH 7.4) were prepared by Vortex
mixing for 5-10 min above the T_m of the lipid. The lipid
dispersions were then sonicated using a bath-type
sonicator (Laboratory Supplies Co., Hicksville, NY) for
3-4 h until they became optically clear. A decrease in
10 pH from 7.4 to 6.8 was observed for the SUV preparations
of DMPG; therefore, the pH of these SUV suspensions was
adjusted to 7.4 using small quantities of 2.5 M NaOH in
PBS, followed by additional sonication. Each type of
vesicle suspension was annealed for 30 min at 37°C and
15 then used in an experiment.

Fluorescence Instrumentation. Steady-state fluorescence
measurements were obtained on a SLM Model 9850
spectrofluorometer with a thermostated cuvette
compartment. This instrument was interfaced with an IBM
20 PS/2 model 55 SX computer. Excitation and emission
spectra were recorded with an excitation resolution of
8 nm and an emission resolution of 4 nm. In all cases
spectra were corrected for background fluorescence and
scatter from unlabeled lipids or from solvents by
25 subtraction of the spectrum of a blank. Steady-state
fluorescence intensity measurements were made in the
absence of polarizers. Steady-state anisotropy (a)
measurements were determined with the instrument in the
"T-format" for simultaneous measurement of two polarized
30 intensities. The alignment of polarizers was checked
routinely using a dilute suspension of 0.25 μ m
polystyrene microspheres (Polysciences, Inc, Warrington,
PA) in water and anisotropy values of >0.99 were

SUBSTITUTE SHEET (RULE 26)

obtained. Alternatively, polarizer orientation was checked using a dilute solution of glycogen in water. The anisotropy was calculated from $a = (I_{VV} - GI_{VH}) / (I_{VV} + GI_{VH})$, where $G = I_{VH} / I_{HH}$ and the subscripts refer to vertical and horizontal orientations of the excitation and emission polarizers, respectively.

Anisotropy measurements for camptothecins were conducted using exciting light of 370 nm and long pass filters on each emission channel in order to isolate the drug's fluorescence signal from background scatter and/or residual fluorescence. All emission filters were obtained from Oriel Corp (Stamford, CT). The combination of exciting light and emission filters allowed adequate separation of fluorescence from background signal. The contribution of background fluorescence, together with scattered light, was typically less than 1% of the total intensity. Since the lactone rings of camptothecin and related congeners undergo hydrolysis in aqueous medium with half-lives of approximately 20 min., all measurements were completed within the shortest possible time (ca. 0.5 to 1 min) after mixing the drug stock solution with thermally pre-equilibrated solutions such that the experiments were free of hydrolysis product.

Determination of Equilibrium Binding Constants. The method of fluorescence anisotropy titration reported in Burke, T. G., Mishra, A. K., Wani, M. C. and Wall, M. E. "Lipid bilayer partitioning and stability of camptothecin drugs," *Biochemistry*. **32**: 5352-5364 (1993) was employed to determine the concentrations of free and bound species of drug in liposome suspensions containing a total drug concentration of 1×10^{-6} M and varying lipid concentrations. All experiments were conducted in glass

SUBSTITUTE SHEET (RULE 26)

tubes. The overall association constants are defined as $K = [A_B] / [A_F][L]$ where $[A_B]$ represents the concentration of bound drug, $[A_F]$ represents the concentration of free drug, and $[L]$ represents the total lipid concentration of the sample. Double-reciprocal plots of the binding isotherms ($1/(\text{bound fraction of drug})$ vs. $1/[\text{lipid}]$) were linear and K values were determined from their slopes by the method of linear least squares analysis. A computer program based on the $K = [A_B] / [A_F][L]$ relationship was written to predict bound drug levels for specified values of K and total drug.

Kinetics of Lactone Ring Opening. The hydrolysis kinetics of camptothecins in the presence of different blood components were determined by a quantitative C18 reversed-phase high-performance liquid chromatography (HPLC) assay as described in the literature. Mi and Burke (1994), *supra*. The preparation of whole blood and fractionated blood samples was carried out as described previously. Crystallized HSA of high purity ($> 97\%$) from Sigma Chemical (St. Louis, MO) was used. HSA stock solutions were prepared in PBS buffer with a final pH of 7.40 ± 0.05 . HSA concentrations were determined by UV absorbance at 278 nm using an extinction coefficient of $39,800 \text{ M}^{-1}\text{cm}^{-1}$ (Porter, 1992). All other agents were reagent grade and were used without further purification. High purity water provided by a Milli-Q UV PLUS purification system (Bedford, MA) was utilized in all experiments.

SUBSTITUTE SHEET (RULE 26)

Anticancer Activities of Highly Lipophilic Camptothecins of the Present Invention Determined In Vitro in Cell Culture Experiments

Cells. Cytotoxicity measurements were
5 conducted using MDA-MB-435 tumorigenic human breast cancer cells. The cells were exposed to a range of drug concentrations for 72 hr exposure periods and then viability was assessed using a sulphorhodamine B (SRB) assay. SRB assays were performed using a standard assay.

10 **Fluorescence Anisotropy Titration Demonstrates that the Camptothecin Analogs of the Present Invention Display Exceptionally High Equilibrium Association Constants for Lipid Vesicles.**

Figures 12 through 15 depict the fluorescence
15 excitation and emission spectra of several of the new camptothecin analogs. Figure 12 summarizes the excitation and emission spectra of 1 μ M DB-172 in phosphate buffered saline solution. The figure indicates that upon introduction of lipid bilayers into the sample
20 there is an increase in the fluorescence emission of the compound, indicative of an interaction between the drug and the membrane. Upon changing the solvent to ethanol the fluorescence also changes. Figures 13 through 15 summarize the emission spectra of DB-173, DB-174, and
25 DB-67, respectively, in the presence and absence of membranes. In each case there is a marked increase in fluorescence intensity as the drug partitions into the lipid bilayer. In each case there is also a prominent blue-shifting or shift in the emission spectra to lower
30 wavelength upon drug interaction with membrane. The spectral data presented in Figures 12 through 15 clearly indicate that the new agents are fluorescent and the spectral parameters of the drugs change upon addition of

SUBSTITUTE SHEET (RULE 26)

lipid bilayer membranes to the samples. Table 2 compares the maximum excitation and emission wavelengths of new camptothecin analogs with congeners that have been made previously. The intrinsic fluorescent nature of the camptothecins allows for the sensitive method of steady-state fluorescence anisotropy titration to be employed to determine the strength of the binding interactions of the various analogs with lipid bilayers.

Table 2. Fluorescence Spectral Parameters for camptothecin analogs in solution and bound to DMPC and DMPG SUVs.

Compound (S)	Excitation (nm)	Emission (nm)		
	PBS	PBS	DMPC	DMPG
camptothecin	367	430	422	415
7-methylcamptothecin	366	421	418	405
7-ethylcamptothecin	367	422	419	406
7-propylcamptothecin	366	422	419	406
7-methyl-10-ethoxycamptothecin	376	430	401	400
7-ethyl-10-methoxycamptothecin	376	430	403	406
7-propyl-10-methoxycamptothecin	376	430	404	404
DB-67	400	550	445	440
DB-172	370	424	424	422
DB-173	395	526	503	502
DB-174	380	550	433	431
DB-202	377	450	439	437
CHJ-792	400	531	517	519

The following designations are used herein:

- 15 DB-172, (20S)-7-[(2-trimethylsilyl)ethyl]camptothecin (36c); DB-173, (20S)-10-amino-7-[(2-trimethylsilyl)ethyl]

SUBSTITUTE SHEET (RULE 26)

camptothecin (36b); DB-174, (20S)-10-hydroxy-7-[(2-trimethylsilyl)ethyl] camptothecin (36a); DB-67, (20S)-10-hydroxy-7-(tert-butyldimethylsilyl)camptothecin; DB-148, (20S)-7-(3-chloropropyl)dimethylsilylcamptothecin; DB-158, (20S)-10-hydroxy-7-(3-chloropropyl)dimethylsilyl camptothecin; DB-202, (20S)-7-(tert-butyldimethylsilyl) camptothecin; CHJ-792, 10-amino-7-trimethylsilylcamptothecin (20); DB-124, 10-hydroxy-7-(3-dimethylaminopropyl)dimethylsilyl camptothecin hydrochloride salt; and DB-104, 7-(3-dimethylaminopropyl)dimethylsilyl camptothecin hydrochloride salt.

A steady-state fluorescence anisotropy (a) measurement is related to the rotational rate of the fluorescent molecule through the Perrin Equation:

$$a_0 / a = 1 + (\tau / \Phi)$$

where a_0 is the limiting fluorescence anisotropy in the absence of depolarizing rotations, τ is the excited-state lifetime, and Φ is the rotational correlation time of the fluorophore. The above equation states that changes in either the τ or Φ values of a fluorescent compound can modulate its steady-state anisotropy.

The excited-state lifetime values of camptothecin in PBS, glycerol, and methanol were examined at 37 °C. The lifetime values were determined to be 4.7 ns, 3.8 ns, and 3.5 ns, respectively. Similarly, camptothecin's lifetime value when associated with DMPC

SUBSTITUTE SHEET (RULE 26)

bilayers were measured at 37 °C, and the average value for membrane-bound drug was found to be 3.7 ns.

Thus the lifetime measurements described above indicate that camptothecin's excited-state lifetime is relatively insensitive to alterations in microenvironment (e.g. a change in solvent or fluorophore relocation from an aqueous milieu to a phospholipid membrane). For a fluorophore whose τ value remains relatively constant during a transition which strongly impacts on its rotational motion (such as a change in solvent viscosity or fluorophore binding to large macromolecular assemblies such as liposomal particles), the Perrin equation indicates a direct relationship between a and Φ values will exist (that is, as the Φ value of the fluorescent compound increases, then so too does its steady-state anisotropy value).

Steady-state fluorescence anisotropy values of the camptothecin analogues are highly sensitive to solvent viscosity and to associations with small unilamellar lipid vesicles. For example, topotecan has an a value of 0.008 in PBS, but its a value increases 9-fold and 40-fold in the viscous solvents octanol and glycerol, respectively. A 21-fold enhancement in the a value of camptothecin is observed upon binding of drug to vesicles composed of either DMPC or DMPG. Because of the sensitivity of a of the camptothecin drugs to membrane associations, the method of fluorescence anisotropy titration was employed to study the equilibrium binding of camptothecin analogs with lipid bilayers. As described previously, the experiment consisted of determining the a values for a set of samples where the drug concentration in each was held constant (typically 1

SUBSTITUTE SHEET (RULE 26)

or 2 μ M), while the lipid concentration among the members of a set was varied from 0 to 0.29 M.

As a consequence of the brilliant fluorescence emissions from the newly synthesized camptothecins (a summary of the spectral parameters can be found in Table 2), the adsorption isotherms summarized in Figures 16 through 18 were relatively free from any background signal. Using drug concentrations of 1 μ M and long pass filters to isolate emitted light from background signal (that is, scattered exciting light and extraneous fluorescence signal due to the possible presence of impurities), signal levels from drugs dissolved in PBS buffer were typically 99.97% in the absence of membrane and greater than 98 % in the presence of membrane. Adsorption isotherms were used to determine overall association constants for the camptothecin drugs. Overall association constants are defined as:

$$K = [A_B] / [A_F][L]$$

where $[A_B]$ represents the concentration of bound drug, $[A_F]$ represents the concentration of free drug, and $[L]$ represents the total lipid concentration in the vesicle suspension. This equation is valid when the concentration of free lipid is approximately equal to the concentration of total lipid (that is, the concentration of free lipid is in significant excess over the concentration of bound drug). Provided this condition is satisfied, K may be determined from the inverse of the slope of a double reciprocal plot. In such a double reciprocal plot (representative data are shown in Figures 19 and 20), 1/fraction of the total drug bound is plotted vs. 1/lipid concentration, with a y-intercept

SUBSTITUTE SHEET (RULE 26)

value of 1 (for a system displaying binding site homogeneity). Such double-reciprocal plots for the associations of the new camptothecin analogs with DMPC and DMPG small unilamellar vesicle (SUV) preparations were linear with good correlation coefficients. The linearity of these plots, as well as the corresponding plots for drug associations with other types of membrane preparations, indicates that fluorophore binding at these lipid concentrations is adequately described by the above equation.

The studies summarized in Table 3 examine the structural basis of camptothecin associations for lipid bilayers. Two types of membrane were included in these studies which were conducted under near physiological conditions of pH and temperature; these membranes include fluid-phase and electroneutral L- α -dimyristoylphosphatidylcholine (DMPC); and fluid-phase and negatively-charged L- α -dimyristoylphosphatidylglycerol (DMPG). DMPC and DMPG have identical chain length but the charge on their head groups differ.

SUBSTITUTE SHEET (RULE 26)

Table 3. Overall association constants for camptothecin analogs interacting with unilamellar vesicles of electroneutral DMPC, negatively-charged DMPG in PBS buffer at PH 7.4 and 37°C.

Compound	$K_{DMPC} (M^{-1})$	$K_{DMPG} (M^{-1})$
20(S)-camptothecin	100	100
7-methyl-20(S)-camptothecin	150	180
7-ethyl-20(S)-camptothecin	250	300
7-propyl-20(S)-camptothecin	540	600
7-methyl-10-methoxycamptothecin	220	200
7-ethyl-10-methoxycamptothecin	340	330
7-propyl-10-methoxycamptothecin	440	570
7-methyl-10-hydroxycamptothecin	220	90
7-ethyl-10-hydroxycamptothecin	260	160
7-propyl-10-hydroxycamptothecin	550	250
7-butyl-10-hydroxycamptothecin	2100	1270
DB-67	2700	2800
DB-172	10500	10600
DB-172 (Carboxylate form)	385	155
DB-173	5800	5800
DB-174	9000	6600
DB-174 (Carboxylate form)	540	60
CHJ-792	820	360

In the studies of Table 3, binding isotherms were constructed using the method of fluorescence anisotropy titration, and K values were determined from the slopes of double-reciprocal plots. The K values are subject to 10% uncertainty. Overall, the most striking feature of the data contained in Table 3 is the strong modulation which can be achieved through either a sole substitution at the 7 position or dual substitution at the 7 and 10 positions. Included in Table 3 are previously known camptothecin compounds. Data for these agents were included to show the highly lipophilic nature of the new camptothecins relative to the previous

SUBSTITUTE SHEET (RULE 26)

compounds. Topotecan was found to have a K value for DMPC liposomes some 10 times less than that for camptothecin. From Table 3 it is clear that the compounds of the present invention are much more lipophilic than either camptothecin or topotecan. For example, the affinities of DB67 for membranes composed of DMPC or DMPG are 27-fold and 28-fold greater than the corresponding values for camptothecin. DB172 and DB174 are some 100-fold and 90-fold more apt to bind DMPC membranes when compared with camptothecin. DB173 is also highly lipophilic, displaying a K value for DMPC some 58-fold greater than that observed for camptothecin. In summary, the novel compounds of the present invention listed in Table 3 were found to display the highest membrane affinities by far when compared against other, previous camptothecin analogs containing the same α -hydroxy- δ -lactone ring system.

Comparison of the Behavior of the Highly Lipophilic Camptothecins in Aqueous Solution.

Figure 21 summarizes the stability of DB172 in phosphate buffered saline (PBS) buffer, pH 7.4, at physiological temperature. Shown in the figure are plots of lactone fraction as a function of time for DB172 at different concentrations. Drug was added to solution from a concentrated DMSO stock solution such that the volumes of DMSO were very small (less than 0.5%) relative to the volume of water. The drug stability was found to be markedly dependent on the drug concentration added. At the more dilute drug concentrations the drug hydrolyzes as previously observed for other camptothecins containing the α -hydroxy- δ -lactone moiety. At high drug concentrations marked stabilization of the lactone ring of DB-172 was observed,

SUBSTITUTE SHEET (RULE 26)

a finding which is not typically observed for other camptothecins.

Figure 22 summarizes the dependence of the fluorescence intensity of DB172 as a function of time and pH. In these experiments DB172 is added to solution as the lactone form. At low pH where the drug remains in the lactone form, the change in intensity with time is the lowest. At pH 10, where the conditions are such that the lactone more readily hydrolyzes and forms carboxylate, a significant change in fluorescence intensity is observed. It appears that a pH 10 nonfluorescent micellular aggregates composed of lactone disassemble and form open-ring carboxylate forms that tend to exist in solution as monomeric fluorescent species.

Figure 23 explores the fluorescence intensity of DB172 as a function of concentration. Following the addition of low concentration of lactone drug to solution, the change in fluorescence signal is the greatest whereas at high drug concentration (10 μ M) the fluorescence intensity changes are minimal. It is believed that at low concentration the micellular aggregates of DB172 displaying reduced fluorescence can disassemble and form fluorescent carboxylate species, but at higher drug concentration the equilibrium favors that the agent remains in the aggregated or reduced fluorescence state. Figure 24 shows that when the carboxylate form of DB172 is added to solution at pH 10, no change in fluorescence signal is observed at pH 10 while at lower pH values where lactone can form the fluorescence intensity decreases with time. Once again this decrease in fluorescence that occurs at reduced pH

SUBSTITUTE SHEET (RULE 26)

appear to be due to the formation of lactone aggregates of reduced fluorescence quantum yield.

Figures 21 through 24 are consistent with the unusual ability of DB172 lactone to self-associate and form micelles at micromolar drug concentrations. The micellular DB172 aggregates display a reduced fluorescence. If conditions allow for hydrolysis to occur such that carboxylate forms, there is an increase in the fluorescence intensity of the sample. Figure 25 compares the relative change in the fluorescence emission of a sample following addition of lactone drug forms to solution. In these experiments the values for each drug are normalized to a value of 1 at time equals to zero, and the ability of the various analogs to disassociate in the event the drugs are aggregated at time = 0 is monitored with time. For several of the agents, hydrolysis to form carboxylate occurs in the solution. Since the carboxylate forms are less likely to self-associate and exhibit reduced fluorescence, disruption of the aggregates by drug hydrolysis proceeds with an increase in fluorescence intensity. While DB172 self-associates to an exceptionally high degree at time = 0, the other agents self-associate to a much lesser extent and hence their signals are more constant with time and not as sensitive to hydrolysis reactions. DB173 and DB67 appear to be much more likely to be found in solution as monomeric drug relative to DB172. This could be a favorable characteristic in that solutions for administration to a patient will be more homogeneous than the aggregated DB172 particle suspensions.

SUBSTITUTE SHEET (RULE 26)

Markedly Enhanced Stabilities of Highly Lipophilic Camptothecins in Human Blood.

In was also demonstrated that the active lactone forms of highly lipophilic camptothecins of the present invention also persist for much longer times in human tissues such as blood when compared with water-soluble analogs. Figure 26 compares the stabilities of several new camptothecin analogs in their free form in PBS buffer (Panel A) versus in whole blood (Panel B). These compounds include: 7-t-butyltrimethylsilylcampothecin (DB202), 7-t-butyltrimethylsilyl-10-hydroxycampothecin (DB67), 7-(3-chloropropyl)dimethylsilylcampothecin (DB148), and 7-(3-chloropropyl)-dimethylsilyl-10-hydroxycampothecin (DB158). Figure 27 summarizes the stability data for DB172, DB173 and DB174 in PBS buffer only (Panel A), PBS buffer containing physiologically relevant 30 mg/ml levels of HSA (Panel B), and human blood (Panel C). All experiments were carried out at physiological temperature.

The highly biologically-active and lipophilic compound, 7-t-butyltrimethylsilyl-10-hydroxycampothecin (DB-67), was found to display superior stability in human blood, with a $t_{1/2}$ of 130 min and a % lactone at equilibrium value of 30 (compare with % lactone at equilibrium values in whole human blood for 9-aminocampothecin (<0.3 %), camptothecin (5.3 %), topotecan (8.6 %), CPT-11 (21.0 %), and SN-38 (19.5 %)). The stability data are summarized in Table 4. The new DB67 agent was found to be 25-times more lipophilic than camptothecin, and its 10-hydroxy functionality was found to markedly aid in promoting stability in the presence of HSA. DB67 may be an ideal candidate for the treatment of

SUBSTITUTE SHEET (RULE 26)

brain cancer. With intrinsic activity several-fold greater than camptothecin, DB67 displays very high equilibrium lactone levels in human blood, is not tightly bound to human albumin like camptothecin and 9-aminocamptothecin, and is highly lipophilic which should enable the agent to more readily cross the blood brain barrier.

SUBSTITUTE SHEET (RULE 26)

Table 3. Stability parameters for Camptothecin analogs in different biological fluids.

DRUG NAME and FLUID	$t_{1/2}$ (minutes)	% Lactone at Equilibrium
DB 202		
Whole Blood	71.9 +/- 4.2	1.0 +/- 0.1
HSA	46.3 +/- 1.0	0.1 +/- 0.2
PBS	27.9 +/- 1.9	12.2 +/- 0.4
RBC	79.4 +/- 3.3	59.4 +/- 0.0
DB 148		
Whole Blood	85.6 +/- 9.2	2.2 +/- 3.6
HSA	16.0 +/- 0.2	2.7 +/- 0.2
PBS	23.3 +/- 2.4	12.0 +/- 0.5
RBC	59.7 +/- 2.9	43.4 +/- 0.8
DB 67		
Whole Blood	133.0 +/- 15.9	30.5 +/- 1.9
HSA	119.0 +/- 5.3	10.5 +/- 2.0
PBS	31.8 +/- 0.4	10.2 +/- 0.3
RBC	51.4 +/- 0.5	41.4 +/- 0.7

SUBSTITUTE SHEET (RULE 26)

DRUG NAME and FLUID	$t_{1/2}$ (minutes)	% Lactone at Equilibrium
CHJ 792		
Whole Blood	37.6 +/- 6.2	12.3 +/- 0.0
HSA	32.0 +/- 1.3	3.7 +/- 0.3
PBS	31.3 +/- 0.6	10.5 +/- 0.3
DB 158		
Whole Blood	65.3 +/- 9.0	17.8 +/- 2.0
HSA	48.0 +/- 0.9	17.2 +/- 0.7
PBS	29.5 +/- 1.7	11.3 +/- 1.8
RBC	67.7 +/- 8.5	50.2 +/- 1.7
7 TMS		
Whole Blood	54.6 +/- 3.6	23.7 +/- 0.0
HSA	58.5 +/- 6.8	16.4 +/- 1.9
PBS	34.6 +/- 1.0	11.1 +/- 0.1
SN 38		
Whole Blood	50.7 +/- 1.4	20.2 +/- 1.9
HSA	88.1 +/- 2.9	24.3 +/- 0.7
Topotecan		
Whole Blood	30.9 +/- 1.4	8.61 +/- 0.4
HSA	22.1 +/- 0.7	7.06 +/- 0.3
DB172		
Whole Blood	106.6 +/- 10.8	24.1 +/- 2.6
HSA	86.1 +/- 10.3	4.3 +/- 1.0

SUBSTITUTE SHEET (RULE 26)

DRUG NAME and FLUID	$t_{1/2}$ (minutes)	% Lactone at Equilibrium
DB173		
Whole Blood	69.0 +/- 4.0	36.3 +/- 1.7
HSA	49.0 +/- 1.3	15.5 +/- 0.5
PBS	45.3 +/- 2.0	11.9 +/- 0.3
DB 174		
Whole Blood	40.3 +/- 3.2	33.0 +/- 0.4
HSA	37.7 +/- 0.9	20.4 +/- 0.2
PBS	29.7 +/- 0.4	13.7 +/- 0.7
DB 124		
Whole Blood	63.1 +/- 7.4	31.8 +/- 0.8
HSA	40.0 +/- 0.3	12.2 +/- 0.3
PBS	30.3 +/- 1.0	8.9 +/- 0.3
DB 104		
Whole Blood	77.2 +/- 1.8	48.1 +/- 2.0
HSA	29.6 +/- 0.8	8.5 +/- 0.2
PBS	24.1 +/- 1.0	7.5 +/- 0.2
Camptothecin		
Whole Blood	21.6 +/- 2.6	5.3 +/- 0.6
HAS	11.9 +/- 0.3	<0.5
PBS	23.8 +/- 1.3	17 +/- 2.0

SUBSTITUTE SHEET (RULE 26)

Also noteworthy are the very high human blood stabilities of DB-173 (36% lactone at equilibrium) and DB174 (33% lactone at equilibrium). These values are significantly greater than clinically relevant water-soluble camptothecins and they compete favorably with lipophilic camptothecins such as DB-172 that contain an unsubstituted A-ring.

Highly Lipophilic Camptothecins Display Oral Bioavailability.

Figure 28 contains data which demonstrate that DB-67 is absorbed from the gastrointestinal tract. To evaluate the blood levels achieved following dosing at 5 mg/kg, four animals were given 0.1 ml intrastomach injections of DB-67 dissolved in DMSO. The stock contained DB67 at a concentration of 1.6 mg/ml. At time points of 30 min, 1 hr, 2 hr, and 4 hr, 1 ml samples of blood were drawn and collected by heart puncturing. The samples were centrifuged for 3 min and stored frozen until analysis was carried out. Note that DB67 levels rise above the 40 ng/ml level with much of the drug persisting as active lactone drug. Thus, the novel highly lipophilic analogs described here may be administered orally and will appear in the bloodstream following administration.

Highly Lipophilic Camptothecins Display High Anticancer Potency Even in the Presence Human Serum Albumin.

As discussed previously, the spontaneous hydrolysis of camptothecin in aqueous solution yields the ring-opened carboxylate form which is far less active than the ring-closed lactone form. Therefore, the equilibrium between the lactone and carboxylate forms is

SUBSTITUTE SHEET (RULE 26)

a most important determinant of the drug activities. Previous studies indicated that human serum albumin (HSA) greatly affects the equilibrium in favor of the carboxylate for camptothecin by preferentially
5 interacting with the carboxylate form. Because of this HSA effect, levels of the biologically-active lactone form of camptothecin can be attenuated at the tumor site. The drug-HSA interactions can be manipulated by drug structural modification: A 10-OH substitution decreases
10 the affinity of drug for HSA approximately 20-fold and an additional 7-ethyl substitution further alters the binding in favor of the lactone form. To determine the impact of HSA on the cytotoxicities of the blood-stable camptothecin analogs of the present invention, the
15 cytotoxic effects of the camptothecin analogs were studied.

Sulphorhodamine B (SRB) assay was used. This assay measures the total protein levels in the living cells. Proteins from dead cells are lysed and removed in
20 the washing step before TCA fixation. However, it is possible that cells in the early stage of death still have their membrane integrity and therefore retain the protein contents inside. As a result, the optical density at 490 nm can sometimes be overestimated and the
25 cytotoxicity underestimated. To validate the SRB assay, a diverse range of chemotherapeutic agents have been tested across multiple panels of tumor cell lines, and close correlations have been found with standard tetrazolium (MT) assay and clonogenic assays. The SRB
30 assay is now a well regarded assay and was recently approved by NCI as a standard assay for anticancer drug screening.

SUBSTITUTE SHEET (RULE 26)

The cytotoxicities of various camptothecins against MDA-MB-435 tumorigenic metastatic human breast cancer cells in the absence and presence of 1 mg/ml HSA are summarized in Table 5. The cytotoxicity values for cells exposed to drug for 72 hrs. are summarized in Table 5. Overall, HSA is able to strongly attenuate the IC_{50} values of camptothecin, but the extent to which HSA modulates the cytotoxicities of the new highly lipophilic analogs is significantly reduced. In fact, 1 mg/ml HSA had no effect on the cytotoxic activity of DB173. In the presence of HAS, DB173 displays a low nM potency against the human breast cancer cells. The ability of the agents to remain potent even in the presence of albumin is potentially significant because of the great abundance of this protein throughout the blood and tissue of the body.

Table 4. IC_{50} Values of Camptothecin and Analogs Against MDA-MB-435 Tumorigenic Metastatic Human Breast Cancer Cells in the Absence and Presence of Human Serum Albumin.

Compound	IC_{50} (nM)	IC_{50} (nM)
	(w/o HSA)	(w/ HSA)
Camptothecin	8	>200
7-Ethyl-10-Hydroxycamptothecin (SN-38)	20	--
DB-174	12	--
DB-67	7	22
DB-173	4	4

The present inventors have thus discovered that introduction of a silyl group or a silylalkyl group (for example, a trimethylsilyl group or a trimethylsilylethyl group) at position 7 of the camptothecin structure typically results in a compound with better anti-tumor

SUBSTITUTE SHEET (RULE 26)

activity and human blood stability than camptothecin (see, for example, the compound of Example 1 as compared to (20S)-CPT) and other previous camptothecin analogs. Dual substitution at the 7 and 10 positions is even more favorable (see, for example, compounds DB-173 and DB-174). The silyl group or the silylalkyl group is also beneficial in the irinotecan series (see, for example, the compound of Example 6 as compared to irinotecan).

The anti-tumor activity remains essentially unchanged when a hydroxy group is introduced at position 10 of the compound of Example 1 to produce the compound of Example 5. The compound of Example 6 is a relative of SN-38, the active metabolite of irinotecan. High activities were also observed in the present studies when a trimethylsilyl group was introduced in conjunction with a fluoro atom at position 11 (see, for example, the compound of Example 7), or a primary amine group at positions 10 or 11 (see, respectively, Examples 8 and 9). Introduction of a fluoro atom in position 12 also results in an analog only approximately 2 times less potent than camptothecin (see, Example 11 as compared to (20S)-CPT). This result is surprising considering the poor activity of the 12-substituted camptothecins reported previously in the literature.

The novel camptothecin analogs of the present invention have unique biophysical and physiological properties. These highly lipophilic camptothecin analogs with B-ring modifications and A- and B- ring modifications display markedly improved α -hydroxy- δ -lactone ring stability in human blood. The camptothecin analogs of the present invention also display oral

SUBSTITUTE SHEET (RULE 26)

bioavailability and potent anticancer activity even in the presence of human serum albumin.

A mammal (human or animal) may thus be treated by a method which comprises the administration to the mammal of a pharmaceutically effective amount of a compound of formula (1) or a pharmaceutically acceptable salt thereof. The condition of the mammal can thereby be improved.

The compounds of the present invention can be administered in a variety of dosage forms including, for example: parenterally (for example, intravenously, intradermally, intramuscularly or subcutaneously); orally (for example, in the form of tablets, lozengers, capsules, suspensions or liquid solutions); rectally or vaginally, in the form of a suppository; or topically (for example, as a paste, cream, gel or lotion).

Optimal dosages to be administered may be determined by those skilled in the art and will vary with the particular compound of formula (1) to be used, the strength of the preparation, the mode of administration, the time and frequency of administration, and the advancement of the patient's condition. Additional factors depending on the particular patient will result in the need to adjust dosages. Such factors include patient age, weight, gender and diet. Dosages may be administered at once or divided into a number of smaller doses administered at varying intervals of time.


SUBSTITUTE SHEET (RULE 26)

Examples

The following examples are provided for illustration of the invention and are not intended to be limiting thereof.

5 Example 1.

Preparation of (20S)-7-trimethylsilylcamptothecin



(1) (S)-4-Ethyl-4-hydroxy-6-iodo-3-oxo-7-(3-trimethylsilyl-2-propynyl)-1H-pyrano[3,4-c]-8-pyridone

- 10 To a solution of (S)-4-ethyl-4-hydroxy-6-iodo-3-oxo-1H-pyrano[3,4-c]-8-pyridone [iodopyridone (2), 250 mg, 0.746 mmol] in DME (2.5 mL) and DMF (0.60 mL) at 0°C under argon was added 60% NaH in mineral oil (31.3 mg, 0.783 mmol). LiBr (150 mg, 1.75 mmol) was added 10 min
- 15 latter. After 15 min at room temperature, 3-trimethylsilyl-2-propynyl bromide (430 mg, 2.24 mmol) was injected and the reaction mixture was heated in the dark at 65 °C for 20 h. The final solution was poured into brine (20 mL), extracted with AcOEt (6 x 15 mL) and dried
- 20 (Na₂SO₄). The residue obtained after removal of the solvents was subjected to flash-chromatography (CHCl₃/AcOEt 95:5) to give 283 mg (85%) of a foam: [α]_D²⁰

SUBSTITUTE SHEET (RULE 26)

+36.7 (c 1, CHCl₃); IR (neat, cm⁻¹) 3384, 2940, 2166, 1730, 1634, 1518, 1406, 1130, 841, 752; ¹H NMR (300 MHz, CDCl₃) δ 0.14 (s, 9 H), 0.95 (t, J = 7.4 Hz, 3 H), 1.77 (m, 2 H), 3.66 (s, 1 H), 5.00 (d, J = 17.2 Hz, 1 H), 5.10 (d, J = 16.4 Hz, 1 H), 5.15 (d, J = 17.2 Hz, 1 H), 5.49 (d, J = 16.4 Hz, 1 H), 7.16 (s, 1 H); ¹³C NMR (75 MHz, CDCl₃) δ -0.40, 7.7, 31.5, 44.5, 66.3, 71.8, 90.9, 97.9, 116.5, 118.1, 148.6, 157.9, 173.3; HRMS (EI) m/z calcd for C₁₆H₂₀INO₄Si (M⁺) 445.0206, found 445.0203; LRMS (EI) m/z 445 (M⁺), 430, 416, 386.

(2) (20S)-7-Trimethylsilylcampthothecin


A solution of the compound prepared in (1) (36.6 mg, 0.082 mmol), phenyl isonitrile (0.25 mmol) and hexamethylditin (42 mg, 0.123 mmol) in benzene (1.3 mL) under argon was irradiated at 70 °C with a 275W GE sunlamp for 10 h. The final reaction mixture was concentrated and subjected to flash-chromatography (CHCl₃/MeOH 96:4) to provide 18.8 mg (54%) of a slightly yellow solid: [α]_D²⁰ +39.0 (c 0.2, CHCl₃/MeOH 4:1); ¹H NMR (300 MHz, CDCl₃/CD₃OD 3:1) δ 0.50 (s, 9 H), 0.83 (t, J = 7.4 Hz, 3 H), 1.74 (m, 2 H), 3.72 (br s, 1 H), 5.12 (d, J = 16.4 Hz, 1 H), 5.16 (br s, 2 H), 5.47 (d, J = 16.4 Hz, 1 H), 7.49 (t, J = 8.1 Hz, 1 H), 7.54 (s, 1 H), 7.62 (t, J = 8.1 Hz, 1 H), 8.02 (d, J = 8.1 Hz, 1 H), 8.07 (d, J = 8.1 Hz, 1 H); ¹³C NMR (75 MHz, CDCl₃/CD₃OD 3:1) δ 0.9, 7.2, 29.3, 31.0, 51.7, 65.5, 98.3, 118.4, 127.3, 128.0, 129.7, 130.0, 131.8, 134.3, 144.7, 145.6, 147.3, 151.1, 173.5; HRMS (EI) m/z calcd for C₂₃H₂₄N₂O₄Si (M⁺)

SUBSTITUTE SHEET (RULE 26)

420.1505, found 420.1501; LRMS (EI) m/z 420 (M^+), 391, 376, 361, 347, 320, 291.

Example 2.

Preparation of (2*S*)-7-*tert*-butyldimethylsilylcamptothecin (DB-202)



(1) (S)-4-Ethyl-4-hydroxy-6-iodo-3-oxo-7-(3-*tert*-butyldimethylsilyl-2-propynyl)-1*H*-pyrano[3,4-*c*]-8-pyridone

- 10 Following the procedure described in Example 1-
 (1), iodopyridone (2) (200 mg, 0.60 mmol) and 3-*tert*-
 butyldimethylsilyl-2-propynyl bromide (280 mg, 1.20 mmol)
 provided, after flash-chromatography (CH₂Cl₂/AcOEt 9:1),
 173 mg (59%) of a white foam: $[\alpha]_D^{20} +58$ (c 0.2, CHCl₃); IR
 15 (CHCl₃, cm⁻¹) 3548, 2950, 2927, 2859, 1745, 1648, 1526;
¹H NMR (300 MHz, CDCl₃) δ 0.08 (s, 6 H), 0.92 (m, 12 H),
 1.79 (m, 2 H), 3.77 (br s, 1 H), 5.00-5.25 (m, 3 H), 5.50
 (d, J = 16.4 Hz, 1 H) 7.19 (s, 1 H); ¹³C NMR (75 MHz,
 CDCl₃) δ -4.9, 7.63, 16.6, 26.0, 31.6, 44.5, 66.3, 71.8,
 20 89.4, 98.6, 100.0, 116.5, 118.1, 148.6, 158.0, 173.2;
 HRMS (EI) m/z calcd for C₁₉H₂₆INO₄Si (M^+) 487.0679, found
 487.0676; LRMS (EI) m/z 487 (M^+), 430, 386, 96, 81, 57.


SUBSTITUTE SHEET (RULE 26)

(2) (20S)-7-*tert*-butyldimethylsilylcamptothecin

Following the procedure described in Example 1-
(2), the compound prepared in (1) (48.7 mg, 0.10 mmol)
afforded, after flash-chromatographies (CH₂Cl₂/MeOH 96:4;
5 CH₂Cl₂/acetone 9:1), 24.8 mg (54%) of an off yellow
solid: $[\alpha]_D^{20} +35.5$ (c 0.2, CHCl₃); IR (CHCl₃, cm⁻¹) 3028,
2980, 2960, 2932, 2859, 1741, 1658, 1600, 1555, 1257,
1198, 1158, 1045; ¹H NMR (300 MHz, CDCl₃) δ 0.69 (s, 6
H), 0.98 (s, 9 H), 1.03 (t, *J* = 7.3 Hz, 3 H), 1.86 (m, 2
10 H), 3.86 (s, 1 H), 5.29 (d, *J* = 16.3 Hz, 1 H), 5.31 (s, 2
H), 5.73 (d, *J* = 16.3 Hz, 1 H), 7.60 (t, *J* = 6.3 Hz, 1
H), 7.60 (t, *J* = 7.0 Hz, 1 H), 7.66 (s, 1 H), 7.74 (t, *J*
= 7.3 Hz, 1 H) 8.20 (t, *J* = 8.1 Hz, 2 H); ¹³C NMR (75
MHz, CDCl₃) δ -0.56, 7.80, 19.2, 27.1, 31.6, 52.4, 66.3,
15 72.8, 97.7, 118.2, 127.0, 129.5, 129.6, 130.8, 132.7,
136.0, 143.0, 146.4, 148.0, 150.1, 150.6, 157.4, 173.9;
HRMS (EI) *m/z* calcd for C₂₆H₃₀N₂O₄Si (M⁺) 462.1974, found
462.1975; LRMS (EI) *m/z* 462 (M⁺), 450, 361, 331, 304,
245, 223, 57.

20 **Example 3.**

Preparation of (20S)-7-*tert*-
butyldiphenylsilylcamptothecin



(1) (S)-4-Ethyl-4-hydroxy-6-iodo-3-oxo-7-(3-tert-butyl-*tert*-butyldiphenylsilyl-2-propynyl)-1*H*-pyrano[3,4-*c*]-8-pyridone

Following the procedure described in Example 1-
5 (1), iodopyridone (2) (200 mg, 0.60 mmol) and 3-*tert*-butyldiphenylsilyl-2-propynyl bromide (428 mg, 1.20 mmol) provided, after flash-chromatography (CH₂Cl₂/AcOEt 9:1), 258 mg (70%) of a white foam: $[\alpha]_D^{20} +45.1$ (c 0.2, CHCl₃); IR (CHCl₃, cm⁻¹) 3546, 2928, 2855, 1741, 1658, 1526; ¹H
10 NMR (300 MHz, CDCl₃) δ 0.97 (t, *J* = 7.3 Hz, 3 H), 1.08 (s, 9 H), 1.80 (m, *J* = 7.1 Hz, 2 H), 3.76 (br s, 1 H), 5.13 (d, *J* = 16.4 Hz, 1 H), 5.29 (d, *J* = 2.5 Hz, 2 H), 5.52 (d, *J* = 16.4 Hz, 1 H), 7.22 (s, 1 H), 7.32-7.40 (m, 6 H), 7.76-7.78 (m, 4 H); ¹³C NMR (75 MHz, CDCl₃) δ 7.6, 18.6,
15 27.0, 31.6, 44.6, 60.4, 66.3, 71.8, 86.5, 99.9, 102.2, 116.6, 127.7, 129.6, 132.6, 135.6, 148.7, 157.8, 173.2; HRMS (EI) *m/z* calcd for C₂₅H₂₁INO₄Si (M-C₄H₉⁺) 554.0279, found 554.0285; LRMS (EI) *m/z* 554 (M-C₄H₉⁺), 587, 510, 220, 143, 105.

20 (2) (2*S*)-7-*tert*-butyldiphenylsilylcamptothecin


Following the procedure described in Example 1-
(2), the compound prepared in (1) (61.1 mg, 0.10 mmol) yielded, after flash-chromatographies (CH₂Cl₂/MeOH 96:4; CH₂Cl₂/acetone 9:1), 26.5 mg (45%) of a light yellow
25 solid: $[\alpha]_D^{20} +35.2$ (c 0.2, CHCl₃); IR (CHCl₃, cm⁻¹) 3003, 2984, 2969, 2958, 2935, 1741, 1658, 1599, 1555, 1428, 1226, 1216, 1158, 1102; ¹H NMR (300 MHz, CDCl₃) δ 1.00 (t, *J* = 7.3 Hz, 3 H), 1.44 (s, 9 H), 1.84 (m, 2 H),

SUBSTITUTE SHEET (RULE 26)

3.75 (s, 1 H), 4.21 (d, $J = 5.7$ Hz, 2 H), 5.19 (d, $J = 16.3$ Hz, 1 H), 5.64 (d, $J = 16.3$ Hz, 1 H), 7.43 (m, 5 H), 7.51 (t, $J = 7.3$ Hz, 2 H), 7.62 (s, 1 H), 7.69 (m, 5 H), 8.10 (d, $J = 8.5$ Hz, 1 H), 8.22 (d, $J = 8.2$ Hz, 1 H);
5 ^{13}C NMR (75 MHz, CDCl_3) δ 7.9, 20.4, 30.2, 31.6, 52.2, 66.4, 72.8, 97.5, 118.2, 126.3, 128.6, 129.8, 130.3, 130.7, 131.9, 132.2, 134.6, 134.64, 136.4, 136.5, 138.1, 140.9, 146.2, 148.4, 149.9, 151.3, 157.1, 174.1; HRMS (EI) m/z calcd for $\text{C}_{36}\text{H}_{34}\text{N}_2\text{O}_4\text{Si}$ (M^+) 586.2281, found
10 586.2288; LRMS (EI) m/z 586 (M^+), 542, 529, 485, 428, 407, 321, 181, 131, 69.

Example 4.

Preparation of (20S)-10-acetoxy-7-trimethylsilylcamptothecin (see Figure 3)



(1) 4-Acetoxyphenyl isonitrile (**14**)

To a solution of 4-acetoxyformanilide (**13**) (358 mg, 1.0 mmol) in CH_2Cl_2 (10 mL) at 0 °C were successively added tetrabromomethane (0.70 g, 2.1 mmol),
20 triphenylphosphine (525 mg, 2.1 mmol), and triethylamine (320 mL, 2.1 mmol), and the resulting mixture was refluxed in the dark for 3 h. After evaporation of the solvents, the crude was triturated in ice-cooled Et_2O (20

SUBSTITUTE SHEET (RULE 26)

mL) and filtered. The solvent was evaporated and the residue was purified by flash-chromatography (hexanes/AcOEt 8:2) to afford 243 mg (76%) of a slightly brown solid: IR (neat, cm^{-1}) 2127, 1768, 1501, 1370, 1201, 1180, 909; ^1H NMR (300 MHz, CDCl_3) δ 2.29 (s, 3 H), 7.11 (d, J = 8.8 Hz, 2 H), 7.38 (d, J = 8.8 Hz, 2 H); ^{13}C NMR (75 MHz, CDCl_3) δ 21.0, 122.8, 127.6, 150.8, 164.3, 168.8; HRMS (EI) m/z calcd for $\text{C}_9\text{H}_7\text{NO}_2$ (M^+) 161.0477, found 161.0474; LRMS (EI) m/z 161 (M^+), 133, 119, 91.


(2) (20S)-10-Acetoxy-7-trimethylsilylcamptothecin (**15**)

Following the procedure described in Example 1-(2), the compound prepared in Example 1-(1) (44.5 mg, 0.10 mmol) and the compound prepared in (1) (48.3 mg, 0.30 mmol) provided, after flash-chromatography (CHCl_3 /acetone 10:1), 29.9 mg (63%) of a slightly yellow oil: $[\alpha]_D^{20}$ +29.9 (c 0.5, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 0.61 (s, 9 H), 0.98 (t, J = 7.4 Hz, 3 H), 1.86 (m, 2 H), 2.38 (s, 3 H), 4.13 (br s, 1 H), 5.24 (d, J = 16.4 Hz, 1 H), 5.27 (s, 2 H), 5.68 (d, J = 16.4 Hz, 1 H), 7.46 (dd, J = 9.2, 2.5 Hz, 1 H), 7.60 (s, 1 H), 7.96 (d, J = 2.5 Hz, 1 H), 8.13 (d, J = 9.2 Hz, 1 H); ^{13}C NMR (75 MHz, CDCl_3) δ 1.4, 7.8, 21.4, 31.5, 51.7, 66.2, 97.6, 118.3, 118.9, 124.6, 132.1, 135.0, 145.7, 146.1, 148.9, 150.1, 150.7, 157.3, 169.1, 173.7; HRMS (EI) m/z calcd for $\text{C}_{25}\text{H}_{26}\text{N}_2\text{O}_6\text{Si}$ (M^+) 478.1560, found 478.1582; LRMS (EI) m/z 478 (M^+), 436, 392, 377, 336, 277.

SUBSTITUTE SHEET (RULE 26)

Example 5.

Preparation of (20S)-10-hydroxy-7-trimethylsilylcamptothecin (**16**)




5 A solution of the compound (**15**) prepared in Example 5-(2) (16.8 mg, 0.035 mmol) and K_2CO_3 (9.6 mg, 0.070 mmol) in MeOH (100 mL) and H_2O (100 mL) was stirred 1 h 30 at room temperature. The reaction mixture was acidified with AcOH (2 drops), diluted with brine (10 mL) and extracted with AcOEt (10 x 10 mL). The combined organic layers were dried (Na_2SO_4) and evaporated, and the residue was purified by flash-chromatographies ($CHCl_3/MeOH/AcOH$ 90:10:2; $CHCl_3/acetone$ 2:1) to give 15.1 mg (99%) of a white solid: $[\alpha]_D^{20} +18.9$ (c 0.2, $CHCl_3/MeOH$ 4:1); 1H NMR (300 MHz, $CDCl_3/CD_3OD$ 4:1) δ 0.45 (s, 9 H), 0.84 (t, $J = 7.3$ Hz, 3 H), 1.75 (m, 2 H), 5.12 (br s, 2 H), 5.12 (d, $J = 16.3$ Hz, 1 H), 5.48 (d, $J = 16.3$ Hz, 1 H), 7.24 (dd, $J = 9.1, 2.5$ Hz, 1 H), 7.39 (d, $J = 2.5$ Hz, 1 H), 7.87 (d, $J = 9.1$ Hz, 1 H); ^{13}C NMR (75 MHz, $CDCl_3/CD_3OD$ 4:1) δ 0.8, 7.4, 31.1, 51.8, 65.7, 97.5, 109.8, 117.5, 122.3, 131.3, 133.7, 134.6, 141.7, 142.6, 146.3, 147.5, 151.1, 156.3, 157.6; HRMS (EI) m/z calcd for $C_{23}H_{24}N_2O_5Si$ (M^+) 436.1454, found 436.1450; LRMS (EI) m/z 436 (M^+), 392, 377, 336, 323.

SUBSTITUTE SHEET (RULE 26)

Reaction of this compound with $\text{NH}_2\text{CH}_2\text{CH}_2\text{NMe}_2$ followed by EtCOCl provided the open E-ring analog for biological testing.

Example 6.

- 5 Preparation of (20S)7-trimethylsilyl-irinotecan (see Figure 6)



- (1) [1,4'] Bipiperidinyl-1'-carboxylic acid 4-nitrophenylester (**32**)
- 10 To a solution of 4-nitrophenyl chloroformate (**31**) (5.15 g, 25.6 mmol) in 150 mL of dry THF at -78°C was added triethylamine (10.7 mL, 76.2 mmol), followed by a solution of 4-piperidinopiperidine (**30**) (4.51 g, 25.6 mmol) in 40 mL of THF. This solution was stirred for two
- 15 hours, after which the solvent was removed, and the residue was taken up in AcOEt, filtered and evaporated. The crude yellow solid was passed through a pad of neutral alumina using AcOEt as an eluent to yield, after evaporation, 6.73 g (79%) of a white solid: IR (CHCl_3 ,
- 20 cm^{-1}) 3046, 2937, 2859, 1704, 1620, 1513, 1466, 1242, 1197; ^1H NMR (300 MHz, CDCl_3) δ 1.20-1.80 (m, 8 H), 1.90 (d, $J = 12.7$ Hz, 2 H), 2.20-2.70 (m, 5 H), 2.87 (t, $J =$

SUBSTITUTE SHEET (RULE 26)

12 Hz, 1 H), 3.01 (t, $J = 12$ Hz, 1 H), 4.30 (br s, 2 H),
7.29 (d, $J = 9$ Hz, 2 H), 8.26 (d, $J = 9$ Hz, 2 H); ^{13}C
NMR (75 MHz, CDCl_3) δ 24.6, 26.3, 27.5, 28.2, 40.1, 44.4,
50.1, 62.0, 122.2, 124.9, 144.8, 151.9, 156.3; HRMS (EI)
5 m/z calcd for $\text{C}_{17}\text{H}_{23}\text{N}_3\text{O}_4$ (M^+) 333.1676, found 333.1688;
LRMS (EI) m/z 333 (M^+), 195, 167, 124, 110, 96, 55.

(2) [1,4'] Bipiperidinyl-1'-carboxylic acid 4-amino-
phenylester

To a solution of the compound prepared in (1)
10 (1.012 g, 3.03 mmol) in AcOEt (125 ml) was added 10% Pd/C
(0.15 g). The system was purged several times with
argon, and a 1 L balloon of H_2 was added. After stirring
the resulting mixture at room temperature for 12 hours,
the catalyst was removed by filtration through celite and
15 the solvent was evaporated to give 835 mg (91%) of a
white solid: IR (CHCl_3 , cm^{-1}) 3453, 3400, 3028, 2936,
2859, 1703, 1513, 1429, 1242, 1226, 1210, 1197; ^1H NMR
(300 MHz, CDCl_3) δ 1.30-1.70 (m, 8 H), 1.86 (d, $J = 12.6$
Hz, 2 H), 2.33-2.62 (m, 5 H), 2.68-3.04 (m, 2 H), 3.58
20 (br s, 2 H), 4.30 (br s, 2 H), 6.64 (d, $J = 6.0$ Hz, 2 H),
6.87 (d, $J = 6.0$ Hz, 2 H); ^{13}C NMR (75 MHz, CDCl_3) δ
24.6, 26.3, 27.5, 28.1, 43.8, 43.9, 50.1, 62.3, 115.4,
122.3, 143.4, 143.7, 154.1; HRMS (EI) m/z calcd for
 $\text{C}_{17}\text{H}_{25}\text{N}_3\text{O}_2$ (M^+) 303.1944, found 303.1947; LRMS (EI) m/z
25 303 (M^+), 195, 167, 124, 108, 96, 80, 65, 55.

SUBSTITUTE SHEET (RULE 26)

(3) [1,4'] Bipiperidiny-1'-carboxylic acid 4-formylamino-phenylester (**33**)

To a stirred solution of dicyclohexylcarbodiimide (272 mg, 1.32 mmol) in CH₂Cl₂ (5 mL) at 0 °C was added 98% formic acid (60.7 mg, 1.32 mmol) dropwise. After 10 minutes, the resulting mixture was added via syringe to a solution of the compound prepared in Example (2) (200 mg, 0.66 mmol) in pyridine (5 mL) at 0 °C. The reaction mixture was then allowed to warm to room temperature and stirred 3 h. The pyridine solvent was evaporated and the residue was taken up in CH₂Cl₂, filtered, evaporated and subjected directly to a basic alumina column (CH₂Cl₂/MeOH 95:5) to give 118 mg (83%) of a white solid, which consists, at room temperature, of a mixture of the cis and trans rotamers originating from hindered rotation around the formamide carbon-nitrogen bond: IR (CHCl₃, cm⁻¹) 3025, 3013, 2937, 2888, 2861, 1703, 1517, 1466, 1275, 1226, 1210; ¹H NMR (300 MHz, CDCl₃) δ 1.38-1.80 (m, 8 H), 1.90 (d, J = 12 Hz, 2 H), 2.40-2.70 (m, 5 H), 2.83 (t, J = 12 Hz, 1 H), 2.97 (t, J = 12 Hz, 1 H), 4.32 (m, 2 H), 7.03-7.11 (m, 3 H), 7.37 (br s, .5 H) (cis), 7.46 (d, J = 10 Hz, 1 H), 7.53 (d, J = 11 Hz, .5 H) (trans), 8.32 (d, J = 2 Hz, .5 H) (cis), 8.59 (d, J = 11 Hz, .5 H) (trans); ¹³C NMR (75 MHz, CDCl₃) δ 24.6, 26.3, 27.6, 28.1, 44.2, 44.0, 50.1, 82.2, 120.0, 121.0, 122.1, 123.0, 133.9, 134.3, 147.5, 148.9, 153.9, 153.4, 159.1, 162.5; HRMS (EI) m/z calcd for C₁₈H₂₅N₃O₃ (M⁺) 331.1884, found 331.1896; LRMS (EI) m/z 331 (M⁺), 244, 202, 167, 124, 80, 55.

SUBSTITUTE SHEET (RULE 26)

(4) [1,4'] Bipiperidinyl-1'-carboxylic acid 4-isonitrilo-phenylester (34)

To a solution of the compound prepared in Example (3) (90.1 mg, 0.272 mmol) in CH₂Cl₂ (10 mL) were successively added triethylamine (69.5 mg, 0.688 mmol) them dropwise, at 0 °C, a solution of triphosgene (68 mg, 0.229 mmol) in dry CH₂Cl₂ (10 mL). The mixture was stirred 2 hours at room temperature, washed with 7% NaHCO₃ (5 mL) and dried (MgSO₄). The crude brown residue obtained after evaporation of the solvent was subjected to flash-chromatography (Et₂O/Et₂NH 95:5) to yield 67.2 mg (79%) of a white solid: IR (CHCl₃, cm⁻¹) 3034, 2937, 2131, 1718, 1504, 1429, 1233, 1224, 1213, 1198, 1184; ¹H NMR (300 MHz, CDCl₃) δ 1.32-1.75 (m, 8 H), 1.90 (br d, J = 12.4 Hz, 2 H), 2.32-2.65 (m, 5 H), 2.84 (t, J = 12.3 Hz, 1 H), 2.98 (t, J = 12.1 Hz, 1 H), 4.20-4.40 (m, 2 H), 7.14 (d, J = 8.8 Hz, 2 H), 7.37 (d, J = 8.8 Hz, 2 H); ¹³C NMR (75 MHz, CDCl₃) δ 25.0, 26.5, 27.8, 28.5, 44.4, 50.6, 62.7, 123.3, 127.8, 152.1, 153.1, 164.4; HRMS (EI) m/z calcd for C₁₈H₂₃N₃O₂ (M⁺) 313.1779, found 313.1790; LRMS (EI) m/z 313 (M⁺), 195, 167, 124, 110, 84, 55.

(5) (20S)-7-Trimethylsilyl-Irinotecan (35)

Following the procedure described in Example 1-(2), the compound prepared in Example 1-(1) (44.5 mg, 0.10 mmol), the compound prepared in (4) (93.9 mg, 0.3 mmol), and hexamethylditin (50 mg, 0.15 mmol) in dry benzene (1.5 mL) were irradiated for 9 hours at 70 ° with a 275W GE sunlamp. The reaction was evaporated, dissolved in MeOH with a few drops of DMSO to aid


SUBSTITUTE SHEET (RULE 26)

solubility and injected into a Waters reverse phase HPLC. The conditions used to effect separation were as follows. A Waters 600E system controller with a Waters 490E Programmable multiwavelength detector, a Sargent Welch plotter and Waters C-18 25x10 cartridge columns were employed. A gradient elution, [5:95 MeCN/H₂O (0.1% TFA) to 30:70 MeCN/H₂O (0.1% TFA)], over 40 minutes time at 20 mL/min gave a semipurified grey solid after lyophilization. The grey solid was further purified (CH₂Cl₂/EtOH 70:30) on a chromatotron using a 1 mm plate to give 12 mg (19%) of a yellow solid: $[\alpha]_D^{20} +14.8$ (c 0.2, CHCl₃); IR (CHCl₃, cm⁻¹) 3023, 2957, 2933, 1720, 1659, 1601, 1216, 1191, 1175, 1158; ¹H NMR (300 MHz, CDCl₃) δ 0.64 (s, 9 H), 1.03 (t, *J* = 7.3 Hz, 3 H), 1.50-1.51 (br m, 2 H), 1.51-1.52 (br m, 6 H), 1.84 (m, *J* = 7.3 Hz, 2 H), 2.01- 2.10 (br m, 2 H), 2.60-2.75 (br s, 5 H), 2.75-3.12 (br m, 2 H), 4.30-4.50 (br m, 2 H), 5.30 (d, *J* = 16.3 Hz, 1 H), 5.31 (s, 2 H), 5.74 (d, *J* = 16.3 Hz, 1 H), 7.55 (dd, *J* = 9.0, 2.4 Hz, 1 H), 7.63 (s, 1 H), 8.01 (d, *J* = 2.3 Hz, 1 H), 8.19 (d, *J* = 9 Hz, 1 H); ¹³C NMR (75 MHz, CDCl₃) δ 1.5, 7.8, 25.4, 29.7, 31.5, 43.8, 50.1, 51.8, 62.5, 66.3, 72.8, 97.5, 118.1, 119.0, 125.1, 132.0, 132.3, 134.9, 143.4, 145.6, 146.4, 150.1, 150.5, 152.8, 157.4, 174.0; HRMS (EI) *m/z* calcd for C₃₄H₄₂N₄O₆Si (M⁺) 630.2898, found 630.2874; LRMS (EI) *m/z* 630 (M⁺), 586, 501, 457, 195, 167, 153, 124, 111, 96, 84.

SUBSTITUTE SHEET (RULE 26)

Example 7.

Preparation of (20S)-11-fluoro-7-trimethylsilylcamptothecin (see Figure 2)



5 (1) 3-Fluoro-2-trimethylsilylbenzaldehyde (7)

The preparation of 3-fluoro-2-trimethylsilylbenzaldehyde proceeds through a selective *ortho*-metallation. See Comins, D. L. et al., *J. Org. Chem.*, 49, 1078 (1984). See also Snieckus, V., *Chem. Rev.*, 90, 879 (1990). To a solution of *N,N,N'*-trimethylethylenediamine (2.70 mL, 20 mmol) in THF (50 mL) was slowly added 1.6 N *n*-BuLi in hexanes (13 mL, 21 mmol) at -20 °C, followed by 3-fluorobenzaldehyde (2.10 mL, 20 mmol) 15 min latter. After 15 minute at this temperature, 1.6 N *n*-BuLi in hexanes (38 mL, 60 mmol) was injected and the solution was stirred 1 h 30 at -35 °C. Chlorotrimethylsilane (15 mL, 120 mmol) was added and the reaction mixture was stirred overnight at room temperature. The final solution was poured into ice-cooled 1 N HCl (150 mL), quickly extracted with Et₂O (3 x 100), washed with brine and dried (Na₂SO₄). After evaporation of the solvents, the residue was purified by flash-chromatography (hexanes/AcOEt 95:5) to provide 3.25 g (83%) of an oil: IR (neat, cm⁻¹) 1701, 1440, 1252, 1233, 1109, 848, 764; ¹H NMR (300 MHz, CDCl₃) δ 0.40 (d,

SUBSTITUTE SHEET (RULE 26)

$J = 2.6$ Hz, 9 H), 7.18 (br t, $J = 9.0$ Hz, 1 H), 7.47 (ddd, $J_1 = J_2 = 8.1$ Hz, $J_3 = 5.4$ Hz, 1 H), 7.70 (br d, $J = 7.5$ Hz, 1 H); ^{13}C NMR (75 MHz, CDCl_3) δ 1.8, 120.8 (d, $J_{\text{CF}} = 29$ Hz), 126.8, 128.2, 131.2, 143.3, 167.6 (d, $J_{\text{CF}} = 244$ Hz), 192.4; HRMS (EI) m/z calcd for $\text{C}_9\text{H}_{10}\text{FOSi}$ (M-CH_3^+) 181.0485, found 181.0482; LRMS (EI) m/z 181 (M-CH_3^+), 151, 125, 103, 91.

(2) 3-Fluoro-2-trimethylsilylbenzoic acid

A classical oxidation to the free acid was then performed. See Hill, L. R. et al., *J. Org. Chem.*, 50, 470 (1985). To a solution of the compound prepared in (1) (3.41 g, 17.3 mmol) in *tert*-butanol (20 mL) were successively added a 2 N solution of 2-methyl-2-butene in THF (55 mL, 110 mmol) then slowly, over a period of 10 minutes, a solution of 80% NaClO_2 (2.55 g, 22.5 mmol) and $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$ (3.10 g, 22.5 mmol) in water (18 mL). The resulting mixture was stirred 16 h at room temperature, the *tert*-butanol was evaporated, and the residue was taken up in 1 N NaOH (50 mL) and washed with hexanes (3 x 20 mL). The aqueous layer was acidified with 1 N HCl to pH 2, saturated with NaCl, and extracted with Et_2O (3 x 50 mL). The combined organic layers were dried (Na_2SO_4) and evaporated to provide 3.13 g (85%) of a white solid: IR (NaCl , cm^{-1}) 2982, 1700, 1434, 1294, 1271, 1253, 1230, 849, 763; ^1H NMR (300 MHz, CDCl_3) δ 0.39 (d, $J = 2.6$ Hz, 9 H), 7.16 (br t, $J = 9.1$ Hz, 1 H), 7.41 (ddd, $J_1 = J_2 = 7.9$ Hz, $J_3 = 5.6$ Hz, 1 H), 7.73 (br d, $J = 7.7$ Hz, 1 H); ^{13}C NMR (75 MHz, CDCl_3) δ 1.3, 119.5 (d, $J_{\text{CF}} = 27$ Hz), 126.0, 127.3, 130.9, 138.0, 167.5 (d, $J_{\text{CF}} = 243$ Hz),

SUBSTITUTE SHEET (RULE 26)

174.5; HRMS (EI) m/z calcd for $C_9H_{10}FO_2Si$ ($M-CH_3^+$)
197.0434, found 197.0433; LRMS (EI) m/z 197 ($M-CH_3^+$),
179, 133, 115, 105.

(3) 3-Fluoro-2-trimethylsilylphenyl isocyanate (**8**)

5 Preparation of the intermediate isocyanate was
carried out via a Curtius rearrangement. See Capson, T.
L. et al., *Tetrahedron Lett.*, 25, 3515 (1984) and
references herein. To a solution of the compound
prepared in (2) (3.03 g, 14.3 mmol) in CH_2Cl_2 (20 mL) was
10 added oxalylchloride (1.30 mL, 15.0 mmol) and the
resulting mixture was stirred 3 h at room temperature.
The residue obtained after evaporation of the solvent was
diluted with THF (10 mL) and injected with vigorous
stirring to a ice-cooled solution of NaN_3 (3.70 g, 57
15 mmol) in H_2O (20 mL) and acetone (50 mL). After 15 min
at 0 °C and 1 min at room temperature, the solution was
extracted with Et_2O (4 x 50 mL) and dried (Na_2SO_4). The
residue obtained after evaporation of solvents was
refluxed in toluene for 1 h 30 to provide, upon solvent
20 removal, 2.85 g (79%) of a slightly yellow oil: IR
(neat, cm^{-1}) 2269, 1598, 1433, 1252, 1228, 846, 788; 1H
NMR (300 MHz, $CDCl_3$) δ 0.38 (d, $J = 1.9$ Hz, 9 H), 6.82
(br t, $J = 8.3$ Hz, 1 H), 6.90 (br d, $J = 8.2$ Hz, 1 H),
7.25 (ddd, $J_1 = J_2 = 8.1$ Hz, $J_3 = 6.6$ Hz, 1 H); ^{13}C NMR
25 (75 MHz, $CDCl_3$) δ 0.4, 112.6 (d, $J_{CF} = 26$ Hz), 120.5,
122.5, 131.5, 139.2, 167.4 (d, $J_{CF} = 241$ Hz).

SUBSTITUTE SHEET (RULE 26)

(4) 3-Fluoro-2-trimethylsilylphenyl isonitrile (9)

A deoxygenation then afforded the expected isonitrile. See Baldwin, J. E. et al., *Tetrahedron*, 39, 2989 (1983). Triethylamine (4.10 mL, 29.3 mmol) was added slowly at 0 °C to a 2 N solution of trichlorosilane in CH₂Cl₂ (8.40 mL, 16.8 mmol) followed, 5 min latter, by the compound prepared in Example (3) (2.35 g, 11.2 mmol). After 1 h 30 at 0 °C and 30 min at room temperature, the solution was saturated with NH₃, filtered over Celite, washed with 5% NaH₂PO₄ and dried (Na₂SO₄). The crude obtained after evaporation of the solvent was then subjected to flash-chromatography (hexanes/AcOEt 95:5) to afford 1.42 g (66%) of a slightly purple liquid: IR (neat, cm⁻¹) 2114, 1598, 1440, 1254, 1237, 1110, 943, 848, 793; ¹H NMR (300 MHz, CDCl₃) δ 0.45 (d, J = 1.8 Hz, 9 H), 7.01 (br t, J = 8.3 Hz, 1 H), 7.17 (br d, J = 7.7 Hz, 1 H), 7.32 (ddd, J₁ = J₂ = 8.0 Hz, J₃ = 6.1 Hz, 1 H); ¹³C NMR (75 MHz, CDCl₃) δ 0.1, 116.5 (d, J_{CF} = 26 Hz), 124.3, 131.6, 166.8 (d, J_{CF} = 243 Hz), 166.9; HRMS (EI) m/z calcd for C₁₀H₁₂FNSi (M⁺) 193.0723, found 193.0715; LRMS (EI) m/z 193 (M⁺), 178, 150, 116, 105.

(5) (20S)-11-Fluoro-7,12-bis(trimethylsilyl)camptothecin (11)

Following the procedure described in Example 1-(2), the compound prepared in Example 1-(1) (43.5 mg, 0.098 mmol) and the compound prepared in Example (4) (76 mg, 0.39 mmol) provided, after flash-chromatography (CHCl₃/acetone 20:1), 33.4 mg (67%) of a slightly yellow oil: [α]_D²⁰ +23.6 (c 0.2, CHCl₃); ¹H NMR (300 MHz, CDCl₃)

SUBSTITUTE SHEET (RULE 26)

δ 0.53 (d, J = 1.7 Hz, 9 H), 0.60 (s, 9 H), 1.02 (t, J = 7.4 Hz, 3 H), 1.88 (m, 2 H), 3.82 (br s, 1 H), 5.28 (d, J = 16.3 Hz, 1 H), 5.29 (br s, 2 H), 5.72 (d, J = 16.3 Hz, 1 H), 7.31 (t, J = 8.7 Hz, 1 H), 7.46 (s, 1 H), 8.18 (dd, J = 9.2, 5.9 Hz, 1 H); ^{13}C NMR (75 MHz, CDCl_3) δ 1.6, 1.7, 7.7, 31.4, 51.8, 66.3, 72.7, 97.2, 117.8 (d, J_{CF} = 33 Hz), 124.3 (d, J_{CF} = 28 Hz), 128.9, 131.1, 133.1, 144.4, 146.7, 150.1, 153.4, 157.4, 167.6 (d, J_{CF} = 245 Hz), 173.9; HRMS (EI) m/z calcd for $\text{C}_{26}\text{H}_{31}\text{FN}_2\text{O}_4\text{Si}_2$ (M^+) 510.1806, found 510.1806; LRMS (EI) m/z 510 (M^+), 495, 466, 451, 395, 319.

(6) (2*S*)-11-Fluoro-7-trimethylsilylcamptothecin (**12**)

A solution of the compound prepared in Example (5) (19.5 mg, 0.038 mmol) in 48% HBr (1 mL) was heated at 50 °C for 20 h. The reaction mixture was slowly poured with vigorous stirring into saturated NaHCO_3 (10 mL), extracted with AcOEt (6 x 20 mL) and dried (Na_2SO_4). After evaporation of the solvent, the residue was purified by flash-chromatography (CHCl_3 /acetone 8:1) to give 12.5 mg (83%) of a slightly yellow solid: $[\alpha]_{\text{D}}^{20}$ +39.6 (c 0.2, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 0.62 (s, 9 H), 1.01 (t, J = 7.4 Hz, 3 H), 1.87 (m, 2 H), 3.81 (br s, 1 H), 5.28 (d, J = 16.4 Hz, 1 H), 5.28 (br s, 2 H), 5.72 (d, J = 16.4 Hz, 1 H), 7.31 (ddd, J = 9.6, 7.8, 2.8 Hz, 1 H), 7.61 (s, 1 H), 7.78 (dd, J = 9.7, 2.7 Hz, 1 H), 8.19 (dd, J = 9.4, 5.8 Hz, 1 H); ^{13}C NMR (75 MHz, CDCl_3) δ 1.6, 7.8, 31.5, 51.7, 66.3, 72.7, 97.8, 114.3 (d, J_{CF} = 20 Hz), 117.7 (d, J_{CF} = 26 Hz), 118.5, 128.9, 130.0, 133.9, 144.4, 146.1, 149.3, 150.1, 151.7, 157.4, 162.6


SUBSTITUTE SHEET (RULE 26)

73

(d, $J_{CF} = 250$ Hz), 173.9; HRMS (EI) m/z calcd for $C_{23}H_{23}FN_2O_4Si$ (M^+) 438.1411, found 438.1412; LRMS (EI) m/z 438 (M^+), 409, 394, 379, 365, 338, 309.

Example 8.

- 5 Preparation of (20S)-10-amino-7-trimethylsilylcampthothecin (see Figure 4) (CHJ-792)



- (1) 4-*tert*-Butyloxycarbonylamino phenyl isonitrile (**18**)

- The isonitrile was prepared in 2 steps via
 10 classical Boc-protection followed by dehydration. See
 Einhorn, J. et al., *Synlett*, 37 (1991). A mixture of 4-
 aminoformanilide (1.71 g, 12.6 mmol), di-*tert*-butyl
 dicarbonate (2.87 g, 13.2 mmol) and $NaHCO_3$ (1.11 g, 13.2
 mmol) in absolute EtOH (50 mL) was sonicated in a
 15 cleaning bath for 4 h. The final solution was filtered
 through a pad of Celite and concentrated to dryness. The
 residue was taken up in half brine (50 mL), extracted
 with AcOEt (6 x 30 mL) and dried (Na_2SO_4). After
 evaporation of the solvent, the residual oil was
 20 subjected to flash-chromatography ($CHCl_3/MeOH$ 95:5) to
 give 2.85 g (96%) of 4-*tert*-
 butyloxycarbonylaminoformanilide, as a white solid. This
 intermediate (945 mg, 4.0 mmol) was subjected to the

SUBSTITUTE SHEET (RULE 26)

conditions described in Example 5-(1) to provide, after flash-chromatography (hexanes/AcOEt 9:1), 502 mg (58%) of a slightly brown solid: IR (NaCl, cm^{-1}) 3370, 2121, 1691, 1524, 1412, 1364, 1239, 1158, 832; ^1H NMR (300 MHz, CDCl_3) δ 1.48 (s, 9 H), 6.75 (br s, 1 H), 7.26 (d, J = 8.8 Hz, 2 H), 7.37 (d, J = 8.8 Hz, 2 H); ^{13}C NMR (75 MHz, CDCl_3) δ 28.2, 81.3, 118.5, 127.1, 139.4, 152.3, 162.7; HRMS (EI) m/z calcd for $\text{C}_{12}\text{H}_{14}\text{N}_2\text{O}_2$ (M^+) 218.1055, found 218.1044; LRMS (EI) m/z 218 (M^+), 162, 144.

10 (2) (20S)-10-tert-Butyloxycarbonylamino-7-trimethylsilyl camptothecin (**19**)

Following the procedure described in Example 1-(2), the compound prepared in Example 1-(1) (44.5 mg, 0.10 mmol) and the compound prepared in Example (1) (65 mg, 0.30 mmol) provided, after flash-chromatography (CHCl_3 /acetone 6:1), 32.5 mg (60%) of a slightly yellow solid: $[\alpha]_{\text{D}}^{20}$ +28.0 (c 0.2, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 0.63 (s, 9 H), 0.99 (t, J = 7.4 Hz, 3 H), 1.53 (s, 9 H), 1.86 (m, 2 H), 4.03 (br s, 1 H), 5.24 (d, J = 16.2 Hz, 1 H), 5.26 (s, 2 H), 5.70 (d, J = 16.2 Hz, 1 H), 7.00 (br s, 1 H), 7.47 (dd, J = 9.2, 2.3 Hz, 1 H), 7.55 (s, 1 H), 8.02 (d, J = 9.2 Hz, 1 H), 8.56 (br s, 1 H); ^{13}C NMR (75 MHz, CDCl_3) δ 1.3, 7.8, 28.2, 31.5, 51.8, 66.3, 72.8, 97.1, 114.4, 117.8, 122.6, 131.3, 132.8, 135.0, 137.2, 142.9, 144.3, 146.6, 149.2, 150.1, 157.4, 173.9; HRMS (EI) m/z calcd for $\text{C}_{23}\text{H}_{25}\text{N}_3\text{O}_4\text{Si}$ (M-Boc $^+$) 435.1614, found 435.1612; LRMS (EI) m/z 535 (M^+), 479, 435, 391, 362, 335.


SUBSTITUTE SHEET (RULE 26)

(3) (20S)-10-Amino-7-trimethylsilylcamptothecin (20)

A solution of the compound prepared in Example (2) (75.5 mg, 0.141 mmol) and TFA (500 mL) in CH₂Cl₂ (2 mL) was stirred 3 h at room temperature. The reaction mixture was then poured into saturated NaHCO₃ (50 mL), extracted with AcOEt (10 x 15 mL) and dried (Na₂SO₄). The residue obtained after evaporation of the solvents was purified by flash-chromatography (CHCl₃/MeOH 95:5) to afford 55.4 mg (90%) of a yellow solid: $[\alpha]_D^{20} +18.7$ (c 0.15, CHCl₃/MeOH 4:1); ¹H NMR (300 MHz, CDCl₃/CD₃OD 4:1) δ 0.40 (s, 9 H), 0.80 (t, *J* = 7.4 Hz, 3 H), 1.70 (m, 2 H), 5.05 (s, 2 H), 5.08 (d, *J* = 16.3 Hz, 1 H), 5.43 (d, *J* = 16.3 Hz, 1 H), 7.05 (br s, 1 H), 7.07 (d, *J* = 8.0 Hz, 1 H), 7.38 (s, 1 H), 7.74 (d, *J* = 8.0 Hz, 1 H); ¹³C NMR (75 MHz, CDCl₃/CD₃OD 4:1) δ 0.6, 7.2, 30.8, 51.8, 65.5, 72.7, 97.0, 107.2, 116.8, 122.0, 130.7, 134.0, 134.7, 139.9, 141.7, 145.8, 146.9, 151.2, 157.5, 173.7; HRMS (EI) *m/z* calcd for C₂₃H₂₅N₃O₄Si (M⁺) 435.1614, found 435.1613; LRMS (EI) *m/z* 435 (M⁺), 391, 376, 335, 290.

20 Example 9.

Preparation of (20S)-11-amino-7-trimethylsilylcamptothecin



SUBSTITUTE SHEET (RULE 26)

(1) 3-*tert*-Butyloxycarbonylamino-phenyl isonitrile

The isonitrile was prepared in 2 steps following the same procedures as described in Example 9-(1). In the first step, the Boc-protection of 3-aminoformanilide (1.80 g, 13.2 mmol) provided, after flash-chromatography (CHCl₃/MeOH 95:5), 2.65 g (85%) of 3-*tert*-butyloxycarbonylaminoformanilide, as a white solid. This intermediate (412 mg, 1.74 mmol) was then subjected to the conditions described in Example 5-(1) to provide, after flash-chromatography (hexanes/AcOEt 9:1), 190 mg (50%) of a brown solid: IR (NaCl, cm⁻¹) 3318, 2126, 1715, 1603, 1547, 1433, 1236, 1162, 782; ¹H NMR (300 MHz, CDCl₃) δ 1.49 (s, 9 H), 6.67 (br s, 1 H), 7.00 (m, 1 H), 7.20-7.30 (m, 2 H), 7.60 (br s, 1 H); ¹³C NMR (75 MHz, CDCl₃) δ 28.2, 81.3, 116.0, 118.9, 120.6, 129.8, 139.5, 152.3, 163.6; HRMS (EI) *m/z* calcd for C₁₂H₁₄N₂O₂ (M⁺) 218.1055, found 218.1047; LRMS (EI) *m/z* 218 (M⁺), 196, 162, 152, 118.

(2) (2*S*)-11-Amino-7-trimethylsilylcamptothecin


Following the procedure described in Example 1-(2), the compound prepared in Example 1-(1) (44.5 mg, 0.10 mmol) and the compound prepared in Example (1) (65.5 mg, 0.3 mmol) afforded, after flash-chromatographies (CHCl₃/MeOH 95:5; CHCl₃/acetone 5:1), 23.1 mg (43%) of a slightly yellow oil. This intermediate (14.7 mg, 0.027 mmol) was then deprotected following the conditions described in Example 9-(3) to provide, after flash-chromatography (CHCl₃/MeOH 9:1), 11.8 mg (99%) of (2*S*)-11-amino-7-trimethylsilylcamptothecin, as a yellow solid

SUBSTITUTE SHEET (RULE 26)

and with the exclusion of other isomers: $[\alpha]_D^{20} +15.0$ (c 0.1, CHCl₃/MeOH 4:1); ¹H NMR (300 MHz, CDCl₃/CD₃OD 4:1) δ 0.44 (s, 9 H), 0.86 (t, *J* = 7.4 Hz, 3 H), 1.76 (m, 2 H), 5.08 (s, 2 H), 5.14 (d, *J* = 16.4 Hz, 1 H), 5.50 (d, *J* = 16.3 Hz, 1 H), 6.97 (dd, *J* = 9.2, 2.5 Hz, 1 H), 7.07 (d, *J* = 2.5 Hz, 1 H), 7.50 (s, 1 H), 7.84 (d, *J* = 9.2 Hz, 1 H); ¹³C NMR (75 MHz, CDCl₃/CD₃OD 4:1) δ 1.1, 7.4, 31.0, 51.7, 65.6, 97.9, 107.9, 117.8, 119.7, 125.9, 127.1, 129.0, 130.4, 135.4, 144.3, 149.5, 149.9, 151.1, 157.6, 175.3; HRMS (EI) *m/z* calcd for C₂₃H₂₅N₃O₄Si (M⁺) 435.1614, found 435.1626; LRMS (EI) *m/z* 435 (M⁺), 406, 391, 376, 335.

Example 10.

Preparation of (20*S*)-11-fluoro-10-amino-7-trimethylsilylcamptothecin (see Figure 5)



(1) 4-*tert*-Butyloxycarbonylamino-3-fluoro-1-nitrobenzene (**22**)

To a solution of 2-fluoro-4-nitroaniline (**21**) [prepared according to Katritsky, A. R. et al., *J. Org. Chem.*, 51, 5039 (1986)] (2.16 g, 13.9 mmol) in CH₂Cl₂ (25 mL) were successively added di-*tert*-butyl dicarbonate

SUBSTITUTE SHEET (RULE 26)

(3.19 g, 14.6 mmol), triethylamine (2.95 mL, 20.8 mmol) and 4-dimethylaminopyridine (210 mg, 1.67 mmol) and the reaction mixture was stirred 16 h at room temperature. The final solution was diluted with CH₂Cl₂ (75 mL), washed with ice-cooled 5% citric acid (4 x 50 mL) and dried (Na₂SO₄). After evaporation of the solvent, the residue was subjected to flash-chromatography (Hexanes/AcOEt 9:5) to provide, in order of elution, first 1.95 g (55%) of the mono-protected derivative, 4-*tert*-butyloxycarbonylamino-3-fluoro-1-nitrobenzene, secondly 1.13 g (23%) of the bis-protected derivative, 4-di-*tert*-butyloxycarbonylamino-3-fluoro-1-nitrobenzene. The characteristics of the mono-protected derivative are as follows: ¹H NMR (300 MHz, CDCl₃) δ 1.52 (s, 9 H), 6.99 (br s, 1 H), 7.95 (m, 1 H), 8.03 (br d, *J* = 9.2 Hz, 1 H), 8.34 (br t, *J* = 8.5 Hz, 1 H); ¹³C NMR (75 MHz, CDCl₃) δ 28.1, 82.5, 110.9 (d, *J*_{CF} = 23 Hz), 118.3, 120.8, 133.5, 141.7, 150.1 (d, *J*_{CF} = 243 Hz), 151.4; HRMS (EI) *m/z* calcd for C₁₁H₁₃FN₂O₄ (M⁺) 256.0859, found 258.0854; LRMS (EI) *m/z* 256 (M⁺), 200, 182, 57.

(2) 4-*tert*-Butyloxycarbonylamino-3-fluoroaniline (**24**)

Reduction of the nitro group to the amine function was carried out following a classical procedure. See Ram, S. et al., *Tetrahedron Lett.*, 25, 3415 (1984). To a solution of the compound prepared in Example (1) (1.62 g, 6.32 mmol) and ammonium formate (1.70 g, 27 mmol) in anhydrous MeOH (12 mL) was added 10% Pd-C (400 mg) in one portion. After 2 h at room temperature, the final solution was filtered over Celite, concentrated and the residue was directly subjected to flash-chromatography (CHCl₃/MeOH 9:1) to provide 1.40 g (98%)

SUBSTITUTE SHEET (RULE 26)

of a slightly yellow oil: ^1H NMR (300 MHz, CD_3SOCD_3) δ 1.40 (s, 9 H), 5.22 (s, 2 H), 6.25-6.35 (m, 2 H), 6.93 (br t, $J = 8.0$ Hz, 1 H), 8.29 (br s, 1 H); ^{13}C NMR (75 MHz, CDCl_3) δ 28.5, 80.4, 102.1 (d, $J_{\text{CF}} = 24$ Hz), 110.7, 117.2, 122.8, 143.4, 153.1, 154.1 (d, $J_{\text{CF}} = 244$ Hz); HRMS (EI) m/z calcd for $\text{C}_{11}\text{H}_{15}\text{FN}_2\text{O}_2$ (M^+) 226.1118, found 226.1116; LRMS (EI) m/z 226 (M^+), 170, 126, 83, 57.


(3) 4-*tert*-Butyloxycarbonylamino-3-fluorophenyl isonitrile (**25**)

10 To a stirred solution of dicyclohexylcarbodiimide (1.51 g, 7.31 mmol) in CH_2Cl_2 (15 mL) at 0 °C was added formic acid (275 mL, 7.31 mmol) dropwise. After 10 minutes, the resulting mixture was added over a period of 5 minutes to a solution of the
15 compound prepared in Example (2) (1.28 g, 5.66 mmol) in CH_2Cl_2 (10 mL) and pyridine (0.61 mL, 7.50 mmol) at 0 °C. The reaction mixture was then allowed to warm to room temperature and stirred 16 h. After filtration over Celite, the final solution was concentrated and subjected
20 to flash-chromatography ($\text{CHCl}_3/\text{AcOEt}$ 85:15) to give 1.44 g (100%) of 4-*tert*-butyloxycarbonylamino-3-fluoroformamide, as a white solid. This intermediate (1.38 g, 5.43 mmol) was dissolved in CH_2Cl_2 (20 mL) and, at 0 °C, were successively added tetrabromomethane (1.93
25 g, 5.80 mmol), triphenylphosphine (1.52 g, 5.80 mmol), and 1.4-diazabicyclo[2.2.2]octane (DABCO, 650 mg, 5.80 mmol). The reaction mixture was allowed to warm to room temperature and stirred 2 h. After evaporation of the solvent, the crude was triturated in ice-cooled Et_2O (20
30 mL) and filtered over Celite. The residue obtained after evaporation of the solvent was purified by flash-

SUBSTITUTE SHEET (RULE 26)

chromatography (hexanes/AcOEt 95:5 to 9:1) to provide 660 mg (51%) of a slightly brown solid: ^1H NMR (300 MHz, CDCl_3) δ 1.51 (s, 9 H), 6.76 (br s, 1 H), 7.05-7.20 (m, 2 H), 8.17 (br t, $J = 8.6$ Hz, 1 H); ^{13}C NMR (75 MHz, CDCl_3) δ 28.1, 81.8, 113.3 (d, $J_{\text{CF}} = 25$ Hz), 119.7, 123.0, 128.6, 150.6 (d, $J_{\text{CF}} = 242$ Hz), 151.8, 164.2; HRMS (EI) m/z calcd for $\text{C}_{12}\text{H}_{13}\text{FN}_2\text{O}_2$ (M^+) 236.0961, found 236.0952; LRMS (EI) m/z 236 (M^+), 180, 163, 136, 08, 57.

(4) (20S)-10-*tert*-Butyloxycarbonylamino-11-fluoro-7-trimethylsilyl-camptothecin (26) and (20S)-10-*tert*-butyloxycarbonylamino-9-fluoro-7-trimethylsilylcamptothecin (27) (mixture respectively 1.9:1)



Following the procedure described in Example 1-(2), the compound prepared in Example 1-(1) (66.8 mg, 0.15 mmol) and the compound described in Example (3) (110 mg, 0.50 mmol) provided, after flash-chromatographies ($\text{CHCl}_3/\text{MeOH}$ 96:4; $\text{CHCl}_3/\text{acetone}$ 10:1), 47.6 mg (57%) of a slightly yellow oil containing the above regioisomers: ^1H NMR (300 MHz, CDCl_3) δ 0.54 (d, $J = 4.9$ Hz, 9 H_{minor}), 0.65 (s, 9 H_{major}), 0.99 (t, $J = 7.3$ Hz, 3 H), 1.86 (m, 2 H), 3.93 (br s, 1 H), 5.24 (d, $J = 16.3$ Hz, 1 H_{minor}), 5.25 (br s, 2 H_{major}), 5.25 (d, $J = 16.3$ Hz, 1 H_{major}),

SUBSTITUTE SHEET (RULE 26)

5.30 (br s, 2 H_{minor}), 5.68 (d, $J = 16.3$ Hz, 1 H_{minor}),
5.69 (d, $J = 16.3$ Hz, 1 H_{major}), 6.98 (d, $J = 3.6$ Hz, 1
H_{minor}), 7.02 (d, $J = 3.6$ Hz, 1 H_{major}), 7.52 (s, 1
H_{minor}), 7.53 (s, 1 H_{major}), 7.74 (d, $J = 12.1$ Hz, 1
5 H_{major}), 7.92 (br d, $J = 9.3$ Hz, 1 H_{minor}), 8.60 (br t, J
= 8.4 Hz, 1 H_{minor}), 9.08 (d, $J = 8.7$ Hz, 1 H_{major});
HRMS (EI) m/z calcd for C₂₈H₃₂FN₃O₆Si 553.2044, found
553.2022; LRMS (EI) m/z 553 (M⁺), 493, 479, 453, 435,
424, 409, 394, 380, 353.

10 (5) (20S)-10-Amino-11-fluoro-7-
trimethylsilylcamptothecin (28)


The compound prepared in Example (4) (41.3 mg,
0.0746 mmol) was deprotected following the conditions
described in Example 9-(3). After workup, the crude was
15 subjected to a flash-chromatography (CHCl₃/acetone/MeOH
70:10:1.5) to provide, in order of elution, first 14.1 mg
(42%) of the pure (20S)-10-amino-11-fluoro-7-
trimethylsilyl-camptothecin, then a 15.2 mg of a c.a. 1:1
mixture of (20S)-10-amino-11-fluoro-7-
20 trimethylsilylcamptothecin and (20S)-10-amino-9-fluoro-7-
trimethylsilylcamptothecin. The characteristics of
(20S)-10-amino-11-fluoro-7-trimethylsilylcamptothecin are
as follows: $[\alpha]_D^{20} +20.0$ (c 0.2, CHCl₃/MeOH 4:1); ¹H NMR
(300 MHz, CDCl₃) δ 0.59 (s, 9 H), 1.00 (t, $J = 7.4$ Hz, 3
25 H), 1.86 (m, 2 H), 3.86 (br s, 1 H), 4.31 (br s, 2 H),
5.21 (br s, 2 H), 5.26 (d, $J = 16.4$ Hz, 1 H), 5.69 (d, J
= 16.4 Hz, 1 H), 7.30 (d, $J = 9.3$ Hz, 1 H), 7.50 (s, 1
H), 7.69 (d, $J = 11.8$ Hz, 1 H); ¹³C NMR (75 MHz,
CDCl₃/CD₃OD 10:1) δ 1.4, 7.7, 31.4, 51.9, 66.1, 72.7,
30 97.1, 109.4, 113.6 (d, $J_{CF} = 20$ Hz), 117.3, 130.8, 134.4,

SUBSTITUTE SHEET (RULE 26)

136.4, 140.2, 142., 146.5, 147.6, 150.6, 153.9, 154.0 (d, $J_{CF} = 251$ Hz), 157.6, 173.9; HRMS (EI) m/z calcd for $C_{23}H_{24}FN_3O_4Si$ (M^+) 453.1520, found 453.1500; LRMS (EI) m/z 453 (M^+), 424, 409, 394, 352, 181, 131, 119.

5 Example 11.

Preparation of (20S)-11,12-difluoro-7-trimethylsilylcamptothecin and (20S)-9,10-difluoro-7-trimethylsilylcamptothecin (mixture respectively 3:1)




10 Following the procedure described in Example 1-
 (2), the compound prepared in Example 1-(1) (44.5 mg,
 0.10 mmol) and 2,3-difluorophenyl isonitrile [prepared in
 20% yield following the procedure of Weber, W. P. et al.,
Tetrahedron Lett., 13, 1637 (1972) with stirring 2 days
 15 at room temperature before workup] (42 mg, 0.30 mmol)
 afforded, after flash-chromatographies ($CHCl_3/MeOH$ 95:5;
 $CHCl_3/acetone$ 10:1 to 4:1), 22.6 mg (50%) of a slightly
 yellow oil containing the above regioisomers: 1H NMR
 (300 MHz, $CDCl_3$) δ 0.56 (d, $J = 4.8$ Hz, 1 H_{minor}), 0.65
 20 (s, 9 H_{major}), 1.00 (t, $J = 7.4$ Hz, 3 H), 1.86 (m, 2 H),
 3.87 (br s, 1 H_{minor}), 3.97 (br s, 1 H_{major}), 5.0-5.47
 (m, 3 H), 5.68 (d, $J = 16.5$ Hz, 1 H), 5.70 (d, $J = 16.4$
 Hz, 1 H_{minor}), 7.31 (m, 1 H_{minor}), 7.44 (dt, $J = 9.4$, 7.4
 Hz, 1 H_{major}), 7.59 (s, 1 H_{minor}), 7.60 (s, 1 H_{major}),

SUBSTITUTE SHEET (RULE 26)

7.68 (m, 1 H_{minor}), 7.93 (m, 1 H_{major}); HRMS (EI) m/z calcd for $C_{23}H_{22}F_2N_2O_4Si$ (M^+) 456.1317, found 456.1321; LRMS (EI) m/z 456 (M^+), 438, 428, 412, 383, 356, 327.

Example 12.

5 Preparation of 20S-7-triisopropylsilylcamptothecin



(1) (S)-4-Ethyl-4-hydroxy-6-iodo-3-oxo-7-(triisopropylsilyl-2-propynyl)-1H-pyrano[3,4-c]-8-pyridone

- 10 Following the procedure outlined in example 1-(1), iodopyridone 2, (200 mg, 0.598 mmol) was combined with triisopropylsilyl-2-propynyl bromide (329 mg, 1.196 mmol). Chromatography (CH_2Cl_2 /AcOEt 9:1) gave 41.1 mg (13%) of a white foam: 1H NMR (300 MHz, $CDCl_3$) δ 0.91 (t, J = 7 Hz, 6 H), 0.99 (s, 18 H), 1.71 (m, J = 7 Hz, 2 H), 3.65 (s, 1 H), 5.0-5.2 (m, 3 H), 5.45 (d, J = 16 Hz, 1 H), 7.13 (s, 1 H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 7.7, 11.2, 18.7, 31.7, 44.6, 66.5, 71.9, 87.7, 100.1, 116.6, 118.2, 148.6, 158.0, 173.4; HRMS (EI) m/z calcd for $C_{22}H_{32}INO_4Si$ (M^+) 529.1162, found 529.1145; LRMS (EI) m/z 529 (M^+), 486, 442, 82, 59.


SUBSTITUTE SHEET (RULE 26)

(2) (20S)-7-Triisopropylsilylcamptothecin

Following the procedure outlined in example 1-(2), the pyridone described above (41 mg, 0.077 mmol) yielded 23.3 mg (60%) of a light yellow solid: $[\alpha]_D^{20} +31.7$ (c 0.2, CH₂Cl₂); IR (CHCl₃, cm⁻¹) 3026, 3008, 2996, 2962, 2950, 2932, 2892, 2869, 1742, 1658, 1598, 1555, 1466, 1230, 1220, 1158; ¹H NMR (300 MHz, CDCl₃) δ 1.02 (t, J = 7 Hz, 3 H), 1.18 (d, J = 7 Hz, 18 H), 1.60-2.0 (m, 5 H), 2.17 (s, 1 H), 5.31 (d, J = 16 Hz, 1 H), 5.41 (s, 2 H), 5.76 (d, J = 16, 1 H), 7.61 (t, J = 7 Hz, 1 H), 7.69 (s, 1 H), 7.78 (t, J = 7 Hz 1 H), 8.20 (t, J = 7 Hz, 2 H); ¹³C NMR (125 MHz, CDCl₃) δ 7.9, 13.5, 19.2, 31.7, 52.6, 66.5, 72.9, 98.4, 118.6, 127.1, 129.7, 130.2, 130.4, 133.6, 136.3, 145.0, 146.0, 150.3, 150.6, 157.4, 174.1; HRMS (EI) m/z calcd for C₂₉H₃₆N₂O₄Si (M⁺) 504.2444, found 504.2436; LRMS (EI) m/z 504 (M⁺), 461, 433, 419, 405, 391, 375, 361, 347, 311, 275, 174, 93, 69, 59.

Example 13.

Preparation of 20S-7-triisopropylsilylcamptothecin



20

SUBSTITUTE SHEET (RULE 26)

(1) (S)-4-Ethyl-4-hydroxy-6-iodo-3-oxo-7-(triethylsilyl-2-propynyl)-1H-pyrano[3,4-c]-8-pyridone

Following the procedure outlined in example 1-(1), iodopyridone **2**, (150 mg, 0.450 mmol) was combined with
5 triethylsilyl-2-propynyl bromide (210 mg, 0.90 mmol). Chromatography (CH₂Cl₂/AcOEt 9:1) gave 97.0 mg (45%) of a white foam: ¹H NMR (300 MHz, CDCl₃) δ 0.54 (q, J = 8 Hz, 6 H), 0.92 (t, J = 8 Hz, 12 H), 1.74 (m, J = 7 Hz, 2 H), 3.57 (s, 1 H), 4.9-5.1 (m, 3 H), 5.46 (d, J = 16 Hz,
10 1 H), 7.13 (s, 1 H); ¹³C NMR (75 MHz, CDCl₃) δ 4.1, 7.4, 7.6, 31.5, 44.5, 66.3, 71.8, 88.7, 99.2, 100.0, 116.5, 118.1, 148.5, 158.0, 173.2; HRMS (EI) m/z calcd for C₁₉H₂₆INO₄Si (M⁺) 487.0676, found 487.0688; LRMS (EI) m/z 487 (M⁺), 458, 430, 420, 402, 360, 332, 153,
15 141, 125, 96, 83, 68, 57.

(2) (20S)-7-Triethylsilylcampthothecin


Following the procedure outlined in example 1-(2), the pyridone described above (48.7 mg, 0.1 mmol) yielded
29.8 mg (65%) of a light yellow solid: [α]_D²⁰ +35.9 (c 0.2,
20 CH₂Cl₂); IR (CHCl₃, cm⁻¹) 3015, 3002, 2960, 2935, 1741, 1658, 1599, 1219, 1199, 1158; ¹H NMR (300 MHz, CDCl₃) δ 0.80-1.00 (m, 12 H), 1.0-1.18 (m, 6 H), 1.70-1.90 (m, 2 H), 5.22-5.27 (m, 3 H), 5.69 (d, J = 16 Hz, 1 H), 7.58 (t, J = 7 Hz, 1 H), 7.63 (s, 1 H), 7.72 (t, J = 7 Hz 1
25 H), 8.18 (m, 2 H); ¹³C NMR (125 MHz, CDCl₃) δ 5.0, 7.6, 7.9, 31.7, 52.1, 66.5, 72.9, 97.7, 118.3, 127.4, 127.9, 129.7, 131.2, 132.6, 136.1, 142.6, 146.6, 147.9, 150.2, 150.9, 157.6, 174.1; HRMS (EI) m/z calcd for

SUBSTITUTE SHEET (RULE 26)

C₂₆H₃₀N₂O₄Si (M⁺) 462.1975, found 462.1982; LRMS (EI)
 m/z 462 (M⁺), 433, 418, 405, 389, 361, 256, 220, 205,
 189, 178, 149, 137, 123, 109, 95, 81, 69, 57.

Example 14.

- 5 Preparation of (20S)-7-(dimethyl-(1'S,2'S,5'S) 7,7
 dimethylnorpinylsilyl)camptothecin



- (1) (S)-4-Ethyl-4-hydroxy-6-iodo-3-oxo-7-(dimethyl-
 (1S,2S,5S) 7,7 dimethylnorpinylsilyl-2-propynyl)-1H-
 10 pyrano[3,4-c]-8-pyridone

- Following the procedure outlined in example 1-(1),
 iodopyridone **2** (150 mg, 0.450 mmol) was combined with
 dimethyl-(1S, 2S, 5S)7,7 dimethylnorpinylsilyl-2-propynyl
 bromide (281 mg, 0.90 mmol). Chromatography
 15 (CH₂Cl₂/AcOEt 9:1) gave 100.8 mg (39%) of a white foam:
¹H NMR (300 MHz, CDCl₃) δ 0.10 (d, J = 2 Hz, 6 H), 0.48-
 0.70 (m, 2 H), 0.72 (s, 3 H), 0.93 (t, J = 7 Hz, 3 H),
 1.10 (s, 3 H), 1.15-1.40 (m, 3 H), 1.60-1.85 (m, 6 H),
 1.88-2.00 (m, 1 H), 2.05-2.20 (m, 1 H), 3.58 (s, 1 H),
 20 4.95 (m, 3 H), 5.46 (d, J = 16 Hz, 1 H), 7.13 (s, 1 H);
¹³C NMR (75 MHz, CDCl₃) δ 0.78, 7.8, 20.2, 23.1, 24.0,

SUBSTITUTE SHEET (RULE 26)

24.8, 25.3, 27.0, 31.3, 31.7, 39.7, 40.7, 44.7, 49.1,
66.5, 71.9, 91.0, 98.5, 100.3, 116.6, 118.3, 148.7,
158.0, 173.4.

(2) (20S)-7-(dimethyl-(1'S,2'S,5'S)
5 dimethylnorpinylsilyl)camptothecin 7,7


Following the procedure outlined in example 1-(2),
the pyridone described above (57.0 mg, 0.1 mmol) yielded
29.4 mg (54%) of a light yellow solid: $[\alpha]^{20}_D$ +29.2 (c
0.2, CH₂Cl₂); IR (CHCl₃, cm⁻¹) 3020, 3000, 2980, 2972,
10 2939, 2914, 2824, 2867, 1741, 1658, 1599, 1556, 1264,
1231, 1201, 1157, 843; ¹H NMR (300 MHz, CDCl₃) δ 0.50-
0.70 (m, 8 H), 0.90-1.10 (m, 9 H), 1.10-1.35 (m, 4 H),
1.40-1.60 (m, 3 H), 1.72 (m, 1 H), 1.80-1.95 (m, 2 H),
2.05-2.11 (m, 2 H), 5.25 (d, J = 16 Hz 1 H), 5.27 (s, 2
15 H), 5.69 (d, J= 16 Hz, 1 H), 7.58 (t, J= 8 Hz, 1 H), 7.62
(s, 1 H), 7.72 (t, J= 8 Hz, 1 H), 8.10-8.2 (m, 2 H); ¹³C
NMR (125 MHz, CDCl₃) δ 1.4, 7.9, 19.9, 23.0, 24.6, 25.3,
26.8, 31.6, 31.7, 39.6, 40.5, 49.3, 52.0, 66.5, 72.9,
97.7, 118.3, 127.3, 128.3, 129.7, 131.2, 132.1, 134.6,
20 144.6, 146.6, 148.0, 150.2, 150.9, 157.6, 174.0; HRMS
(EI) m/z calcd for C₃₂H₃₈N₂O₄Si (M⁺) 542.2601, found
542.2588; LRMS (EI) m/z 542 (M⁺), 498, 487, 460, 443,
431, 406, 387, 377, 362, 333, 318, 304, 289, 275, 219,
178, 166, 141, 115, 95, 67.

25 Example 15.

(20S)-7-(3-cyanopropyldimethylsilyl)camptothecin

SUBSTITUTE SHEET (RULE 26)

88



(1) (S)-4-Ethyl-4-hydroxy-6-iodo-3-oxo-7-(3-cyanopropyl dimethylsilyl-2-propynyl)-1H-pyrano[3,4-c]-8-pyridone

5 Following the procedure cited by Rico and co-workers (*J. Org. Chem.* 1994, **59**, 415), iodopyridone **2**, (150 mg, 0.450 mmol) was combined with 3-cyanopropyl dimethylsilyl-2-propynyl bromide (165 mg, 0.678 mmol), K₂CO₃ (124 mg, 0.90 mmol), Bu₄N⁺Br⁻ (14.5 mg, 0.045 mmol), H₂O (0.02 mL),
 10 and toluene (3.6 mL). This mixture was refluxed for 1 h. After filtration and chromatography (CH₂Cl₂/AcOEt 9:1) 34.0 mg (15%) of a white oil was obtained: ¹H NMR (300 MHz, CDCl₃) δ 0.17 (s, 6 H), 0.70-0.80 (m, 2 H), 0.98 (t, J = 7 Hz, 3 H), 1.70-1.90 (m, 4 H), 2.39 (t, J = 7, 2 H), 3.66 (s, 1 H), 4.9-5.22 (m, 3 H), 5.51 (d, J = 16 Hz, 1 H), 7.19 (s, 1 H); ¹³C NMR (125 MHz, CDCl₃) δ -2.1, 7.8, 15.4, 20.5, 20.6, 31.6, 44.6, 66.4, 71.9, 89.1, 99.6, 100.0, 116.7, 118.3, 119.7, 148.8, 158.0, 173.3; HRMS (EI) m/z calcd for C₁₉H₂₃IN₂O₄Si (M⁺) 498.0472, 15
 20 found 498.0480; LRMS (EI) m/z 498 (M⁺), 483, 470, 445, 430, 416, 402, 392, 371, 348, 335, 306, 290, 266, 223, 202, 185, 163, 136, 126, 109, 98, 81, 69, 57.


(2) (20S)-7-(3-cyanopropyl dimethylsilyl)camptothecin

SUBSTITUTE SHEET (RULE 26)

Following the procedure outlined in example 1-(2), the pyridone described above (25.0 mg, 0.05 mmol) yielded 9.8 mg (41%) of a light yellow solid: $[\alpha]_D^{20} +34.3$ (c 0.2, CH₂Cl₂); IR (CHCl₃, cm⁻¹) 3025, 3016, 1741, 1659, 1600, 1264, 1222; ¹H NMR (300 MHz, CDCl₃) δ 0.71 (s, 6 H), 1.05 (t, *J* = 7 Hz, 3 H), 1.26 (m, 2 H), 1.66 (m, 2H), 1.90 (m, 2 H), 2.35 (t, *J* = 7 Hz, 2 H), 3.76 (s, 1 H), 5.31 (d, *J* = 16 Hz, 1 H), 5.31 (s, 2 H), 5.75 (d, *J* = 16 Hz, 1 H), 7.67 (m, 2 H), 7.82 (t, *J* = 8 Hz, 1 H), 8.17 (d, *J* = 8 Hz 1 H), 8.24 (d, *J* = 8 Hz, 1 H); ¹³C NMR (125 MHz, CDCl₃) δ 0.2, 7.9, 16.8, 20.7, 20.73, 31.7, 50.9, 66.5, 72.8, 97.9, 118.5, 119.2, 127.7, 127.8, 130.0, 131.4, 131.9, 135.2, 141.9, 146.3, 148.1, 150.3, 151.1, 157.5, 174.0; HRMS (EI) *m/z* calcd for C₂₆H₂₇N₃O₄Si (M⁺) 473.1771, found 473.1755; LRMS (EI) *m/z* 473 (M⁺), 444, 429, 414, 400, 389, 373 362, 344, 331, 303, 289, 2.75, 245, 219, 166, 152, 130, 98, 71.

Example 16.

Preparation of (20*S*)-7-(3-halopropyldimethylsilyl) camptothecin (the chloropropyl derivative is DB-148)

**SUBSTITUTE SHEET (RULE 26)**

(1) (S)-4-Ethyl-4-hydroxy-6-iodo(and 6-bromo)-3-oxo-7-(3-chloropropyltrimethylsilyl-2-propynyl)-1H-pyrano[3,4-c]-8-pyridone

Following the procedure outlined in example 1-(1),
5 [iodopyridone **2** (150 mg, 0.450 mmol) was combined with 3-chloropropyltrimethylsilyl-2-propynyl bromide (228 mg, 0.90 mmol). Chromatography (CH₂Cl₂/AcOEt 9:1) gave 75.4 mg (33%) of a clear oil. Analysis of the NMR showed the presence of the alkyl bromide in addition to the desired
10 chloro derivative in a 1.6:1 ratio in favor of the former.: ¹H NMR (300 MHz, CDCl₃) δ 0.09 (s, 6 H), 0.60-0.70 (m, 2 H), 0.85-0.89 (t, J = 7 Hz, 3 H), 1.60-1.95 (m, 4 H), 3.33 (t, J = 7 Hz, 2 H, assigned to iodo), 3.44 (t, J = 7 Hz, 2 H, assigned to bromo), 3.75 (s, 1 H),
15 4.91-5.18 (m, 3 H), 5.42 (d, J = 16 Hz, 1 H), 7.12 (s, 1 H).

(2) (20S)-7-(3-halopropyltrimethylsilyl)camptothecin


Following the procedure outlined in example 1-(2), the pyridone described above (51 mg, 0.1 mmol) yielded 23
20 mg (49%) of a light yellow solid. Analysis of the spectral data identified this solid as a 3 component mixture corresponding to the chloro, bromo and the iodo derivatives in a 1.6:1:1.3 ratio: [α]_D²⁰ +30.8 (c 0.2, CH₂Cl₂); IR (CHCl₃, cm⁻¹) 3029, 3012, 2980, 2963, 2933,
25 1742, 1658, 1600, 1556, 1258, 1233, 1218, 1200, 1158, 1045, 843, 822, 794; ¹H NMR (300 MHz, CDCl₃) δ 0.69 (s, 6 H), 1.04 (t, J = 7 Hz, 3 H), 1.18-1.30 (m, 2 H), 1.60-2.0 (m, 4 H), 3.15 (t, J = 7 Hz, 2 H, assigned to iodo), 3.36 (t, J = 7 Hz, 2 H, assigned to bromo), 3.48 (t, J = 7

SUBSTITUTE SHEET (RULE 26)

Hz, 2 H, assigned to chloro), 3.88 (s, 1 H), 5.30 (d, J = 16 Hz, 1 H), 5.31 (s, 2 H), 5.74 (d, J = 16 Hz, 1 H), 7.62-7.66 (m, 2 H), 7.87 (t, J = 8 Hz, 1 H), 8.18 (d, J = 8 Hz, 1 H), 8.22 (d, J = 8 Hz, 1 H); ^{13}C NMR (125 MHz, CDCl_3) δ 0.2, 7.9, 14.7, 27.5, 31.7, 47.4, 51.9, 66.4, 72.8, 98.2, 118.6, 127.7, 127.9, 130.0, 131.0, 132.0, 135.2, 146.1, 147.6, 150.2, 157.5, 174.0; HRMS (EI) m/z calcd for $\text{C}_{25}\text{H}_{27}\text{ClN}_2\text{O}_4\text{Si}$ (M^+) 482.1429, found 482.1413; LRMS (EI) m/z 482 (M^+), 453, 438, 361, 305, 275.

10 **Example 17.**

Preparation of (20*S*)10-acetoxy-7-*tert*-butyldimethylsilylcamptothecin



Following the procedure outlined in example 1-(2), the pyridone described above (34.5 mg, 0.071 mmol) and *p*-acetoxyisonitrile yielded 21.3 mg (58%) of a light yellow solid: $[\alpha]_{\text{D}}^{20} +36.2$ (c 0.2, CH_2Cl_2); IR (CHCl_3 , cm^{-1}) 3029, 3000, 2958, 2931, 2902, 2885, 2859, 1742, 1659, 1600, 1557, 1504, 1464, 1371, 1256, 1232, 1195, 1166, 1045; ^1H NMR (300 MHz, CDCl_3) δ 0.69 (s, 6 H), 0.90 (s, 9 H), 1.04 (t, J = 7 Hz, 3 H), 1.80-2.00 (m, J = 7 Hz, 2 H), 2.40 (s, 3 H), 3.81 (s, 1 H), 5.30 (d, J = 16 Hz, 1 H), 5.31 (s, 2 H), 5.75 (d, J = 16 Hz, 1 H), 7.53 (dd, J_1 = 9

SUBSTITUTE SHEET (RULE 26)

Hz, $J_2 = 2$ Hz, 1 H), 7.65 (s, 1 H), 8.08 (d, $J = 2$ Hz, 1 H), 8.21 (d, $J = 9$ Hz, 1 H); ^{13}C NMR (125 MHz, CDCl_3) δ 0.6, 7.9, 19.3, 21.5, 27.2, 31.7, 52.5, 66.5, 72.9, 97.7, 118.4, 120.4, 124.8, 132.1, 133.2, 136.7, 142.8, 146.2, 146.4, 149.0, 150.2, 150.8, 157.5, 169.1, 174.1; LRMS (EI) m/z 520 (M^+), 478, 463, 421, 377, 347, 320, 291, 57.


Example 18.

(2) (20S)10-Acetoxy-7-tert-butyltrimethylsilylcamptothecin

Following the procedure outlined in example 2-(2), the pyridone described above (34.5 mg, 0.071 mmol) yielded, using the same chromatographic conditions, 21.3 mg (58%) of a light yellow solid: $[\alpha]_D^{20} +36.2$ (c 0.2, CH_2Cl_2); IR (CHCl_3 , cm^{-1}) 3029, 3000, 2958, 2931, 2902, 2885, 2859, 1742, 1659, 1600, 1557, 1504, 1464, 1371, 1256, 1232, 1195, 1166, 1045; ^1H NMR (300 MHz, CDCl_3) δ 0.69 (s, 6 H), 0.90 (s, 9 H), 1.04 (t, $J = 7$ Hz, 3 H), 1.80-2.00 (m, $J = 7$ Hz, 2 H), 2.40 (s, 3 H), 3.81 (s, 1 H), 5.30 (d, $J = 16$ Hz, 1 H), 5.31 (s, 2 H), 5.75 (d, $J = 16$ Hz, 1 H), 7.53 (dd, $J_1 = 9$ Hz, $J_2 = 2$ Hz, 1 H), 7.65 (s, 1 H), 8.08 (d, $J = 2$ Hz, 1 H), 8.21 (d, $J = 9$ Hz, 1 H); ^{13}C NMR (125 MHz, CDCl_3) δ 0.6, 7.9, 19.3, 21.5, 27.2, 31.7, 52.5, 66.5, 72.9, 97.7, 118.4, 120.4, 124.8, 132.1, 133.2, 136.7, 142.8, 146.2, 146.4, 149.0, 150.2, 150.8, 157.5, 169.1, 174.1; HRMS (EI) m/z calcd for $\text{C}_{28}\text{H}_{32}\text{N}_2\text{O}_6\text{Si}$ (M^+) 520.2030, found 520.2014 LRMS (EI) m/z 520 (M^+), 478, 463, 421, 377, 347, 320, 291, 57.

SUBSTITUTE SHEET (RULE 26)

Example 19.




(20S)-10-Hydroxy-7-tert-butyldimethylsilylcamptothecin
(DB-67)

- 5 Following the procedure outlined in example 5,
(13.4 mg, 0.026 mmol) of the compound described in
example 18 was converted to the hydroxy derivative.
Purification (2:1 CH₂Cl₂:Acetone) on a preparative TLC
plate gave 10.6 mg (85%) of a yellow solid: $[\alpha]_D^{20} +17.4$ (c
10 0.2, 3:1 CH₂Cl₂/MeOH); ¹H NMR (300 MHz, 3:1 CDCl₃/CD₃OD)
 δ 0.66 (s, 6 H), 0.88-1.05 (m, 12 H), 1.80- 2.00 (m, 2
H), 5.25-5.30 (m, 3 H), 5.70 (d, *J* = 16 Hz, 1 H), 7.37
(dd, *J*₁ = 9 Hz, *J*₂ = 2 Hz, 1 H), 7.54 (d, *J* = 2 Hz, 1 H),
7.60 (s, 1 H), 8.05 (d, *J* = 9 Hz, 1 H); ¹³C NMR (125
15 MHz, (3:1) CDCl₃:CD₃OD) δ 8.1, 20.6, 27.6, 30.4, 31.9,
53.6, 66.5, 73.9, 98.6, 112.1, 118.8, 123.3, 132.1,
135.6, 137.4, 141.6, 143.8, 147.3, 148.4, 152.6, 157.5,
158.7, 174.7; HRMS (EI) *m/z* calcd for C₂₆H₃₀N₂O₅Si (M⁺)
478.1924, found 478.1947 LRMS (EI) *m/z* 478 (M⁺), 434,
20 421, 377, 304, 284, 227, 178, 149, 137, 109, 97, 83, 69,
57.

SUBSTITUTE SHEET (RULE 26)

Example 20

Preparation of (20S)-7-(trimethylsilylmethyl)camptothecin



(1) (S)-4-Ethyl-4-hydroxy-6-iodo-3-oxo-7-(4-trimethylsilyl-2-butyryl)-1H-pyrano[3,4-c]-8-pyridone

Following the procedure described in Example 1-(1), iodopyridone (2) (200 mg, 0.60 mmol) and 4-trimethylsilyl-2-butyryl bromide (245 mg, 1.20 mmol) gave, after flash-chromatography (CH₂Cl₂/AcOEt 9:1), 77.7 mg (28%) of a white foam: $[\alpha]_D^{20} +62.7$ (c 0.2, CHCl₃); IR (CHCl₃, cm⁻¹) 3540, 3026, 2955, 1742, 1649, 1607, 1529, 1250, 1219, 1208, 1158, 1140; ¹H NMR (300 MHz, CDCl₃) δ 0.06 (s, 9 H), 0.92 (t, *J* = 7.4 Hz, 3 H), 1.44 (t, *J* = 2.4 Hz, 2 H), 1.76 (m, *J* = 7.4 Hz, 2 H), 3.74 (s, 1 H), 4.98 (br s, 2 H), 5.07 (d, *J* = 15 Hz, 1 H), 5.48 (d, *J* = 16.4 Hz, 1 H), 7.15 (s, 1 H); ¹³C NMR (75 MHz, CDCl₃) δ -1.96, 7.5, 7.6, 31.5, 44.8, 66.3, 71.7, 84.3, 100.3, 116.3, 118.1, 148.3, 157.9, 173.3; HRMS (EI) *m/z* calcd for C₁₇H₂₂INO₄Si (M⁺) 459.0352, found 459.0363; LRMS (EI) *m/z* 459 (M⁺), 444, 386, 348, 73, 57.

(2) (20S)-7-(Trimethylsilylmethyl)camptothecin


SUBSTITUTE SHEET (RULE 26)

Following the procedure described in Example 1-(2), the compound prepared in (1) (46 mg, 0.10 mmol) yielded, after flash chromatographies (CH₂Cl₂/MeOH 96:4; CH₂Cl₂/acetone 9:1), 16.2 mg (38%) of a light

- 5 yellow solid: $[\alpha]_D^{20} +37.6$ (c 0.2, CHCl₃); IR (CHCl₃, cm⁻¹) 3002, 2984, 2962, 1741, 1659, 1601, 1572, 1559, 1253, 1219, 1197, 1157, 849; ¹H NMR (500 MHz, CDCl₃) δ -0.34 (s, 9 H), 0.62 (t, *J* = 7.3 Hz, 3 H), 1.48 (m, 2 H), 2.31 (d, *J* = 3.0 Hz, 2 H), 3.53 (s, 1 H), 4.74 (s, 2 H), 4.89 (d, *J* = 16.2 Hz, 1 H), 5.34 (d, *J* = 16.2 Hz, 1 H), 6.85 (s, 1 H), 7.20 (t, *J* = 7.8 Hz, 1 H), 7.36 (t, *J* = 7.4 Hz, 1 H), 7.57 (d, *J* = 8.4 Hz, 1 H), 7.78 (d, *J* = 8.4 Hz, 1 H); ¹³C NMR (75 MHz, CDCl₃) δ -0.32, 1.1, 7.9, 31.6, 50.3, 66.4, 72.9, 98.1, 112.3, 124.4, 125.84, 126.91, 10
15 127.2, 130.1, 130.5, 144.6, 147.4, 149.2, 150.3, 151.5, 157.7, 174.1; HRMS (EI) *m/z* calcd for C₂₄H₂₆N₂O₄Si (M⁺) 434.1676, found 434.1662; LRMS (EI) *m/z* 434 (M⁺), 390, 362, 316, 290, 242, 223, 185, 147, 93, 73.

Example 21.

- 20 (20S)-10-Hydroxy-7-[(2-trimethylsilyl)ethyl]camptothecin (36a) (DB-174)



- (1) (4,4-Dibromo-but-3-enyl)trimethylsilane

SUBSTITUTE SHEET (RULE 26)

This known compound was prepared by a modification of the procedure in Piers, E.; Gavai, A. V. *J. Org. Chem.* **1990**, *55*, 2374. To a flame dried flask was added dry CH₂Cl₂ (150 mL) and triphenylphosphine (16 g, 61.2 mmol). The temperature was lowered to 0° C and CBr₄ (10.15 g, 30.6 mmol) was added portionwise. After 30 min, a solution of 3-trimethylsilylpropanal (2.0 g, 15.3 mmol) in dry CH₂Cl₂ (20 ml) was added. After 1 h at 0°C, the reaction was diluted with ether and filtered through celite. The celite was rinsed with ether (4x50 mL) and the combined ether solution was extracted with H₂O (100 mL), saturated NaHCO₃ (100 mL), saturated NH₄Cl (100 mL) and brine (100 mL). The organic layer was dried (MgSO₄), filtered and evaporated to give a crude white solid. The solid residue was washed with pentane. The pentane solution was concentrated and the oily residue was chromatographed on silica gel (pentane 100%) to give (4,4-dibromo-but-3-enyl)trimethylsilane as a clear oil weighing 3.7 g. ¹H NMR showed 27% contamination by remaining pentane which gives a corrected yield of 62%: IR (neat, cm⁻¹) 2953, 2922, 2898, 1620, 1443, 1413, 1249, 1176, 1034, 986, 859, 837; ¹H NMR (300 MHz, CDCl₃) δ 0.03 (s, 9 H), 0.62-0.67 (m, 2 H), 2.06-2.14 (m, 2 H), 6.41 (t, J = 7 Hz 1 H); ¹³C NMR (75 MHz, CDCl₃) δ -1.9, 15.1, 27.7, 87.5, 141.2.

(2) 5-Trimethylsilanylpent-2-yn-1-ol (**40**)

To a flame dried flask was added (4,4-dibromo-but-3-enyl)trimethylsilane (3.43 g, 12 mmol). Dry THF (150 mL) was added and the mixture was cooled to -78° C. BuLi 1.6N in hexanes (24 mmol, 15 mL) was added and the mixture was stirred 1 h at -78° C, warmed to 22° C, and

SUBSTITUTE SHEET (RULE 26)

stirred for an additional 1 h. Finally, paraformaldehyde (1.4 g) was added and the mixture was refluxed. After 3.5 h the reaction was cooled to 22° C and sat. NH₄Cl (50 mL) was added. The contents of the flask were transferred to a separatory funnel and extracted with ether (3x200 mL). The organic layer was dried (Na₂SO₄), filtered and evaporated to give a crude yellow oil. Flash chromatography on silica gel (pentane/ether 5:1) afforded 1.57 g (84%) of 5-trimethylsilylpent-2-yn-1-ol: IR (neat, cm⁻¹) 3350, 2953, 2219, 1436, 1412, 1318, 1249, 1178, 1124, 1015, 905, 853; ¹H NMR (300 MHz, CDCl₃) δ -0.003 (s, 9 H), 0.76 (t, J = 8 Hz 2 H), 1.75 (s, 1 H), 2.20-2.24 (m, 2 H), 4.21 (br s, 2 H); ¹³C NMR (75 MHz, CDCl₃) δ -1.3, 13.8, 16.4, 51.7, 78.2, 88.9; HRMS (EI) m/z calcd for C₇H₁₃OSi (M - CH₃) 141.0736, found 141.0733 LRMS (EI) m/z 141 (M - CH₃), 123, 113, 103, 97, 91, 85, 75, 66, 59.

(3) (5-Bromopent-3-ynyl)trimethylsilane (41)

To a flame dried flask was added PPh₃ (1.76 g, 6.73 mmol) followed by dry CH₂Cl₂ (60 mL). The mixture was placed in an ice bath and bromine (0.34 mL, 6.41 mmol) was added dropwise. A small amount of PPh₃ was added until the reaction went from yellow to clear in color. After 0.5 h at 0° C, 5-trimethylsilylpent-2-yn-1-ol (1.0 g, 6.41 mmol) was dissolved in CH₂Cl₂ (5 mL) and added dropwise. After 4 h at 0° C, the reaction mixture was poured into a separatory funnel, diluted with pentane (250 mL) and extracted with H₂O (100 mL) and sat. NaHCO₃ (100 mL). The organic layer was dried (MgSO₄), filtered and reduced in volume to 50 mL. The crude solution was chromatographed on a pad of silica gel with

SUBSTITUTE SHEET (RULE 26)

pentane (500 mL). After evaporation of the pentane, (5-bromopent-3-ynyl)trimethylsilane (1.2 g 87%) was obtained as a clear oil: IR (neat, cm^{-1}) 2953, 2922, 2899, 2230, 1431, 1317, 1248, 1208, 852; ^1H NMR (300 MHz, CDCl_3) δ 0.03 (s, 9 H), 0.79 (t, $J = 8$ Hz, 2 H), 2.28 (tt, $J_1 = 8$ Hz, $J_2 = 2$ Hz, 2 H), 3.92 (t, $J = 2$ Hz, 2 H); ^{13}C NMR (75 MHz, CDCl_3) δ 1.7, 13.6, 15.7, 15.8, 74.6, 90.2; HRMS (EI) m/z calcd for $\text{C}_7\text{H}_{12}\text{BrSi}$ ($M - \text{CH}_3$) 202.9892, found 202.9889 LRMS (EI) m/z 203 ($M - \text{CH}_3$), 137, 73, 66.

- 10 (4) (20S)-4-Ethyl-4-hydroxy-6-iodo-3-oxo-7-(5-trimethylsilylpent-2-ynyl)-1H-pyrano[3,4-c]-8-pyridone (43)

Following the procedure described in Example 1-(1), iodopyridone (2), (0.2 g, 0.6 mmol)] and (5-bromopent-3-ynyl)trimethylsilane (260 mg, 1.19 mmol) provided after flash chromatography ($\text{CH}_2\text{Cl}_2/\text{EtOAc}$ 95:5) 0.21 g (74%) of (20S)-4-ethyl-4-hydroxy-6-iodo-3-oxo-7-(5-trimethylsilylpent-2-ynyl)-1H-pyrano[3,4-c]-8-pyridone as a white foam: $[\alpha]_D^{20} +54.4$ (c 0.2, CH_2Cl_2); IR (CHCl_3 , cm^{-1}) 2952, 1746, 1648, 1528, 1427, 1138, 856, 755; ^1H NMR (300 MHz, CDCl_3) δ - 0.03 (s, 9 H), 0.76 (t, $J = 8$ Hz, 2 H), 0.96 (t, $J = 7$ Hz, 3 H), 1.70-2.00 (m, $J = 7$ Hz, 2 H), 2.16 (t, $J = 8$ Hz, 2 H), 3.77 (s, 1 H), 5.04 (s, 2 H), 5.10 (d, $J = 16$ Hz, 1 H), 5.49 (d, $J = 16$ Hz, 1 H), 7.16 (s, 1 H); ^{13}C NMR (75 MHz, CDCl_3) δ -1.6, 7.8, 13.6, 15.7, 31.7, 44.8, 66.5, 71.9, 72.4, 88.1, 100.5, 116.6, 118.3, 148.6, 158.2, 173.5; HRMS (EI) m/z calcd for $\text{C}_{18}\text{H}_{24}\text{INO}_4\text{Si}$ (M^+) 473.0519, found 473.0507 LRMS (EI) m/z 473 (M^+), 458, 386, 360, 346, 139, 73, 57.

SUBSTITUTE SHEET (RULE 26)

(5) (2*S*)-10-Acetoxy-7-[(2-trimethylsilyl)ethyl]camptothecin (**45**)

Following the procedure described in Example 1-(2), a mixture of the iodopyridone prepared in (4) above (56.8 mg, 0.12 mmol) and *p*-acetoxyphenyl isonitrile (48 mg, 0.3 mmol) provided after flash chromatography (CH₂Cl₂/Acetone 10:1) 33.2 mg (55%) of (2*S*)-10-acetoxy-7-[(2-trimethylsilyl)ethyl]camptothecin as a tan solid: $[\alpha]_D^{20} +21.0$ (c 0.2, CH₂Cl₂); IR (CHCl₃, cm⁻¹) 3039, 2996, 2954, 1744, 1660, 1602, 1509, 1371, 1229, 1177; ¹H NMR (300 MHz, CDCl₃) δ 0.17 (s, 9 H), 0.88-0.95 (m, 2 H), 1.03 (t, *J* = 7 Hz, 3 H), 1.80-2.00 (m, *J* = 7 Hz, 2 H), 2.42 (s, 3 H), 3.00 (m, 2 H), 4.01 (br s, 1 H), 5.22 (s, 2 H), 5.30 (d, *J* = 16 Hz, 1 H), 5.74 (d, *J* = 16 Hz, 1 H), 7.54 (dd, *J*₁ = 9 Hz, *J*₂ = 2 Hz 1 H), 7.66 (s, 1 H), 7.72 (d, *J* = 2 Hz, 1 H), 8.22 (d, *J* = 2 Hz, 1 H); ¹³C NMR (125 MHz, CDCl₃) δ -1.8, 7.9, 17.7, 21.4, 24.3, 31.7, 49.3, 66.4, 72.9, 98.1, 114.5, 118.6, 125.4, 126.6, 127.2, 132.2, 146.8, 147.0, 147.5, 149.6, 150.3, 151.9, 157.7, 169.4, 174.0; HRMS (EI) *m/z* calcd for C₂₇H₃₀N₂O₆Si (M⁺) 506.1873, found 506.1869 LRMS (EI) *m/z* 506 (M⁺), 464, 436, 420, 347, 336, 277, 193, 151, 109, 73.

(6) (2*S*)-10-Hydroxy-7-[(2-trimethylsilyl)ethyl]camptothecin (**36a**)

A mixture of the compound prepared in (5) above (17.7 mg, 0.035 mmol) and K₂CO₃ (9.7 mg, 0.07 mmol) in MeOH (0.2 mL) and H₂O (0.2 mL) was stirred for 1.5 h at room temperature. The mixture was acidified with AcOH (8

SUBSTITUTE SHEET (RULE 26)


drops), diluted with brine (10 mL) and extracted with EtOAc (10x20 mL). The combined organic layers were dried (Na₂SO₄) and evaporated. The crude residue was subjected to two chromatographies (CH₂Cl₂/MeOH/AcOH 96:3:1 followed by CH₂Cl₂/Acetone 5:1), which gave 7.6 mg (47%) of (20S)-10-hydroxy-7-[(2-trimethylsilyl)ethyl]camptothecin as a yellow solid: $[\alpha]_D^{20} +31.3$ (c 0.2, CH₂Cl₂/MeOH 3:1); ¹H NMR (300 MHz, CDCl₃) δ 0.15 (s, 9 H), 0.84-0.95 (m, 2 H), 0.99 (t, J = 7 Hz, 3 H), 1.80- 2.00 (m, J = 7 Hz, 2 H), 2.99-3.05 (m, 2 H), 5.20 (s, 2 H), 5.29 (d, J = 16 Hz 1 H), 5.62 (d, J = 16 Hz 1 H), 7.33 (d, J = 2 Hz, 1 H), 7.40 (dd, J₁ = 9 Hz, J₂ = 2 Hz, 1 H), 7.63 (s, 1 H), 8.01 (d, J = 9 Hz, 1 H); ¹³C NMR (125 MHz, CDCl₃) δ -1.8, 8.3, 17.9, 25.1, 32.2, 66.9, 74.4, 99.1, 106.0, 116.1, 119.7, 124.0, 128.4, 129.8, 132.3, 145.5, 146.8, 148.3, 150.1, 153.0, 158.6, 159.4, 175.1; HRMS (EI) m/z calcd for C₂₅H₂₈N₂O₅Si (M⁺) 464.1767, found 464.1788 LRMS (EI) m/z 464 (M⁺), 420, 405, 391, 364, 347, 167, 149, 104, 91, 73.

This compound showed activity inhibiting cell proliferation in several lines of glioma cells (U87, A172, SG388, T98G, LN-Z308) with median effective concentrations of 10-100 ng/ml.

Example 22

(20S)-10-Amino-7-[2-trimethylsilyl)ethyl]camptothecin
(36b) (DB-173)

SUBSTITUTE SHEET (RULE 26)



(1) (20S)-10-tert-Butyloxycarbonylamino-7-[(2-trimethylsilyl)ethyl]camptothecin (**45b**)

Following the procedure described in Example 1-(2), a solution of the iodopyridone prepared in Example 21-(4) above (56.8 mg, 0.12 mmol) was reacted with 4-tert-butyloxycarbonylamino phenyl isonitrile (65.4 mg, 0.3 mmol). Column chromatography (CH₂Cl₂/Acetone 10:1) gave 38 mg (56%) (20S)-10-tert-butyloxycarbonylamino-7-[(2-trimethylsilyl)ethyl]camptothecin as a tan solid: $[\alpha]_D^{20} + 18.5$ (c 0.2, CH₂Cl₂); IR (CHCl₃, cm⁻¹) 3019, 1738, 1658, 1600, 1531, 1215, 1155, 761; ¹H NMR (300 MHz, CDCl₃) δ 0.19 (s, 3 H), 0.90-0.96 (m, 2 H), 1.03 (t, *J* = 7 Hz, 3 H), 1.58 (s, 9 H), 1.8-2.0 (m, 2 H), 3.02-3.08 (m, 2 H), 3.89 (s, 1 H), 5.21 (s, 2 H), 5.30 (d, *J* = 16 Hz, 1 H), 5.75 (d, *J* = 16 Hz, 1 H), 6.85 (br s, 1 H), 7.57 (dd, *J*₁ = 9 Hz, *J*₂ = 2 Hz, 1 H), 7.61 (s, 1 H), 8.11 (d, *J* = 9 Hz, 1 H), 8.31 (br s, 1 H); ¹³C NMR (75 MHz, CDCl₃) δ -1.7, 8.0, 17.5, 24.4, 28.5, 31.8, 49.5, 66.5, 73.0, 77.4, 81.4, 97.7, 110.1, 118.2, 123.3, 126.7, 127.6, 131.4, 137.8, 146.2, 147.4, 150.37, 150.4, 152.6, 157.8, 174.1; HRMS (EI) *m/z* calcd for C₃₀H₃₇N₃O₆Si (M⁺) 563.2452, found 563.2426 LRMS (EI) *m/z* 463 (M - C₅H₈O₂), 419, 404, 363, 363, 346, 332, 289, 246, 149, 131, 73, 57.

SUBSTITUTE SHEET (RULE 26)

(2) (2*S*)-10-Amino-7-[2-trimethylsilyl]ethyl]camptothecin
(36b)

The camptothecin derivative prepared in (2) above (17.5 mg, 0.031 mmol) was dissolved in CH₂Cl₂ (1 mL) and trifluoroacetic acid (0.25 mL) was added. After 3 h at 22°C, the mixture was poured into saturated NaHCO₃ (20 mL) and extracted with EtOAc (10 x 15 mL). The organic phase was dried (Na₂SO₄), concentrated and chromatographed (CH₂Cl₂/Acetone 85:15), to give 9.4 mg (65%) of a yellow solid: $[\alpha]_D^{20} +17.0$ (c 0.2, CH₂Cl₂/MeOH 3:1); ¹H NMR (300 MHz, CDCl₃) δ 0.15 (s, 9 H), 0.85-0.91 (m, 2 H), 0.99 (t, *J* = 7 Hz, 3 H), 1.87-2.05 (m, 2 H), 2.85-2.98 (m, 2 H), 5.04 (d, *J* = 19 Hz, 1 H), 5.09 (d, *J* = 19 Hz, 1 H), 5.29 (d, *J* = 16 Hz, 1 H), 5.58 (d, *J* = 16 Hz, 1 H), 7.01 (d, *J* = 2 Hz, 1 H), 7.25 (dd, *J*₁ = 9 Hz, *J*₂ = 2 Hz, 1 H), 7.54 (s, 1 H), 7.84 (d, *J* = 9 Hz, 1 H); ¹³C NMR (75 MHz, CDCl₃) δ 1.8, 8.1, 17.4, 24.5, 31.8, 50.0, 66.4, 73.8, 98.4, 102.3, 118.2, 123.4, 127.2, 129.6, 131.3, 144.1, 145.2, 147.6, 147.9, 148.5, 152.4, 158.7, 174.6; HRMS (EI) *m/z* calcd for C₂₅H₂₉N₃O₄Si (M⁺) 463.1927, found 463.1941 LRMS (EI) *m/z* 463 (M⁺), 434, 419, 404, 390, 362, 346, 332, 167, 131, 104, 91, 73, 57.

Example 23

25 (2*S*)-7-[(2-Trimethylsilyl)ethyl]camptothecin (36c)
(DB-172)

SUBSTITUTE SHEET (RULE 26)

Following the procedure described in example 1-(2), a mixture of the iodopyridone (43) prepared in Example 21-(4) above (56.8 mg, 0.12 mmol) and phenylisocyanide (30.9 mg, 0.3 mmol) provided after flash chromatography (CH₂Cl₂/acetone 10:1) 28 mg (52%) of (20S)-7-[(2-trimethylsilyl)ethyl]camptothecin as a tan solid: $[\alpha]_D^{20} + 29.8$ (c 0.2, CH₂Cl₂); IR (CHCl₃, cm⁻¹) 2996, 2954, 1742, 1659, 1601, 1557, 1250, 1158, 856; ¹H NMR (300 MHz, CDCl₃) δ 0.18 (s, 9 H), 0.90-0.96 (m, 2 H), 1.04 (t, $J = 7.3$ Hz, 3 H), 1.86-1.95 (m, 2 H), 3.07-3.13 (m, 2 H), 3.87 (s, 1 H), 5.23 (s, 2 H), 5.31 (d, $J = 16.3$ Hz, 1 H), 5.76 (d, $J = 16.3$ Hz, 1 H), 7.64-7.69 (m, 2 H), 7.80 (td, $J_1 = 8$ Hz, $J_2 = 0.87$ Hz, 1 H), 8.03 (d, $J = 8.3$ Hz, 1 H), 8.23 (d, $J = 8.3$ Hz, 1 H); ¹³C NMR (75 MHz, CDCl₃) δ - 1.75, 7.95, 17.9, 24.2, 31.7, 49.4, 66.5, 72.9, 98.1, 118.5, 123.4, 126.1, 126.7, 127.7, 130.3, 130.8, 147.1, 147.2, 149.6, 150.2, 152.0, 157.8, 174.1; HRMS (EI) m/z calcd for C₂₅H₂₈N₂O₄Si (M⁺) 448.1818, found 448.1819 LRMS (EI) m/z 448 (M⁺), 431, 374, 358, 311, 301, 208, 195, 165, 149, 131, 118, 105, 93, 73.

Although the present invention has been described in detail in connection with the above examples, it is to be understood that such detail is solely for that purpose and that variations can be made by those skilled in the art without departing from the spirit of the invention except as it may be limited by the following claims.

SUBSTITUTE SHEET (RULE 26)

103a


The word 'comprising' and forms of the word 'comprising' as used in this description and in the claims does not limit the invention claimed to exclude any variants or additions.

Modifications and improvements to the invention will be readily apparent to those skilled in the art. Such modifications and improvements are intended to be within the scope of this invention.




WHAT IS CLAIMED IS:


1. A method of synthesizing compounds when used for synthesizing compounds having the formula:



via a 4+1 radical annulation/cyclization wherein the precursor



is reacted with an aryl isonitrile having the formula



wherein R^1 and R^2 are independently the same or different and are hydrogen, an alkyl group, a hydroxyalkyl group, a haloalkyl group, an aminoalkyl group, an alkylaminoalkyl group, a dialkylaminoalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an aryloxy group, an acyloxy group, $-OC(O)OR^d$, wherein R^d is an alkyl group, a carbamoyloxy group, a halogen, a hydroxy group, a nitro group, a cyano group, an azido group, a formyl group, a hydrazino group, $-C(O)R^f$ wherein R^f is an alkyl group, an alkoxy group, an amino group or a hydroxy group, an amino group, an alkylamino group, a dialkylamino group, $-SR^e$, wherein R^e is hydrogen, $-C(O)R^f$, an alkyl group, or an aryl group; or R^1 and R^2 together form a group of the formula $-O(CH_2)_nO-$ wherein n represents the integer 1 or 2;

R^3 is H, a halogen atom, a nitro group, an amino group, a hydroxy group, or a cyano group; or R^2 and R^3 together form a group of the formula $-O(CH_2)_nO-$ wherein n represents the integer 1 or 2;

R^4 is H, F, a C_{1-3} alkyl group, a C_{2-3} alkenyl group, a C_{2-3} alkynyl group, a trialkylsilyl group or a C_{1-3} alkoxy group;

wherein at least one of R^1 , R^2 , R^3 , and R^4 is not H, a halogen, an alkyl group, an amino group or a nitro group;

R^5 is a C_{1-10} alkyl group, an allyl group, a benzyl group or a propargyl group;

R^6 , R^7 and R^8 are independently a C_{1-10} alkyl group, a C_{2-10} alkenyl group, a C_{2-10} alkynyl group, an aryl group or a $-(CH_2)_N R^9$ group, wherein N is an integer within the range of 1 through 10 and R^9 is a hydroxy group, alkoxy group, an amino group, an alkylamino group, a dialkylamino group, a halogen atom, a cyano group or a nitro group;

R^{11} is an alkylene group, an alkenylene group, or an alkynylene group;

R^{12} is $-CH=CH-CH_2-$ or $-C\equiv C-CH_2-$; X is Cl, Br or I; and

pharmaceutically acceptable salts thereof.

2. The method of Claim 1, wherein R^4 is H.

3. The method of Claim 1, wherein R^1 and R^2 are independently the same or different and are H, a hydroxy group, a halogen, an amino group, a nitro group, a cyano group, a C_{1-3} alkyl group, a C_{2-3} alkenyl group, a C_{2-3} alkynyl group or a C_{1-3} alkoxy group.

4. The method of Claim 1, wherein R^1 and R^2 are independently the same or different and are H, a C_{1-3} perhaloalkyl group, a C_{1-3} aminoalkyl group, a C_{1-3} alkylamino group or a C_{1-3} dialkylamino group.

5. The method of Claim 1, wherein R^1 and R^2 are independently the same or different and are H, a methyl group, an amino group, a nitro group, a cyano group, or a hydroxy group.

6. The method of Claim 1, wherein R^1 and R^2 are independently the same or different and are H, a methylamino group, a dimethylamino group, an ethylamino group, a diethylamino group, a hydroxymethyl group, an aminomethyl group, a methylaminomethyl group, or a dimethylaminomethyl group.

7. The method of Claim 1, wherein R^3 is F, an amino group, or a hydroxy group.

8. The method of Claim 1, wherein R^5 is an ethyl group.

9. The method of Claim 1, wherein R^6 , R^7 and R^8 are independently the same or different and are a C_1-6 alkyl group, a phenyl group or a $-(CH_2)_N R^9$ group, wherein N is an integer within the range of 1 through 6 and R^9 is a hydroxy group, alkoxy group, an amino group, an alkylamino group, a dialkylamino group, a halogen atom, a cyano group or a nitro group.

10. The method of Claim 1, wherein R^6 , R^7 and R^8 are methyl groups.

11. The method of Claim 1, wherein R^2 and R^3 form a methylenedioxy group, or a 1,2-ethylenedioxy group.

12. The method of Claim 1, wherein R^2 is OH.

13. The method of Claim 1, wherein R^2 is NH_2 .


14. The method of Claim 1, wherein R^{11} is a C_1-C_{10} alkylene group, a C_2-C_{10} alkenylene group or a C_2-C_{10} alkynylene group.

15. The method of Claim 14, wherein R^{11} is a C_1-C_6 alkylene group, a C_2-C_6 alkenylene group or a C_2-C_6 alkynylene group.

16. The method of Claim 14, wherein R^{11} is $(CH_2)_m$ wherein m is an integer of 1 to 6.

17. The method of Claim 1 wherein X is Br or I.

18. A compound having the formula:



wherein R^1 and R^2 are independently the same or different and are hydrogen, an alkyl group, a hydroxyalkyl group, a haloalkyl group, an aminoalkyl group, an alkylaminoalkyl group, a dialkylaminoalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an aryloxy group, an acyloxy group, $-OC(O)OR^d$, wherein R^d is an alkyl group, a carbamoyloxy group, a halogen, a hydroxy group, a nitro group, a cyano group, an azido group, a formyl group, a hydrazino group, $-C(O)R^f$ wherein R^f is an alkyl group, an alkoxy group, an amino group or a hydroxy group, an amino group, an alkylamino group, a dialkylamino group, $-SR^e$, wherein R^e is hydrogen, $-C(O)R^f$, an alkyl group, or an aryl group; or R^1 and R^2 together form a group of the formula $-O(CH_2)_n-$ wherein n represents the integer 1 or 2;

R^3 is H, a halogen atom, a nitro group, an amino group, a hydroxy group, or a cyano group; or R^2 and R^3 together form a group of the formula $-O(CH_2)_n-$ wherein n represents the integer 1 or 2;

R^4 is H, F, a C₁₋₃ alkyl group, a C₂₋₃ alkenyl group, a C₂₋₃ alkynyl group, a trialkylsilyl group, or a C₁₋₃ alkoxy group;

wherein at least one of R^1 , R^2 , R^3 , and R^4 is not H, a halogen, an alkyl group, an amino group or a nitro group;

R^5 is a C₁₋₁₀ alkyl group, an allyl group, a benzyl group or a propargyl group;

R^6 , R^7 and R^8 are independently a C₁₋₁₀ alkyl group, a C₂₋₁₀ alkenyl group, a C₂₋₁₀ alkynyl group, an aryl group or a $-(CH_2)_N R^9$ group, wherein N is an integer within the range of 1 through 10 and R^9 is a hydroxy group, alkoxy group,

an amino group, an alkylamino group, a dialkylamino group, a halogen atom, a cyano group or a nitro group; and

R^{11} is an alkylene group or an alkenylene group; and

pharmaceutically acceptable salts thereof.

19. The compound of Claim 18, wherein R^4 is H.

20. The compound of Claim 18, wherein R^1 and R^2 are independently the same or different and are H, a hydroxy group, a halogen, an amino group, a nitro group, a cyano group, a C₁₋₃ alkyl group, a C₂₋₃ alkenyl group, a C₂₋₃ alkynyl group or a C₁₋₃ alkoxy group.

21. The compound of Claim 18, wherein R^1 and R^2 are independently the same or different and are H, a C₁₋₃ perhaloalkyl group, a C₁₋₃ aminoalkyl group, a C₁₋₃ alkylamino group or a C₁₋₃ dialkylamino group.

22. The compound of Claim 18, wherein R^1 and R^2 are independently the same or different and are H, a methyl group, an amino group, a nitro group, a cyano group, or a hydroxy group.


23. The compound of Claim 18, wherein R^1 and R^2 are independently the same or different and are H, a methylamino group, a dimethylamino group, an ethylamino group, a diethylamino group, a hydroxymethyl group, an aminomethyl group, a methylaminomethyl group, or a dimethylaminomethyl group.

24. The compound of Claim 18, wherein R^3 is F, an amino group, or a hydroxy group.

25. The compound of Claim 18, wherein R^5 is an ethyl group.

26. The compound of Claim 18, wherein R^6 , R^7 and R^8 are independently the same or different and are a C₁₋₆ alkyl group, a phenyl group or a $-(CH_2)_N R^9$ group, wherein N is an integer within the range of 1 through 6 and R^9 is a hydroxy group, alkoxy group, an amino group, an alkylamino group, a dialkylamino group, a halogen atom, a cyano group or a nitro group.

27. The compound of Claim 18, wherein R^6 , R^7 and R^8 are methyl groups.
28. The compound of Claim 18, wherein R^2 and R^3 form a methylenedioxy group, or a 1,2-ethylenedioxy group.
29. The compound of Claim 18, wherein R^2 is OH.
30. The compound of Claim 18, wherein R^2 is NH_2 .
31. The compound of Claim 18, wherein R^{11} is a C_2 - C_{10} alkylene group, a C_2 - C_{10} alkenylene group or a C_1 - C_{10} alkynylene group.
32. The compound of Claim 31, wherein R^{11} is a C_2 - C_6 alkylene group, a C_2 - C_6 alkenylene group or a C_1 - C_6 alkynylene group.
33. The compound of Claim 31, wherein R^{11} is $(CH_2)_m$ wherein m is an integer of 1 to 6.
34. The compound of Claim 18, wherein at least two of R^1 , R^2 , R^3 , and R^4 are not H.
35. The compound of Claim 18 wherein R^5 is a methyl group, a C_3 -10 alkyl group, an allyl group, a benzyl group or a propargyl group.
36. A compound having the formula:



wherein R^5 is a C_1 -10 alkyl group, an allyl group, a benzyl group or a propargyl group;

R^6 , R^7 and R^8 are independently a C_1 -10 alkyl group, a C_2 -10 alkenyl group, a C_2 -10 alkynyl group, an aryl group or a $-(CH_2)_N R^9$ group, wherein N is an integer within the range of 1 through 10 and R^9 is a hydroxy group, alkoxy group, an amino group, an alkylamino group, a dialkylamino group, a halogen atom, a cyano group or a nitro group;

R^{11} is an alkylene group or an alkenylene group; and


R^{12} is $-\text{CH}=\text{CH}-\text{CH}_2-$ or $-\text{C}\equiv\text{C}-\text{CH}_2-$; X is Cl, Br or I.

37. The compound of Claim 36, wherein R^6 , R^7 and R^8 are independently the same or different and are a C_{1-6} alkyl group, a phenyl group or a $(\text{CH}_2)_N\text{R}^9$ group, wherein N is an integer within the range of 1 through 6 and R^9 is a hydroxy group, alkoxy group, an amino group, an alkylamino group, a dialkylamino group, a halogen atom, a cyano group or a nitro group.

38. The compound of Claim 36, wherein R^6 , R^7 and R^8 are methyl groups.

39. The compound of Claim 36, wherein X is Br or I.

40. A compound having the formula:



wherein R^1 and R^2 are independently the same or different and are hydrogen, an alkyl group, a hydroxyalkyl group, a haloalkyl group, an aminoalkyl group, an alkylaminoalkyl group, a dialkylaminoalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an aryloxy group, an acyloxy group, $-\text{OC}(\text{O})\text{OR}^d$, wherein R^d is an alkyl group, a carbamoyloxy group, a halogen, a hydroxy group, a nitro group, a cyano group, an azido group, a formyl group, a hydrazino group, $-\text{C}(\text{O})\text{R}^f$ wherein R^f is an alkyl group, an alkoxy group, an amino group or a hydroxy group, an amino group, an alkylamino group, a dialkylamino group, $-\text{SR}^e$, wherein R^e is hydrogen, $-\text{C}(\text{O})\text{R}^f$, an alkyl group, or an aryl group; or R^1 and R^2 together form a group of the formula $-\text{O}(\text{CH}_2)_n\text{O}-$ wherein n represents the integer 1 or 2;

R^3 is H, a halogen atom, a nitro group, an amino group, a hydroxy group, or a cyano group; or R^2 and R^3 together form a group of the formula $-\text{O}(\text{CH}_2)_n\text{O}-$ wherein n represents the integer 1 or 2;

R^4 is H, F, a C₁₋₃ alkyl group, a C₂₋₃ alkenyl group, a C₂₋₃ alkynyl group, a trialkylsilyl group or a C₁₋₃ alkoxy group;

R^5 is a C₁₋₁₀ alkyl group, an allyl group, a benzyl group or a propargyl group;

R^6 , R^7 and R^8 are independently a C₁₋₁₀ alkyl group, a C₂₋₁₀ alkenyl group, a C₂₋₁₀ alkynyl group, an aryl group or a $-(CH_2)_N R^9$ group, wherein N is an integer within the range of 1 through 10 and R^9 is a hydroxy group, alkoxy group, an amino group, an alkylamino group, a dialkylamino group, a halogen atom, a cyano group or a nitro group;

R^{11} is an alkylene group, an alkenylene group, or an alkynylene group;

R^{13} is H, $-C(O)R^f$, or $-C(O)OR^d$; and

pharmaceutically acceptable salts thereof.

41. The compound of Claim 40, wherein R^4 is H.

42. The compound of Claim 40, wherein R^1 and R^2 are independently the same or different and are H, a hydroxy group, a halogen, an amino group, a nitro group, a cyano group, a C₁₋₃ alkyl group, a C₂₋₃ alkenyl group, a C₂₋₃ alkynyl group or a C₁₋₃ alkoxy group.

43. The compound of Claim 40, wherein R^1 and R^2 are independently the same or different and are H, a C₁₋₃ perhaloalkyl group, a C₁₋₃ aminoalkyl group, a C₁₋₃ alkylamino group or a C₁₋₃ dialkylamino group.

44. The compound of Claim 40, wherein R^1 and R^2 are independently the same or different and are H, a methyl group, an amino group, a nitro group, a cyano group, or a hydroxy group.

45. The compound of Claim 40, wherein R^1 and R^2 are independently the same or different and are H, a methylamino group, a dimethylamino group, an ethylamino group, a diethylamino group, a hydroxymethyl group, an aminomethyl group, a methylaminomethyl group, or a dimethylaminomethyl group.

46. The compound of Claim 40, wherein R^3 is F, an amino group, or a hydroxy group.

47. The compound of Claim 40, wherein R^5 is an ethyl group.

48. The compound of Claim 40, wherein R^6 , R^7 and R^8 are independently the same or different and are a C_{1-6} alkyl group, a phenyl group or a $-(CH_2)_N R^9$ group, wherein N is an integer within the range of 1 through 6 and R^9 is a hydroxy group, alkoxy group, an amino group, an alkylamino group, a dialkylamino group, a halogen atom, a cyano group or a nitro group.

49. The compound of Claim 40, wherein R^6 , R^7 and R^8 are methyl groups.

50. The compound of Claim 40, wherein R^2 and R^3 form a methylenedioxy group, or a 1,2-ethylenedioxy group.

51. The compound of Claim 40, wherein R^2 is OH.

52. The compound of Claim 40, wherein R^2 is NH_2 .

53. The compound of Claim 40, wherein R^{11} is a C_1-C_{10} alkylene group, a C_2-C_{10} alkenylene group or a C_2-C_{10} alkynylene group.

54. The compound of Claim 53, wherein R^{11} is a C_1-C_6 alkylene group, a C_2-C_6 alkenylene group or a C_2-C_6 alkynylene group.

55. The compound of Claim 53, wherein R^{11} is $(CH_2)_m$ wherein m is an integer of 1 to 6.

56. A method of treating a patient for cancer or leukemia, comprising the step of administering a pharmaceutically effective amount of a compound of Claim 18 or a pharmaceutically acceptable salt thereof.

57. The method of Claim 56, wherein the patient is treated for brain cancer, breast cancer or leukemia.

113

58. A method of treating a patient for cancer or leukemia, comprising the step of administering a pharmaceutically effective amount of a compound of Claim 41 or a pharmaceutically acceptable salt thereof.

59. The method of Claim 58, wherein the patient is treated for brain cancer, breast cancer or leukemia.


University of Pittsburgh

16 September 2004

3
3
3

3
3
3
3
3

1/25



Synthesis of 3




Figure 1

SUBSTITUTE SHEET (RULE 26)

2/25




Figure 2

SUBSTITUTE SHEET (RULE 26)

3/25




Figure 3

SUBSTITUTE SHEET (RULE 26)

4/25




Figure 4

SUBSTITUTE SHEET (RULE 26)

5/25




Figure 5

SUBSTITUTE SHEET (RULE 26)

6/25




Figure 6

SUBSTITUTE SHEET (RULE 26)

7/25


(36a) $R^1 = \text{OH}$ (36b) $R^1 = \text{NH}_2$ (36c) $R^1 = \text{H}$

Figure 7




Figure 8

SUBSTITUTE SHEET (RULE 26)




Figure 9




Figure 10





Figure 11


SUBSTITUTE SHEET (RULE 26)

9/25

**Figure 12**


SUBSTITUTE SHEET (RULE 26)

10/25

**Figure 13**


SUBSTITUTE SHEET (RULE 26)

11/25

**Figure 14**


SUBSTITUTE SHEET (RULE 26)

12/25

**Figure 15**


SUBSTITUTE SHEET (RULE 26)

13/25

**Figure 16**


SUBSTITUTE SHEET (RULE 26)

14/25

**Figure 17**


SUBSTITUTE SHEET (RULE 26)

15/25

**Figure 18**


SUBSTITUTE SHEET (RULE 26)

16/25

**Figure 19**


SUBSTITUTE SHEET (RULE 26)

17/25

**Figure 20**


SUBSTITUTE SHEET (RULE 26)

18/25

**Figure 21**


SUBSTITUTE SHEET (RULE 26)

19/25

**Figure 22**

SUBSTITUTE SHEET (RULE 26)

20/25

**Figure 23**

SUBSTITUTE SHEET (RULE 26)

21/25





Figure 24

SUBSTITUTE SHEET (RULE 26)

22/25

**Figure 25**

SUBSTITUTE SHEET (RULE 26)

23/25




Figure 26

SUBSTITUTE SHEET (RULE 26)

24/25





Figure 27

SUBSTITUTE SHEET (RULE 26)

25/25

**Figure 28**

SUBSTITUTE SHEET (RULE 26)